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Part 1
Introduction and clinical and methodological background
The case report in paragraph 1.1 has been published as: 
Claassen JA, Jansen RW.  Carotid sinus syndrome: looking sideways is sufficient cause for syncope. 
J Am Geriatr Soc 2006;54(1):188-9.
Chapter 1
Introduction and outline
16 17
1.1  Case report
Carotid sinus syndrome (CSS) is found in up to one-third of older patients presenting 
with unexplained falls.1 CSS is diagnosed when carotid sinus massage elicits a drop 
in systolic blood pressure of more than 50 mmHg, asystole of longer than 3 seconds, 
or both. This procedure is safe in older patients.2 How CSS may lead to syncope 
outside test settings is still a matter of debate.3 Wearing a tight collar, shaving, or 
turning the head are suggested to be eliciting factors. The present case clearly 
illustrates how merely looking sideways may be a sufficient cause for syncope.
A healthy 70-year-old woman participated in research in our department. She had 
been treated for hypertension in the past but was currently not taking any medication. 
She had never smoked and consumed alcohol with moderation. There were no 
abnormalities on physical examination, and her electrocardiogram (ECG) showed 
normal sinus rhythm. Carotid ultrasonography gave no evidence for atherosclerotic 
plaques or stenosis. It was noted that the left internal carotid artery had a marked 
tortuous trajectory, although flow patterns over both carotid arteries and both middle 
cerebral arteries (using transcranial Doppler) were symmetrically normal. 
She underwent the following test protocol in the morning, after an overnight fast, in 
a quiet, cool room, wearing a loose-fitting shirt. Beat-to beat blood pressure (BP) 
and single-lead ECG were recorded using the Finometer (Finapres Medical 
Systems, Amsterdam, the Netherlands). 
After 10 minutes of supine rest, mean BP ± standard deviation during the last 
minute was 178 ± 7 mmHg systolic, 79 ± 4 mmHg diastolic; heart rate was 62 ± 2 
beats per minute (bpm). Upon standing, BP dropped to 119 mmHg systolic; mean 
BP during the 5-second nadir was 124 ± 4 mmHg systolic, 63 ± 3 diastolic, and 
heart rate was 83 ± 1 bpm. The subject was asymptomatic, and BP recovered 
quickly. After 1 minute of stable BP (165 ± 4 mmHg systolic, 86 ± 2 diastolic, heart 
rate 77 ± 2 bpm), the subject was asked to look to her right. BP decreased to 124 
mmHg systolic, with mean BP during the 5-second nadir 127 ± 4 mmHg systolic, 
67 ± 1 diastolic, with heart rate 74 ± 2 bpm. After 1 minute of stable BP (167 ± 5 
mmHg systolic, 87 ± 3 mmHg diastolic, heart rate 82 ± 2 bpm), she was asked to 
look to her left. BP now decreased to 70 mmHg systolic, and heart rate briefly 
1
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1.2  Blood pressure and cerebral blood flow
Hypertension
Hypertension affects nearly a third of the general population.1 The prevalence of 
hypertension increases dramatically with age, such that as much as 77% of subjects 
over age 70 are hypertensive.2 The majority (≈60%) of hypertensive patients have 
isolated systolic hypertension. Hypertension is an important risk factor for 
cardiovascular disease. For example, hypertension is the strongest risk factor for 
stroke, with a more than doubling of stroke mortality risk for each 20 mmHg increase 
in systolic blood pressure, departing from 115 mmHg.1 This association is found in 
all age groups, importantly however, the absolute risk is higher with advanced age.
The benefits of antihypertensive treatment have been well established, and although 
data in the very old (those over 80 and especially those over 85 years old) are 
scarce, these benefits clearly extend to elderly subjects over age 70. Despite these 
facts, only a third of hypertensive patients over age 70 receive proper treatment and 
have adequately controlled blood pressure; another third receive treatment but 
have inadequate control of hypertension; the final third is untreated.2 Looking 
specifically at secondary prevention, e.g. hypertensive patients with a history of 
stroke, the number of patients receiving antihypertensive treatment is higher 
(70-80%). However, also in this group only a third of patients have adequate control 
of BP, defined as a systolic BP ≤ 140 mmHg.2
dropped to 40 bpm immediately after turning the head. Mean BP during the 
10-second nadir was: 73 ± 3 mmHg systolic, 42 ± 2 mmHg diastolic, and heart rate 
was 70 ± 4 bpm. At this time, she complained of transient fatigue and light-
headedness. After hemodynamic stabilization, carotid sinus massage was 
performed in the supine position. On the right side, BP fell 40 mmHg, after brief 
bradycardia of 40 bpm. On the left side, BP decreased 33 mmHg after brief 
bradycardia of 45 bpm. 
This case illustrates three important points. First, evidence is presented that a turn 
of the head to look sideways can contribute to syncope in a patient with CSS. In this 
subject, systolic BP fell 94 mmHg. This is sufficient to diagnose CSS of the 
vasodepressor type. A possible explanation for the greater sensitivity of the carotid 
sinus on the left side than on the right is the observed variant anatomy of the 
internal carotid artery.
Second, this case represents a healthy, community dwelling subject, without a 
history of falls or syncope, in whom CSS was diagnosed by chance. A population 
study in healthy volunteers found CSS in four of 32 participants.4 Apparently, CSS 
is asymptomatic in certain affected individuals.
The third point illustrates that despite severe reductions in BP during standing, head 
turning, and carotid sinus massage, this subject was only symptomatic when her 
systolic BP fell almost 100 mmHg. This means that adequate or even improved 
dynamic cerebral autoregulation was able to prevent cerebral hypoperfusion and 
thus syncope, explaining her complete lack of symptoms in everyday life. 
1
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It is interesting to note that in orthostatic hypotension/ post-prandial hypotension as 
well as in carotid sinus hypersensitivity, all attention is focused on blood pressure 
measurements. Arbitrarily defined cut-off values for reductions in blood pressure 
determine whether or not a “diagnosis” is made - with the exception of carotid sinus 
syndrome, where cardio-inhibition (asystole) is also taken into account. Still, also in 
the cardio-inhibitory carotid sinus syndrome the duration of asystole is arbitrary. 
The clinical relevance of these and other disorders of blood pressure regulation lies 
in their symptoms, for example dizziness, or falls -with (syncope) or without loss of 
consciousness, which often causes severe decline in health related quality of life. 
The symptoms mentioned are fully explained by impaired cerebral perfusion.10 Mild 
symptoms (dizziness/light headedness) represent a mild or short-lasting reduction 
in cerebral blood flow, and severe symptoms (syncope) represent a substantial and/
or prolonged reduction in cerebral blood flow. 
In clinical practice and thinking, however, these symptoms are attributed directly to 
the observed reduction in blood pressure. This means that it is assumed -often 
inexplicitly- that cerebral blood flow varies proportionally to perfusion pressure 
(blood pressure). 
Pressure-flow relationship of the cerebral circulation
According to Ohm’s law, flow F is determined by pressure P and resistance R as 
F=P/R. As long as resistance is not changed, flow varies in proportion with 
pressure.
However, the brain is capable of adapting cerebrovascular resistance in order to 
compensate or reduce the effects of pressure on brain blood flow. This process is 
known as cerebral autoregulation. Consequently, it is incorrect to assume that 
changes in cerebral blood flow always parallel changes in blood pressure, and 
therefore that measurements of changes in blood pressure can suffice to predict 
the clinical symptoms associated with disorders of blood pressure regulation. 
This is clearly illustrated by the case report in the beginning of this chapter. 
It logically follows that measurements of cerebral blood flow will better predict these 
symptoms, and would make a useful addition to measurements of blood pressure 
alone. A preceding dissertation from our group, “Hypotensive syndromes and 
An important contribution to these low treatment rates is the widespread concern 
that the benefits of antihypertensive treatment in elderly patients are offset by 
negative effects of blood pressure (BP) lowering on morbidity and quality of life.3,4 
Specifically, it is feared that lowering of BP to targets set by current guidelines (ESH/
ESC 2007, JNC-7) may cause cerebral hypoperfusion, resulting in ischemia, 
cognitive decline and/or falls. Hypothetically, cerebrovascular remodeling due to 
longstanding hypertension could impair vasodilatation, and together with diffuse 
small-vessel disease and age-related increases in vascular stiffness, this may pose 
an increased risk for cerebral hypoperfusion when blood pressure is lowered in 
elderly patients. These observations indicate the need for further studies that 
investigate the effects of hypertension and antihypertensive treatment on cerebral 
hemodynamics.
As a step in this direction, we have investigated the effects of rapid (within 1-2 
weeks) blood pressure reduction, as well as of prolonged blood pressure lowering 
treatment (3 months) on cerebral hemodynamics in middle-aged subjects. 
Specifically, we have studied effects on dynamic cerebral autoregulation5 (see 
chapter 2 for detailed information on cerebral autoregulation) and vasomotor 
reactivity (chapter 5 and 7). 
Blood pressure instability
The case report (1.1), describing an elderly subject with carotid sinus hypersensitivity, 
is just one example of a wide array of common and less common causes of blood 
pressure instability in the elderly.
Orthostatic hypotension and post-prandial hypotension are commonly found in 
geriatric patients6, and carotid sinus hypersensitivity has emerged as an important 
factor contributing to falls in the elderly.7 As often in geriatric medicine, the 
underlying causes remain unknown, or are multifactorial.8 For example, factors 
contributing to blood pressure instability may include volume deletion, cardiovascular 
(side) effects of medication, cardiac disease, or hypertension. In addition, an 
underlying condition may be autonomic dysfunction, associated with diabetes, 
Parkinson’s disease or related lewy body diseases, frontotemporal dementia and 
possibly Alzheimer disease.9        
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The interaction between dementia and cerebral blood flow is very complex, and has 
only begun to be unraveled. A brief introduction to those aspects that are relevant 
for this thesis will follow.
Vascular innervation
In chapter 3, using the example of Alzheimer’s disease, the evidence is reviewed 
that there is an “intrinsic” brain vascular innervation that can alter cerebral perfusion. 
For example, cholinergic neurons, originating from the nucleus basalis of Meynert 
–located at the base of the brain- have both direct and indirect (through nitrergic 
interneurons) contact with cortical blood vessels.12 Stimulation of these neurons 
causes vasodilatation, and inhibition leads to vasoconstriction.
Alzheimer’s disease is characterized by a profound loss of cholinergic innervation. 
As explained in chapter 3, this may in part explain the reduction in cerebral blood 
flow in this disease. Also, this suggests that treatment aimed at restoring cholinergic 
balance may influence cerebral perfusion. Of interest, loss of cholinergic function is 
also found in vascular dementia, dementia with Lewy bodies, and Parkinson’s 
dementia.12 The chapter concludes with suggestions for measurement techniques 
to further study this topic.
Vascular disease and dementia
A simplified description of current views on dementia would see Alzheimer’s 
disease as a neurodegenerative disease characterized by amyloid-beta deposition 
in plaques and hyperphosphorilated tau in tangles. It is distinguished from vascular 
dementia, characterized by cerebrovascular lesions secondary to vascular disease. 
Current consensus criteria (NINCDS-ADRDA, 1984) are such that the diagnosis of 
Alzheimer’s disease is made by exclusion; importantly, “vascular” criteria are 
among the excluded conditions.
However, large epidemiological studies such as the Rotterdam study have 
demonstrated an association between vascular risk factors and Alzheimer’s 
disease. For example, the presence of mid-life hypertension,13 or carotid artery 
disease,14 increase the risk of developing Alzheimer’s disease dementia in later life 
(relative risk up to 2.5). However, these studies were not designed to identify the 
nature of this association.15 Regardless, these findings are difficult to reconcile with 
cerebral oxygenation in elderly patients” (Mehagnoul-Schipper, 2003), made this 
transition by adding measurements of cerebral hemodynamics to research into 
disorders of blood pressure regulation.
Chapter 2 of this thesis provides an extensive review of the concept of cerebral 
autoregulation. It includes an overview of the historical developments of techniques 
to measure cerebral perfusion. From this it is clear that in the past, easily performed 
measurements of blood pressure were used as a surrogate marker of changes in 
flow, because the techniques available at that time to measure cerebral blood flow 
were not clinically applicable. This has changed with the development of transcranial 
Doppler ultrasonography by Rune Aaslid in the 1980’s. As detailed in chapter 2, this 
technique has enabled us to perform non-invasive and non-obtrusive measurements 
of changes in brain blood flow that have now been incorporated in clinical 
practice.11
Application in clinical geriatrics
Chapter 2 introduces examples of diseases and conditions that are prevalent in the 
aging population and that have in common that knowledge of cerebral hemodynamics 
is important to further our understanding of these conditions and to develop or 
improve therapeutic options. It also becomes clear that at present only limited 
information is available on cerebral autoregulation in aging, especially in those 
older than 75 years.
Together, the findings laid out in this chapter indicate the importance of identifying 
methods that can provide information on the dynamic pressure-flow relationship of 
the cerebral circulation, and that at the same time remain well suited for use in 
elderly subjects and geriatric patients. 
1.3 Dementia and cerebral blood flow
So far, we have considered how the cerebral circulation is affected by changes in 
blood pressure. Now, we will take a different approach by looking at how disorders 
of the brain itself, or more specifically, dementia syndromes, lead to alterations in 
perfusion.
1
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transcranial Doppler ultrasonography (TCD) to measure cerebral blood flow-velocity, 
a technique that will be used throughout this thesis. The concept of cerebral 
autoregulation is explained and the currently available methods to test and quantify 
cerebral autoregulation are described. Specifically, the technique of transfer 
function analysis is explained in detail, as this technique is further explored in this 
thesis. 
Chapter 3 provides background information about the interaction of dementia and 
Cerebral Blood Flow (CBF). This review indicates the need for methods to measure 
cerebral hemodynamics in patients with Alzheimer’s disease, on the one hand to 
identify the effects of the disease on cerebral perfusion, and on the other hand the 
possible effects of treatment on cerebral perfusion.
Chapter 4 continues research into the application of NIRS in the elderly. NIRS can 
be used for example to measure cerebral oxygenation. Several validation studies 
have been performed, however, studies in aging were lacking. In this chapter, the 
reproducibility of NIRS in an aging population will be examined.  
Chapter 5 introduces vasomotor reactivity as a method to investigate cerebral 
hemodynamics. Brain vasculature is extremely sensitive to changes in CO2, and 
this has led to the developments of tests to measure the reduction in cerebral blood 
flow during hypocapnia, and the increase in flow during hypercapnia. In this 
chapter, a new method is reported that investigates dynamic changes in the 
CO2-CBF relationship, and takes into account the confounding effects of changes 
in blood pressure.
Chapter 6 proposes a new method to measure dynamic cerebral autoregulation. 
Specifically, transfer function analysis of spontaneous oscillations (see chapter 2) 
has certain limitations. This chapter introduces a method of repeated squat-stand 
maneuvers to induce oscillatory changes in blood pressure and cerebral blood flow, 
aimed at enhancing transfer function analysis.  
Chapter 7 applies the method that was introduced in chapter 5 to investigate the 
effects of blood pressure lowering on cerebral vasomotor reactivity in patients with 
hypertension.
a view of Alzheimer’s disease that excludes  a possible contribution of vascular 
pathology, and call for further research to address the interaction of Alzheimer’s 
disease and cerebrovascular pathology. In this way, this epidemiological research 
generates questions and hypotheses that can be further explored by basic 
science.16
1.4  Aims
This thesis addresses two primary questions. First, we aimed to investigate how 
dysregulation of blood pressure, which is often seen in elderly subjects with and 
without cognitive decline, is related to changes in cerebrovascular perfusion, and 
how this relationship can be reliably and validly measured. As such this research is 
a continuation of the research presented in the dissertation “hypotensive syndromes 
and cerebral oxygenation in elderly patients” by Mehagnoul-Schipper, 2003. In the 
latter thesis, Near Infra-Red Spectroscopy (NIRS) was introduced as a method to 
study the effect of hypotensive syndromes on cerebral oxygenation. In the present 
thesis, the emphasis was shifted to the role of transcranial Doppler ultrasonography 
(TCD) to measure changes in cerebral hemodynamics, with the ultimate goal to use 
combined measurements of Finapres, TCD and NIRS.
The second question approaches this matter from a different angle. With the 
hypothesis that Alzheimer’s disease may be associated with alterations in blood 
pressure regulation and cerebral perfusion, our aim was to investigate whether such 
changes can be measured with the proposed techniques of Finapres and TCD. 
1.5  Outline of this thesis
These two general aims have been translated in a series of experiments and 
background studies, which are presented in the subsequent chapters of this 
thesis.
Chapter 2 provides a further clinical background for the evaluation of cerebral 
hemodynamics in the elderly population, and describes the application of 
1
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Chapter 2
Cerebral autoregulation: 
an overview of current concepts and methodology 
with special focus on the elderly
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Abstract
Cerebral autoregulation (CA) refers to the properties of the brain vascular bed to 
maintain cerebral perfusion despite changes in blood pressure (BP). Whereas classic 
studies have assessed CA during changes in BP that have a gradual onset, dynamic 
studies quantify the fast modifications in cerebral blood flow (CBF) in relation to rapid 
alterations in BP. There is a lack of standardization in the assessment of dynamic CA. 
This review provides an overview of the methods that have been applied, with special 
focus on the elderly. We will discuss the relative merits and shortcomings of these 
methods with regard to the aged population. Furthermore, we summarize the effects 
of variability in BP on CBF in older people. Of the various dynamic assessments of 
CA, a single sit-tostand procedure is a feasible and physiologic method in the elderly. 
The collection of spontaneous beat-to-beat changes in BP and CBF allows estimation 
of CA using the technique of transfer function analysis. A thorough search of the 
literature yielded eight studies that have measured dynamic CA in the elderly aged 
< 75 years. Regardless of the methods used, it was concluded from these studies 
that CA was preserved in this population.
Introduction
The brain has a high metabolic demand and therefore requires adequate nutritional 
flow. To maintain stable cerebral blood flow (CBF), the brain’s vasculature must 
respond to changes in arterial blood pressure (BP) or intracranial pressure. Thus, 
cerebral blood vessels have an inherent ability to keep CBF constant over a wide 
range of systemic BP levels, by means of myogenic, neurogenic, or metabolic 
mechanisms.1,2 In response to a variation in perfusion pressure (mean arterial 
pressure–intracranial pressure), an adaptation in cerebrovascular resistance (CVR) 
will cause CBF to return to its baseline. This hemodynamic process is known as 
cerebral autoregulation (CA).1,3
The term ‘autoregulation’ within the cerebral circulation was introduced by Lassen4. 
His review covered more than 200 clinical studies assessing CBF using the inert 
gas method (which measures arterial-venous gas difference), developed by Kety 
and Schmidt, and the indicator dilution method (which measures the venous 
dilution of an intraarterially injected indicator), developed by Gibbs, Maxwell, and 
Gibbs.4 Notably, the more recently developed positron emission tomography 
scanning technique enabling, for example, measurement of cerebral oxygen 
metabolism, is founded on these principles.
Lassen’s review included the now classic studies regarding static CA (sCA), which 
describes the response of CBF, averaged over a longer period of time, to long-term 
changes in BP with gradual onset. By plotting these changes in CBF and BP, it was 
found that CBF remains constant over a wide range of BP changes – the ‘plateau 
phase,’ with the upper and lower limits forming the boundaries of CA. It should be 
noted, however, that this classic single curve was a composite of many studies, and 
critical analysis of this work brings into question its validity.1 Frequently, a slight 
slope exists over the pressure range where the supposed plateau had been 
plotted.5 Predictions from a physiologic computer model are that in between the 
lower and upper boundaries of this plateau phase, CBF actually changes from 80% 
to 120% of baseline.6 Nonetheless, between these upper and lower limits, 
auto regulation of CBF is effective. It is important to realize that these boundaries are 
not fixed.1 Chronic hypertension, for example, shifts these limits of autoregulation 
toward higher BP levels. This adaptation protects the brain against hypertension, 
2
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In hypertension, dCA has been addressed only in those who were < 75 years old. 
In mild-to-moderate hypertension, dCA is unimpaired14, and reduction of BP to 
achieve normotension is not associated with cerebral hypoperfusion in middle-aged 
subjects15 and elderly subjects < 75 years.16 Although the beneficial effects of 
antihypertensive treatment in preventing cardiac disease and stroke are well 
known17, whether it is similarly safe to treat hypertension in the elderly cannot be 
answered at present.18
In contrast with studies of sCA, no uniform method exists to measure, analyze, and 
report dCA. In fact, the various methods applied differ in the type of BP stimuli 
(spontaneous or induced BP fluctuations) and in the model for analysis and 
interpretation.
Studies describing dCA in the elderly and in diseases affecting older people have 
used different methods to evaluate the dynamic autoregulatory capacity of the 
brain. The important clinical question whether aging affects CA can therefore only 
be attempted to be answered after careful interpretation of these different 
methodologies.
In this review, we will first provide an overview of measurements of the various 
parameters that have been applied to assess dCA. Also, we will discuss the 
different methods to provoke cerebral hemodynamics and allow dynamic 
assessments of CA. Later, we present an overview of dynamic studies of CA in the 
elderly and will discuss the interaction between CA and disease.
Review of Methods
Measurements
To evaluate the dynamic process of the autoregulatory capacity of the human brain, 
assessment of BP and CBF with high temporal resolution is essential, and 
photoplethysmography (Finapres) and TCD enable these measurements, 
respectively.19-21 During all measurements of cerebral hemodynamics, changes in 
end-tidal CO2 should be closely monitored. We will address the measurements of 
these parameters in more detail below.
but may also render it more vulnerable to hypoperfusion during episodes of 
hypotension.1 
The classic studies of CA are performed in the semi-steady state. The changes in 
BP occur gradually and the measured CBF values reflect the results of adaptation 
of CVR to the new, stable BP value. In other words, these studies assess the 
outcome of CA rather than the process of CA itself. In terms of maintaining sufficient 
nutritional blood flow, these semi-steady state studies provide no information as to 
whether a period of hypoperfusion precedes the eventual return to stable perfusion. 
Furthermore, the clinical applicability of sCA estimation is limited, because it 
requires pharmacological interventions to establish a sustained period of 
hypertension and hypotension.
More recent technological developments, such as transcranial Doppler 
ultrasonography (TCD) and servo-controlled finger photoplethysmography 
(Finapres), have offered possibilities to investigate the dynamics of the pressure–flow 
relationship of the cerebral circulation. In contrast to the classic studies, dynamic 
studies of CA quantify the fast modifications in CBF velocity (CBFV) in a major 
cerebral artery in relation to rapid alterations in BP within the upper and lower limits 
(plateau phase) of sCA. This approach allows differentiation of the CA response to 
fluctuations in beat-to-beat BP of different magnitudes and durations. Also in 
contrast to the classic studies, dynamic studies can identify episodes of reduced 
flow in this major perfusing artery in the period needed for CBF to return to baseline 
after hypotension. However, these dynamic studies are not able, at present, to 
measure flow at the brain tissue level. For studies of dynamic CA (dCA), a 
pharmacological intervention is not required, and the method is entirely noninvasive, 
which makes it clinically suitable. Recently, dCA has been shown to be impaired in 
several conditions that are highly prevalent in the elderly, such as ischemic stroke7 
and carotid stenosis8. Therefore, the vulnerable brain in these patients is insufficiently 
protected against the effects of rapid BP changes. Furthermore, postprandial 
hypotension or orthostatic hypotension, both common hypotensive syndromes in 
elderly patients9, may lead to cerebral symptoms like syncope, falls, and dizziness.10,11 
Whether these hypotensive syndromes result in symptoms and clinical signs and 
thus have clinical consequences is largely determined by the process of CA.12,13
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hypoxia and hypercapnia, whereas during either hypoxia or hypercapnia alone, no 
change in vessel diameter was noted.26 These data suggest that stability of vessel 
diameter cannot be assumed under all conditions.
Arterial blood pressure: Blood pressure can be measured noninvasively and beat 
to beat with a servo-controlled finger photoplethysmography as in the Finapres 
device.21 The obtained BP recordings using this device correspond well to invasive 
BP recordings in the brachial artery under various conditions, including during 
assessment of dCA.20
The combination of Finapres and TCD has made it possible to study the dynamic 
process of CA. 
During BP recordings with Finapres, the finger is held at heart level. In autoregulation 
research using Finapres, changes in mean BP measured at heart level are used to 
estimate changes in cerebral perfusion pressure both in the supine position and 
during standing or head-up tilt. However, it has been argued that finger BP does not 
represent cerebral perfusion pressure because of the hydrostatic gradient between 
finger and brain when the subject is sitting or standing. Conversely, if the heart–brain 
circulation is considered to represent a closed-loop system, the subject’s body 
position should not matter. This is based on the assumption that the intracranial and 
cerebral venous pressures are relatively low and constant and that, during standing 
or sitting, hydrostatic components of intracranial and cerebral venous pressure at 
head level are reduced commensurate with arterial pressure as for a closed 
circulatory system.27 However, controversies regarding these assumptions must be 
recognized.28 Currently, there are no experimental data that either unequivocally 
support or disprove this theory.29 
Carbon dioxide: Monitoring of CO2, mostly as endtidal CO2, is essential in studies 
on cerebral perfusion and autoregulation. CO2 is a very potent cerebral vasodilator, 
and hypercapnia may cause a 3% to 5% increase in CBF per mm Hg rise in endtidal 
CO2.30,31 Hypocapnia induces vasoconstriction and can reduce CBF by 2% to 3% 
per mm Hg reduction in end-tidal CO2. Thus, changes in respiratory pattern during 
tests of autoregulation may greatly confound the measurements of CBF. Moreover, 
CO2 causes sympathetic activation and may cause a substantial increase in BP.31 
Cerebral blood flow: The inert gas method and the indicator dilution methods 
measure global CBF as blood flow in volume per unit weight per unit time (for 
example, mL per 100 g per min). These methods are rather invasive and 
time-consuming, and the indicator dilution methods have a low temporal 
resolution.
In contrast, TCD is noninvasive, easy to use, and offers a very high temporal 
resolution (< 0.1 secs) to monitor changes in CBF.19 Transcranial Doppler 
ultrasonography measures flow-velocity, in centimeter per second, in one of the 
supplying arteries of the brain, usually the middle cerebral artery (MCA). The 
flow-velocity in the MCA measured by TCD is determined by both the flow in the 
MCA and by its diameter, or rather its cross-sectional area. Therefore, changes in 
flowvelocity recorded with TCD represent changes in flow, provided that the 
diameter of the insonated vessel remains constant. It has been shown in (neuro)
surgical patients that the diameter of the MCA does not significantly increase or 
decrease during, respectively, a mean decrease or increase in BP of 30 (SD 16) mm 
Hg.22,23 Furthermore, in healthy subjects, lower body negative pressure at 20 or 
40 mm Hg induced decreases in flow-velocity in the MCA, whereas diameter 
changes did not occur during these tests.24 These hemodynamic changes are 
similar to those encountered in dynamic tests of autoregulation, as will be illustrated 
later. In this review, consistent with the literature on this subject, flow-velocity in the 
MCA as recorded with TCD is denoted as CBFV, and it is assumed that the changes 
in CBFV reflect changes in CBF. However, in contrast with other methods (see 
above), this representation of CBF does not include brain tissue weight. As a further 
caveat, these measurements only reflect changes in flow for the perfused territory. 
It is conceivable that the perfused territory of the insonated vessel (mostly the MCA) 
might change under pathologic conditions, such as focal cerebral ischemia or 
vasogenic edema, and under nonpathologic conditions, such as hyper- or 
hypocapnia and extreme hypoxia.
Some TCD devices include a provision to determine an index of the cross-sectional 
area of the vessel being insonated, according to the backscattered power. 
In surgical patients, the vessel area increased after inhalation of isoflurane, whereas 
CBFV remained unchanged.25 A similar observation was made during combined 
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causing a reduction in cardiac output and hence a decrease in BP, which in turn 
leads to baroreflexmediated vasoconstriction.37 The increase in intrathoracic 
pressure also causes an increase in intracranial pressure38, leading to a considerably 
stronger reduction in the cerebral perfusion pressure than indicated by the BP 
decrease. In addition, an increase in end-tidal CO2 pressure during the Valsalva 
maneuver has been observed39 and the effect on cerebral vessels of a change in 
arterial CO2 pressure has to be taken into account. These observations suggest 
that the Valsalva maneuver is too complex a method to quantify the effects of 
changes in BP on CBFV.
Placing a hand in ice water (cold pressor test), as well as isometric exercise such as 
sustained handgrip, result in increased BP by stimulating sympathetic efferent 
pathways. Both methods have been used for the assessment of dCA.40-42 However, 
the CBFV response to these tests is very heterogeneous.
A different stimulator of the sympathetic nervous system is passive head-up tilt.43 
Cerebral blood flow velocity decreases during head-up tilt, and this test has been 
used to assess dCA in patients with syncope.44 However, during head-upright tilt in 
healthy subjects, a slight but significant decrease in both end-tidal CO2 pressure 
and CBFV has been observed, without a change in the rate of breathing.45 
The change in end-tidal CO2 is thought to be due to the changes in the ventilation–
perfusion relationship during tilting.
The role of the sympathetic nerve system in the regulation of CBF remains 
controversial. The cerebrovascular bed is well innervated by both sympathetic and 
parasympathetic nerve fibers46, but most studies in animals have found that 
baseline CBF does not change after autonomic denervation.47 On the contrary, 
Zhang et al.48 found that dCA was altered markedly after ganglion blockade, 
suggesting that autonomic neural control of the cerebral circulation is involved in 
beat-to-beat regulation of CBFV. Therefore, possible direct effects on cerebral 
vessels of sympathetic activation have to be taken into account when using these 
tests to induce an increase in BP and assess dCA.
A more straightforward technique used to assess dCA is the sit-to-stand procedure, 
which induces a depressor change in BP and CBFV. The reduction in BP (of 
Methods to Induce Hemodynamic Changes
Essential for the evaluation of CA dynamics is to observe the response of cerebral 
perfusion to an alteration in BP. There are several potential methods to induce 
oscillations or rapid changes in BP, of which the thigh cuff method was the first to 
be introduced.
Step decreases in blood pressure: Aaslid et al.32 introduced the thigh cuff method, 
which induces step decreases in BP by rapid deflation of cuffs around both thighs 
after an inflation lasting at least 2 mins. A different approach to reduce BP is lower 
body negative pressure. If the atmospheric pressure surrounding the lower body 
(which is enclosed in a sealed box) is reduced, this reduces the extravascular 
pressure, which causes dilatation of veins and a lowered vascular resistance, 
increasing the flow to the lower limbs.33 
Of interest, even without a change in mean BP, CBFV decreases during lower body 
negative pressure.15,34 The exact mechanism that is responsible for this reduction in 
CBFV during lower body negative pressure remains uncertain; recently it was shown 
that it is not likely due to cerebral vasoconstriction caused by sympathetic activation.15
Both the thigh cuff and the lower body negative pressure techniques have been 
developed to allow assessment of dCA in the supine position. This is of relevance 
in patients who are confined to bed, for example, in head trauma patients in an 
intensive care unit. The thigh cuff method can be painful35 and is not a method of 
choice in aged subjects, although pain can be reduced if large-sized cuffs are used 
(R Aaslid, personal communication). Lower body negative pressure is also an 
uncomfortable procedure that is not well tolerated and cannot be applied in obese 
subjects. Therefore, both techniques are not ideally suited for the assessment of 
dCA in elderly patients. As the majority of these patients can be tested in an upright 
position, alternative methods to induce oscillations in BP can be used more 
efficiently.
A simple and feasible method used to assess dCA is the Valsalva maneuver, which 
causes characteristic changes in BP and CBFV.36 In this procedure, the decrease in 
BP is due to elevation of intrathoracic and intraabdominal pressure induced by 
straining. With the increase in intrathoracic pressure, the venous return decreases, 
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procedure is a useful and feasible method to test dCA in elderly subjects. An 
additional benefit of this method is that it represents a physiologic challenge that 
occurs in daily life. 
Oscillations in blood pressure: The techniques described above provide a 
single-step challenge to cerebral hemodynamics. In contrast, periodic squatting52, 
oscillatory lower body negative pressure53,54, oscillatory thigh cuff inflation and 
deflation55, and periodic breathing56 give rise to almost sinusoidal oscillations in BP. 
When BP is forced to oscillate at a determined frequency, CBFV follows these 
induced oscillations. These induced periodic variations in BP and CBFV can be 
used for the assessment of dCA. 
A disadvantage of the periodic breathing approach is that it may lead to a larger 
tidal volume and induce hypocapnia. Instructing patients to breathe slowly and with 
small tidal volumes can prevent hypocapnia. However, older subjects and subjects 
with cognitive impairment may not be able to adequately perform this technique. 
The same holds true for the technique of periodic squatting. The disadvantages of 
lower body negative pressure and thigh cuffs have been described above. A single 
sit-to-stand maneuver is well tolerated in elderly subjects. Therefore, repeated 
sit-stand maneuvers may be easier to perform and better tolerated in the elderly 
population. However, this procedure has never been tested to produce sinusoidal 
oscillations in BP. It could be useful to test a well-developed, repeated, sit-to-stand 
protocol in experiments in the elderly population.
Fortunately, it is also possible to estimate dCA without inducing changes in BP. 
Blood pressure oscillations ranging from 0.02 to 0.4 Hz occur in humans during 
daytime and nighttime without an externally triggered BP manipulation, independent 
of stimuli of daily life.57 If spectral analysis is applied to this BP variability, three 
frequency ranges are noticeable: one around the respiratory frequency showing 
peaks at 12 cycles per minute (the high-frequency region, respiratory waves, around 
0.2 to 0.4 Hz); one around 6 cycles per minute related to variations in vasomotor 
tone (mid-frequency region, Mayer waves at 0.1 Hz); and the lowest frequency 
region, of which the cause is speculative, around 1 cycle per minute (low-frequency 
region, 0.02 to 0.07 Hz; alternatively named the very low frequency).58 Similarly, 
CBFV measured by TCD is not constant over time. Lindegaard et al.59 found 
approximately 25%), resulting from an immediate and marked decrease in total 
peripheral resistance upon standing, is presumably caused by cardiopulmonary 
baroreflex mechanisms.49 This characteristic decrease in BP, named initial orthostatic 
hypotension, is absent in passive tilt testing.50 After this initial decrease in total 
peripheral resistance, the arterial baroreceptors respond to the hypotension and the 
cardiopulmonary receptors react to the decline in preload, leading to an increase in 
total peripheral resistance. In Figure 1, we present a typical BP and CBFV response 
in a healthy elderly subject during a sit-to-stand maneuver. Standing up causes a 
small decrease in end-tidal CO2, which cannot, however, explain the immediate 
decrease in CBFV upon standing.51
When changing position from sitting to standing, the Doppler probe remains in the 
same spatial in relation to the heart and Finapres finger cuff throughout the 
procedure in contrast to passive head-up tilt, and thus avoiding the issue of a 
possible hydrostatic effect on cerebral perfusion pressure. The sit-to-stand 
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Continuous beat-to-beat blood pressure (BP) and cerebral blood flow-velocity (CBFV) measurements during a sit to 
stand maneuver in a healthy elderly subject. Beat-to-beat data were resampled at 2 Hz to create an equal time base. 
The subject starts standing after 30 s. 
Figure 1  Blood pressure (BP) and cerebral blood flow velocity (CBFV) 
 response during a sit to stand maneuver 
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CVR =
 BPmean
 CBFmean
The use of CBF to calculate CVR takes into account the brain weight, whereas 
studies that use TCD and measure flow-velocity lack this tissue weight. These 
studies calculate the CVR index (CVRi), which is defined by the mean BP divided by 
mean CBFV:
CVRi = 
 BPmean
 CBFVmean
 
Studies that use CBFV ideally would have to take into account the cross-sectional 
area factor between CBF and CBFV in addition to brain tissue weight in their 
estimates of CVR. Furthermore, it should be emphasized that the use of the ratio 
between BP and CBF (velocity) to represent CVR (index) corresponds to a model 
where the cerebrovascular circulation is characterized by a single parameter. This 
calculation infers from Ohm’s law and is based on a number of hypotheses, and 
resistance is not measured directly.
Gosling’s pulsatility index (PI) is sometimes used to reflect CVR.63 This index is 
defined as the difference between systolic and diastolic extremes of CBFV divided 
by the mean CBFV:
PI = 
CBFVsys - CBFVdias
 CBFVmean
The PI changes with alterations in CVRi in the following manner. CVRi and the PI are 
both inversely correlated to CBFV in steady state (e.g., reduction in CVRi causes an 
increase in CBFV and a reduction in PI). Under these stable conditions, a quantitative 
relationship indeed exists between CVR and PI. However, during neurally mediated 
syncope, CVRi decreases, whereas the PI increases.44 Therefore, the PI cannot 
serve as an adequate parameter to assess dCA.
Another estimate for vasomotor resistance is the critical closing pressure, determined 
from the systolic–diastolic pressure–flow relationship within each heartbeat. 
The critical closing pressure of the cerebral circulation indicates the value of BP at 
which CBF is projected to approach zero.64 This value is obtained by linear 
extrapolation of the BP and CBFV values in the systolic to diastolic range that were 
individual ranges of spontaneous fluctuations between ±15% and ±35% of the 
mean flow in patients after carotid endarterectomy. Diehl et al (1991) found 
oscillations up to 30% of the mean CBFV with low-frequency oscillations between 
0.4 and 9 cycles per min. In conclusion, spontaneous fluctuations of BP and CBFV 
may be useful for the assessment of dCA.60 This mechanism limits the need for the 
above-mentioned methods to induce alterations in BP and seems to be the simplest 
method for the assessment of dCA in a clinical setting.
Baseline (resting) measurements of BP are the most physiologic situation to assess 
dCA. However, they depend on the magnitude of the spontaneous oscillations. This 
magnitude, in turn, depends on the variability of BP, which is not always high 
enough to allow estimations of dCA. Furthermore, spontaneous oscillations in the 
low-frequency range appear inconsistently. These reasons may explain the lack of 
coherence between BP and CBFV (we will further explain and discuss the coherence 
below) in approximately 10% of all spontaneous oscillation recordings.61 In this 
situation, augmented oscillations are expected to increase coherence between BP 
and CBFV, and it will be necessary to induce these oscillations using repeated 
maneuvers as described above.
Quantifications of Dynamic Cerebral Autoregulation
After a change in BP, the relationship between CBF and BP has to be quantified. 
Here, we will discuss the methods that are most commonly used in clinical 
situations. These methods approach the relationship between BP and CBF as if it 
is linear. It should be noted that more complex mathematical models have been 
developed that allow for nonlinear dynamics.62
In Table 1, we provide an overview of the different quantifications discussed below.
Cerebrovascular resistance: Linear system analysis facilitates the examination 
of the transfer of BP oscillations to CBF as a measure of autoregulation. 
It quantifies the extent to which the BP input signal is reflected in the CBFV output 
signal. The regulator between the input and output is the resistance of the small 
cerebral vessels distal to the site of insonation. According to Ohm’s law, this 
resistance is defined as mean BP/CBF. Thus, CVR is defined by mean BP divided 
by mean CBF:
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The time domain is used to describe the analysis of physical signals with respect to 
time. The signal’s value is known at various discrete time points and a time domain 
graph shows how a signal changes over time.
Rate of recovery: The time of CBFV recovery after a single pressor or depressor 
stimulus is taken as a measure for the efficiency of dCA. One of the quantifications 
used in this approach is the rate of recovery. The rate of recovery is defined as the 
normalized changes in CVRi per second during a BP decrease32:
Rate of Recovery = 
 ∆ CVR / ∆ T
 ∆ BP
This rate uses CVRi in the calculation, but, as mentioned above, this does not take 
into account the cross-sectional area factor between CBF and CBFV and lacks 
brain weight.
Furthermore, this method has not been tested specifically in an elderly population.
Autoregulatory index: Using the alterations in CVRi in relation to the change in BP 
during thigh cuff maneuvers, Tiecks et al.65 introduced the autoregulatory index. For 
an observed decrease in BP, a hypothetical CBFV curve without autoregulation is 
calculated. Eight other different computer models of possible flow-velocity curves 
are calculated as well, each assuming a higher degree of dCA. An autoregulatory 
index of 0 indicates that CBFV passively follows BP (in other words, the percentage 
change in CBFV is equal to that of BP); a value of 9 indicates that CBFV recovers 
much faster than BP. 
Panerai et al.66 showed that this model can also be used to grade autoregulation 
using baseline recordings of BP and CBFV, estimating the impulse response 
function. This function expresses the relationship between BP and CBFV after a 
very short, impulse-like disturbance in BP.
The autoregulation index has been applied in elderly subjects with hypertension, 
stroke, and carotid sinus syndrome (see section on CA in aging and 
comorbidity).
obtained within each cardiac cycle. The slope of this ‘intrabeat’ BP–CBFV curve is 
nonlinear, however, and therefore it remains uncertain if the true critical closing 
pressure can be accurately predicted by linear extrapolation. The critical closing 
pressure has not been validated in disease states or in elderly subjects, and further 
research will be necessary to determine if it could be a useful tool (for a review, we 
refer to Panerai64).
Time Domain versus Frequency Domain 
A linear system can be described in the time domain or in the frequency domain. 
We will first describe the techniques used in the time domain.
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Table 1  Overview of the various dynamic quantifications of cerebral  
autoregulation in the time domain.
CA measurement Abbreviation Unit / Value Definition 
CerebroVascular   CVR mmHg per mL per min  
Resistance
CerebroVascular  CVRi mmHg per cm per sec
Resistance Index  
Pulsatility Index PI -- 
Critical Closing   CrCP  mmHg The extrapolated value of 
Pressure   BP at which CBF approaches 
   zero 
Rate of Recovery  RoR  CBFV per sec  
Autoregulatory Index ARI 0 – 9  9 models for CA:
   0 indicates no autoregualion
   9 indicates very fast regulation
Correlation Coefficient Mx 0 – 1  Pearson’s correlation
   coefficient between BP 
   and CBFV
BP, blood pressure; CBFV, cerebralblood flow velocity
BPmean
CBFmean
BPmean
CBFVmean
CBFVsys - CBFVdias
 CBFVmean
∆CVR / ∆T
 ∆BP
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autoregulation. It quantifies the extent to which the input signal, BP, is reflected in the 
output signal, CBF, with CA as the regulator between the input (BP) and output (CBF).
The regulation of CBFV is effective in the low-frequency range of BP fluctuations, 
but not in the high-frequency range because of the time delay required to initiate 
cerebrovascular adaptations to the changes in perfusion pressure. Therefore, CA 
functions like a high-pass filter, allowing rapid BP changes to be transmitted to 
CBFV, whereas slow BP changes are filtered. Cerebral blood flow velocity in relation 
to BP can therefore be expressed by transfer function analysis using a high-pass 
filter model in the frequency range of 0.07 to 0.30 Hz.71,72
Correlation index: In patients with head injury, Czosnyka et al.67 calculated 
Pearson’s correlation coefficients between consecutive samples of averaged 
cerebral perfusion pressure and flow velocity for every 3-min period determining a 
correlation index known as ‘Mx.’ Lang et al.68 showed that this index is valid if BP is 
used instead of cerebral perfusion pressure in these patients. This obviates the 
need for the invasive measurement techniques to determine intracranial pressure. 
Presently, however, the Mx has not been validated in nonbrain trauma patients, and 
the proposed cutoff values were not valid in healthy subjects.69 
The Frequency Domain 
In the frequency domain, physical signals are described with respect to frequency. 
In Figure 2 we illustrate two signals that show clear repetitive patterns over time. In 
fact, they can be described as two sinusoidal waveforms (oscillations) with a given 
period, T, and amplitudes A and B. The frequency in hertz (Hz) is calculated from 
the period:
F =
 1
 T
 
Giller was the first to use frequency domain analysis to describe the relation 
between oscillatory patterns of BP and CBFV.70
In Figure 3A, we present an example of the spontaneous oscillations in BP and 
CBFV recorded in a healthy old subject over a period of 5 mins of rest in sitting 
position. The signals are composed of several different oscillations with different 
periods (and thus frequencies) and amplitudes. Spectral analysis makes it possible 
to create the frequency domain graph that shows the frequency spectrum of these 
different oscillations that are hidden in the signal. In Figure 3B, we illustrate the 
power spectra of the two signals presented in Figure 3A. A power spectrum is a 
frequency graph that describes how much of the signal lies within a given 
frequency.    
In the frequency domain analysis, the regulation of CBF in response to changes in BP 
can be described using transfer function analysis. Transfer function analysis makes it 
possible to examine the transfer of the BP oscillations to CBF as a measure of 
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Graphical explanation of the concept of transfer function analysis. Two sinusoidal waveforms with the same period 
(T) are presented. Waveform frequency (F) is defined as 1/T. The solid line represents waveform 1 (W1), with a larger 
amplitude than the dashed line, representing waveform 2 (W2). The gain is the damping effect between  W1 and 
W2, and the phase shift represents the time delay between W1 and W2. Provided that W1 is the input and W2 is the 
output of the transfer function, the regulator in this system attenuates the amplitude of the input leading to a lower 
amplitude (gain) of W2. The phase shift of W2 characterizes the displacement in time of this waveform relative to W1. 
Figure 2  Transfer function analysis 
Gain
W1 - W2
Phase Shift
W1 - W2
Period = T (s)
F = 1/T Hz
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In the transfer function between BP and CBFV, the gain represents the damping 
effect of CA on the magnitude of the BP oscillations. The gain of this transfer 
function marks the efficiency of the regulator, which is the response of CA. A low 
gain indicates an efficient autoregulation, whereas an increase in gain represents a 
diminished efficiency of the dynamic process of CA. According to the high-pass 
filter model of CA, the gain rises with increasing frequencies of BP oscillations.54
A specific problem in the interpretation of gain is that absolute measures of gain 
(estimated from transfer function analysis of absolute changes in CBFV and BP) are 
influenced by baseline values of CBFV and BP. Especially for CBFV, interindividual 
differences can be substantial and reflect the differences in MCA diameter rather 
than baseline differences in flow. Therefore, normalization of gain has been 
proposed. This can be achieved by substituting gain by the product of gain and 
CVR, named normalized gain. If the CVRi is determined from averaged baseline 
values for BP and CBFV, normalized gain is mathematically similar to gain calculated 
from relative changes in BP and CBFV.73,74
The second parameter of the transfer function we will discuss is the phase shift. 
Synchronous waveforms are ‘in phase.’ The phase shift of a waveform therefore 
represents the displacement of this waveform relative to another waveform with the 
same period (Figure 2). The phase shift can be expressed in degrees from 0º to 
360º, or in radians from 0 to 2 p, thus ranging from no phase shift to a phase shift 
of one full period. The phase shift can be recalculated to a time difference between 
two signals: a 90º phase shift between two signals with 10-sec periods equals a 
time delay of 2.5 secs between these signals.
The oscillations of CBFV do not occur simultaneous to those of BP. Changes in 
CBFV recover faster than the changes in BP, which causes a displacement of CBFV 
relative to BP in such a manner that CBFV oscillations appear to lead BP oscillations. 
This is interpreted as intact dCA.75 In relation to BP, this leftward shift is 
mathematically negative. However, in literature, the phase shift between BP and 
CBFV is often given as a positive number and is defined as a ‘phase lead’. A 
positive phase indicates an intact CA, whereas in patients with a complete loss of 
CA, the phase shift between CBFV and BP is expected to be close to 0º. In a clinical 
Gain, phase, and coherence: The transfer function between the oscillations in BP 
and CBFV in this autoregulatory system is characterized by three parameters: gain 
(or magnitude), phase shift, and coherence.
The gain, or transfer magnitude, quantifies the damping effect between the input 
and output of the transfer function. Provided that in Figure 2, waveform 1 is the input 
and waveform 2 is the output of the transfer function, the regulator in this system 
attenuates the amplitude of the input (A), yielding a low value for gain.
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(A) Spontaneous oscillations of blood pressure (BP) and cerebral blood flow velocity (CBFV). Five minutes of conti-
nuous BP and CBFV measurements in a healthy elderly subject in sitting position, showing spontaneous oscillations 
in both signals. (B) Power spectra of BP and CBFV. The power spectra of BP and CBFV data presented in panel (A), 
obtained after spectral analysis. The power spectra describe how much of the BP and CBFV oscillations lie within a 
given frequency. Note the different scales on the y axis illustrating the difference of the magnitude of the oscillations 
in BP and CBFV.
Figure 3  A power spectrum is a frequency graph that describes how much 
of the signal lies within a given frequency. 
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and the lowest in the very low frequency region, whereas phase shifts are the highest 
in the very low frequency region and the lowest in the high-frequency region.14,71,80
Dynamic Cerebral Autoregulation in Elderly Subjects
Healthy Elderly
To include all the literature regarding the dynamic process of CA in healthy elderly 
subjects, we performed a literature search with the following search terms: 
cerebrovascular circulation, cerebrovascular disorders, and aged. Furthermore, we 
used free text words, aging, ageing, elderly and the found eight studies that have 
investigated dCA in healthy elderly subjects.81-83 These studies compared the 
autoregulatory capacity of healthy young subjects with healthy aged people. An 
overview of these studies is presented In Table 2. The age range was 50 to 75 years. 
All studies measured BP and assessed CBFV in the MCA, using TCD; one study 
also measured CBFV in the posterior cerebral artery (PCA).84 Unfortunately, 
important methodological differences exist among these studies in the measurements 
and assessments of dCA.
Different investigators measured spontaneous oscillations of BP and CBFV during 
sitting and standing, and calculated transfer functions (resulting in values of gain, 
phase shifts, and coherence) in elderly people.14,80 Yam et al.69 also made use of 
spontaneous BP and CBFV recordings in moderately aged people, but these 
investigators calculated the correlation index between BP and CBFV. Sorond et al.84 
measured BP and CBFV in elderly subjects during a sit-to-stand procedure and 
evaluated the rate of recovery of CBFV. Carey et al.81,82 used lower body negative 
pressure, the Valsalva maneuver, spontaneous oscillations, the thigh cuff test and 
head-up tilt to induce BP changes, and for each test they assessed the 
autoregulatory index. These investigators measured dCA in 25 aged subjects, 
including five subjects > 75 years. Heckmann et al.85 determined dCA during 
ergomotor exercise in older subjects and calculated the PI. Franke et al.83 assessed 
the PI in two different groups of elderly people; one group of fit elderly subjects and 
another group of frail elderly subjects. They measured CBFV continuously, but 
assessed BP only once every minute. To determine dCA, BP should ideally be 
measured continuously.
population of patients with carotid stenosis or occlusion, phase shifts were 
significantly lower than in normal subjects and could sometimes approach 0º.56,76 
Phase shifts can be considered surrogate measures for the time delay of the 
autoregulatory response. When we translate the phase shift to the time domain, a 
phase shift of 0 means no time delay between oscillations of BP and CBFV.
The measurement of phase shifts and gain is applicable to all stationary models 
that induce oscillatory BP and CBFV changes, and these parameters have an 
apparent relationship to the rate of autoregulation. During induced oscillations in the 
three frequencies regions (the high, > 0.2 Hz; low, 0.07 to 0.20 Hz; and very low 
frequencies, < 0.07 Hz), the gain values increased and the phase shifts decreased 
with increasing frequency.54 Analysis of spontaneous oscillations yielded the same 
results.71,72 These results all confirm the high-pass filter model of dynamic CA. In 
assessing dCA, gain should be calculated in combination with phase shifts. For the 
calculation of phase shifts during an short, nonstationary BP/CBFV response, 
multimodal pressure–flow analysis has been introduced as a mathematical tool.77
The third parameter of the transfer function the coherence function tests the linearity 
of the relation between input and output. Coherence approaching unity in a specific 
frequency range suggests a linear relationship in this domain, whereas coherence 
approximating zero may indicate no relationship between the signals. However, a 
low coherence could also indicate severe extraneous noise in the signals.70,78 
Therefore, for the calculation of phase shifts and gain values, thresholds of 
coherence of >0.4 or >0.5 have been used by most researchers.71,72 Conversely, 
low coherence can also be an expression of the nonlinear qualities of dCA, and the 
validity of using these cutoff and maximum points is debatable.79 A solution to this 
limitation is to induce oscillatory changes in BP and CBFV. Several maneuvers (as 
described above) induce oscillations. These enlarge the power of the oscillations 
and thereby the coherence of the transfer function.54 These maneuvers can be 
performed in the different frequency regions. Another possible solution is nonlinear 
analysis and the use of more complex mathematical models.
In accordance with the high-pass filter model of dCA, in healthy older people, values 
of coherence and gain are the highest in the high-frequency region of BP oscillations 
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dynamic CA is that the classic measurements are performed in the semisteady 
state and that the use of vasoactive medication is necessary to drive these 
prolonged changes in BP. In contrast to this approach, dCA measures flow changes 
in response to BP fluctuations that are mostly within the limits of autoregulation.
In one study in normal human subjects, dynamic measurement of CA yielded 
results similar to static testing under conditions of intact autoregulation and 
following pharmacologically induced impairment of autoregulation.65 However, very 
few studies have combined estimations of sCA and dCA. Therefore, further research 
should combine sCA and dCA and attempt to describe the behavior of dCA around 
the lower and upper limits of BP as identified by the classic sCA curve.
However, for clinical applications, dynamic measurements of CA are probably the 
method of choice. This practice is noninvasive and less prolonged, it could be 
performed at bedside, and pharmacological interventions are not necessary.
Diseases such as acute ischemic stroke may bilaterally impair sCA leaving the brain 
tissue unprotected against the potentially harmful effect of BP changes.1 Stroke is 
more common in older subjects, and 72 to 96 h after an acute stroke, dCA is 
bilaterally impaired, rendering CBFV dependent on BP.7,88 Reinhard et al.61,76,89 found 
no major disturbance of dCA after 4 to 48 h after stroke. However, after 72 to 171 h, 
they found a trend toward poorer autoregulatory values. Therefore, it could be 
argued that in poststroke patients, BP should be well controlled to stabilize CBF and 
to prevent cerebral hyperperfusion or ischemia. However, which levels of BP are 
acceptable in the acute stroke phase, and to which level BP can or should be 
lowered, is still uncertain.90
Further research addressing the dynamic pressure–flow relationship in acute stroke 
may help to shed light on this important issue. 
For hypertensive patients, estimations of CA offer a simple method to evaluate not 
only the effect of hypertension but also the effect of antihypertensive treatment on 
cerebral perfusion. Because of an upward shift of the lower limit of the sCA curve 
toward higher pressure, and with this, a possible impaired tolerance to a decline in 
BP, a conservative approach in elderly patients with hypertension has been 
Regardless of the method by which it was assessed, all studies concluded that in 
healthy aged subjects, dCA is preserved during induced decreases in BP and during 
spontaneous oscillations in BP in the low-frequency range (0.07 to 0.20 Hz). In the 
high-frequency range (> 0.15 Hz), dCA is less efficient in both young and older 
people.14 This is in agreement with the concept that the relationship between CBFV 
and BP can be expressed by transfer function analysis using a high-pass filter model 
(see above). The studies that calculated changes in the CVRi and the PI also 
concluded that cerebral autoregulatory capacity is retained, regardless of physical 
fitness.83,85 However, these investigators noted that the change of the PI in healthy 
elderly is delayed during ergomotor exercise compared with young subjects.85 The 
CVRi and the PI only have a quantitative relationship under stable conditions, and 
therefore these parameters are difficult to interpret during exercise.
Most investigators studied dCA in the MCA, but the PCA can also be insonated with 
the TCD19, and dCA can be investigated in the posterior circulation. Sorond et al.84 
observed that CBFV in the PCA declined to a greater extent than in the MCA. In both 
young and aged humans, the characteristics of dCA in the PCA differ from that in 
the MCA. The regulation of CBFV in the PCA to spontaneous BP oscillations acts as 
a high-pass filter similar to the MCA.86 The phase shifts in the PCA suggest that the 
latency of CA is sufficient, as it is in the MCA territory, but in all frequency ranges, 
the gain values in the PCA were significantly higher compared with the values in the 
MCA. These higher magnitudes do not necessarily indicate an inefficient 
auto regulation in the PCA, considering the similar phase shifts. This dissimilarity in 
gain more likely is reflective of the different resonance properties of the two vascular 
beds and of the combination of different flow and different vessel diameters; 
flowvelocity in the MCA is approximately 1.5 times higher than in the PCA.84,86 
In summary, no evidence was found for an effect of aging on dCA in the age ranges 
studied (50 to 75 years). Whether dCA is preserved at more advanced age (> 75 
years) is at present unknown 
CA in Aging and Comorbidity
With TCD, CBFV can be measured during gradual and prolonged changes in BP, cf. 
the classic method to determine CA.87 Under normal conditions, the upper and 
lower limits of CA are found at 60 and 150 mm Hg mean arterial pressure, 
respectively. The important difference between the measurement of classic and 
2
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Conclusion
Classic studies regarding CA are performed in the semi-steady state, and they 
measure CBF after a persistent change in BP with a gradual onset. In contrast, 
recent studies have investigated the fast modifications of CBF in relation to rapid 
changes in BP. Technological developments, such as TCD and servo-controlled 
finger photoplethysmography, have offered the possibilities to investigate more 
thoroughly the dynamics of the process of CA. This dynamic approach is the most 
promising approach for the clinical evaluation of CA. These measurements are less 
time consuming, entirely noninvasive, and could be performed at bedside. However, 
no uniform method exists to assess the dynamic cerebral autoregulatory capacity 
of the human brain. Researchers have introduced several techniques to challenge 
CA, ranging from a single episode of induced hypotension to induced oscillatory 
changes in BP, and additionally have used spontaneous BP oscillations to quantify 
dCA. The quantifications used vary from calculated indices using regression 
analysis to rate of CVR changes and to transfer function analysis. We have provided 
an overview of the various methods applied to study CA dynamically.
Subsequently, we have reviewed the literature regarding dCA in healthy elderly 
subjects. Regardless of the assessment used, dCA is preserved in healthy elderly 
subjects < 75 years. Owing to this intact dCA, a lowering of BP should not influence 
CBF. However, in diseases affecting the elderly, symptoms of cerebral hypoperfusion 
are frequent. Testing the dynamic cerebral autoregulatory capacity could be a 
promising tool to determine the risk of hypoperfusion and ischemia of the brain. To 
determine dCA during orthostatic stress, the sit-to-stand procedure is a feasible 
method in elderly patients. Baseline measurements of spontaneous fluctuations in 
BP and CBFV are elegant measurements to assess dCA and ask little of the patient. 
If the magnitude of the spontaneous oscillations in BP is not high enough to assess 
dCA (i.e., coherence is < 0.4), it may be necessary to induce oscillations with any 
of the methods described above. In both situations, CBFV in relation to BP can then 
be expressed by transfer function analysis using a high pass-filter model resulting 
in values of gain, phase, and coherence. More clinical studies are necessary to 
investigate the effect of a truly old age (80 years and older) and comorbidity on the 
dynamic pressure–flow relationship. At present, technological developments have 
given good prospects to study this relationship in the elderly population.
suggested.91 However, classic studies of sCA have shown that this rightward shift 
with hypertension undergoes a leftward shift with treatment92. Indeed, with dCA, 
middle-aged and elderly (< 75 years) hypertensive patients were found to retain the 
ability to maintain CBFV in the face of acute BP changes, assessed by the 
autoregulatory index during different maneuvers.93 Using the autoregulatory index 
during the Valsalva maneuver, Novak et al.77 did not find any difference between 
healthy normotensive and hypertensive middle-aged subjects. However, when they 
used the multimodal pressure–flow analysis, they observed a smaller phase shift 
pointing toward less efficient autoregulation in the hypertensive group. In patients 
with controlled hypertension, the cerebral autoregulatory response was preserved.94 
In newly diagnosed middle-aged patients with untreated mild to moderate 
hypertension, dCA was normal. Shortand long-term reduction of BP did not 
compromise dCA.15 Furthermore, in uncontrolled hypertensive patients with a mean 
age of 72 years, 6 months of successful, aggressive treatment with antihypertensive 
therapy increased CBFV significantly compared with controlled hypertensive 
patients and healthy controls.16 This therapy did not impair dCA assessed with an 
active sit-to-stand procedure.
Autoregulation studies can contribute valuable clinical information regarding CBF 
control by identifying or confirming patients at high risk for impaired cerebral 
perfusion. Transient cerebral hypoperfusion can lead to syncope, which is a 
common medical problem in the elderly.95 In addition, many older patients are 
vulnerable to cerebral hypoperfusion after orthostatic BP decreases.10 The combined 
mechanisms of (baroreflex mediated) BP regulation and CA limit the reduction of 
the cerebral perfusion induced by the postural position. However, if, despite these 
protective mechanisms, cerebral perfusion becomes impaired, symptoms of 
orthostatic hypotension such as dizziness and syncope occur.96 For recurrent falls 
among elderly subjects, orthostatic hypotension is an independent risk factor, but 
orthostatic hypotension alone may not be sufficient to produce symptoms like falls 
in most elderly patients.97 In contrast, decreases in standing BP that are smaller 
than the formal definition of orthostatic hypotension (a decrease of 20mm Hg or 
more) may exceed the threshold for CA in some patients and therefore be sufficient 
to cause cerebral hypoperfusion. In many patients with orthostatic hypotension, BP 
remains within the autoregulatory range. Because of CA, the effect of a given 
change in BP on cerebral perfusion cannot be predicted.
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Chapter 3
Cholinergically mediated augmentation 
of cerebral perfusion in Alzheimer’s disease 
and related cognitive disorders: 
The Cholinergic–Vascular Hypothesis
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Abstract
The treatment of Alzheimer's disease (AD) with cholinesterase inhibitors (ChEIs) is 
based on the cholinergic hypothesis. This hypothesis fails to account for the global 
nature of the clinical effects of ChEIs, for the replication of these effects in other 
dementias, and for the strong and unpredictable intraindividual variation in response 
to treatment. These findings may be better explained by the premise that ChEIs 
primarily act by augmenting cerebral perfusion: the cholinergic–vascular hypothesis. 
This article will review the evidence from preclinical and clinical investigations on 
the vascular role of the cholinergic neural system. The clinical relevance of this 
hypothesis is discussed with respect to its interactions with the vascular and 
amyloid hypotheses of AD. Implications for treatment are indicated. Finally, we 
propose that the role of the cholinergic system in neurovascular regulation and 
functional hyperemia elucidates how the cholinergic deficit in AD contributes to the 
clinical and pathological features of this disease.
The treatment of Alzheimer’s disease (AD) with cholinesterase inhibitors (ChEIs) is 
based on the cholinergic hypothesis1–3. Thirty years ago, post mortem studies 
revealed a severe loss of cholinergic innervation in brains of AD patients1,2. The 
severity of this cholinergic deficit was later found to correlate with the level of 
cognitive impairment4,5. Furthermore, it was observed that the loss of cholinergic 
innervation in AD occurs most prominently in the hippocampus and temporal 
cortex; this loss could account for the clinical presentation with a predominant and 
severe loss of memory6,7. Although the concept of a cholinergic deficit as a 
monocausal model for AD has long since been abandoned, there is solid evidence 
for the important role of the cholinergic system in the processes of memory, 
attention, and behavior6,8. 
ChEIs (donepezil, galantamine, and rivastigmine) reduce the synaptic breakdown of 
acetylcholine (Ach) and thus partially correct the cholinergic deficit. Early 
expectations were that these drugs would produce a significant improvement in 
memory. In practice, however, treatment effects are far more global and consist of 
modest improvements in cognition, attention, executive function (including activities 
of daily living), and global rating scales9–11. In addition, the response to treatment 
varies markedly among patients, and it is currently unpredictable whether an 
individual patient will benefit from therapy. These findings cannot be fully explained 
from the cholinergic hypothesis. 
Moreover, the observed treatment effects are not specific for AD. Very similar 
outcomes can be found in patients with vascular cognitive impairment, dementia 
with Parkinson’s disease, and dementia with Lewy bodies12–15. It should be noted 
that this nonspecificity of treatment effects may in part reflect the current lack of 
precision in diagnosing and separating ‘‘pure’’ forms of AD and other dementias. In 
contrast, these data could point toward a different mode of action of ChEIs than is 
suggested by the cholinergic hypothesis. A further argument for this explanation is 
the finding that healthy individuals receiving ChEIs show increased attention and 
reaction speed and, in airline pilots, improved scores on flight simulator tasks16.
There is substantial evidence for the hypothesis that ChEIs primarily act by 
improving cerebral blood flow (CBF). We will refer to this premise as the cholinergic–
vascular hypothesis. A cholinergic augmentation of CBF could account for the 
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The neurotransmitter for cholinergic neurons is Ach, which is also a potent 
vasodilator and can bind to two receptor types: nicotinic and muscarinic. Basal 
forebrain cholinergic neurons primarily involve muscarinic receptors. Evidence that 
Ach can induce vasodilatation as a postsynaptic neurotransmitter has come from 
the identification of these muscarinic receptors in perivascular astrocytes, smooth 
muscle cells, and endothelial cells, in cortical arterioles 22,23. 
In addition to these direct connections between NBM cholinergic neurons and 
cortical blood vessels, indirect connections involving nitrergic interneurons have 
been identified20,21,24. Cholinergic stimulation of these interneurons causes 
vasodilatation through the release of nitric oxide.
Stimulation and Inhibition of Cholinergic Neurons Modulates Cerebral Perfusion 
Experiments in rats demonstrated that electrical and chemical stimulation of 
cholinergic neurons in the NBM results in a significant increase in CBF in several 
cortical areas25–29. It is uncertain, however, if these stimuli were truly selective to the 
NBM. Other groups of neurons may have been activated as well. In contrast, 
inhibition of cholinergic neurons can be achieved with high selectivity. Following 
complete destruction of the NBM by a cholinergic immunologic toxin (192 
immunoglobulin G–saporin), CBF decreased globally. Most severely affected 
regions included the posterior parietal and temporal regions (24%–40% decrease)30. 
It is remarkable that the regional distribution of hypoperfusion corresponded to the 
regions of the brain that are most prominently affected in AD. 
The long-term effects of cholinergic inhibition were described in one study that 
found deposits of amyloid-betaprotein (aß) in the cerebral vasculature 6 months 
after a lesion to the NBM31. In patients with AD, deposits of aß are found in the cortex 
in the form of neuritic plaques, but also around cortical vessels, especially in 
patients with vascular comorbidity32,33. These data can be interpreted as follows: 
The cholinergic deficit promotes perivascular aß-deposition, which could contribute 
to chronic brain hypoperfusion. Alternatively, vascular aß-deposition may be a result 
of the chronic hypoperfusion that follows a cholinergic lesion.
global nature of the observed clinical improvement. It also serves to explain why this 
benefit is not limited to AD. Finally, it may clarify the intraindividual variation in 
response to treatment. These aspects will be further addressed in this article. The 
clinical relevance of this hypothesis is found in the recent recognition of the 
importance of vascular disease in the etiology of AD, in the frequent occurrence of 
cerebrovascular comorbidity in AD, and in the growing interest in the use of ChEIs 
for the spectrum of vascular cognitive impairment.
The cholinergic–vascular hypothesis is based on the property of the brain’s 
cholinergic neurons to induce cerebral vasodilatation and to augment CBF17,18. 
These attributes of cholinergic neurons, together with the vascular effects of ChEIs, 
have been thoroughly investigated. This article will review the pertinent evidence for 
this hypothesis and discuss its implications for patient care and research. 
The classic cholinergic deficit hypothesis and the new cholinergic–vascular 
hypothesis can be mutually viable, and the interaction between these hypotheses 
will be addressed, with an additional comment on a possible interaction with the 
amyloid hypothesis.
Evidence for the cholinergic–vascular hypothesis 
Cholinergic Vasodilatory Innervation of Cerebral Blood Vessels 
The basal forebrain is the major source of brain cholinergic neurons. The hippo - 
campus receives most of its input from the medial septal nucleus and the diagonal 
band of Broca, whereas the whole of the cerebral cortex is supplied by the nucleus 
basalis of Meynert (NBM)19. The most compelling evidence for the cholinergic–
vascular hypothesis was found with the demonstration that these basal forebrain 
cholinergic neurons have projections to cerebral blood vessels. More precisely, in 
both rats and humans, arterioles in the frontoparietal cortex were found to contain 
perivascular cholinergic nerve terminals, and their origin could be traced back to 
the NBM20,21. When brains of AD patients were compared with those of age-matched 
controls, there was a loss of cholinergic innervation in cortical arterioles in AD, most 
prominently in the temporal lobes21. 
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also confirmed the lack of activation of glucose metabolism by physostigmine in 
rats and humans55,56. In AD patients receiving ChEIs, the effects on CBF, paralleled 
by clinical effects, preceded effects on glucose metabolism by months45,57.
Effects of CBF on Cognition 
Central to the cholinergic–vascular hypothesis is the assumption that an increase in 
CBF improves cognition. To the best of our knowledge, direct evidence for this 
assumption is lacking, although the available circumstantial evidence is highly 
suggestive. In patients with carotid stenosis and impaired cerebral perfusion, 
restoration of normal cerebral perfusion by carotid endarterectomy improved 
cognitive functioning58,59. In these studies, impairment in cerebrovascular reserve 
was used as a surrogate marker for chronic cerebral hypoperfusion, and 
postoperative restoration of cerebrovascular reserve was interpreted as an increase 
in cerebral perfusion. A recent investigation, however, found no improvement in 
cognition related to carotid endarterectomy60. The cerebral hemodynamic status of 
these patients was not reported in this study. Therefore, an absence of cerebral 
hypoperfusion prior to surgery could explain the lack of cognitive benefit, which 
would be consistent with the previous investigations. 
Two brief reports have mentioned an improvement in cognition after pacemaker 
implantation in older patients with bradycardia61,62. In the first report, an improvement 
in CBF after implantation was correlated with an improvement in cognition. In the 
second report, the most striking effect on cognition was observed in three patients 
with dementia; in one of these patients, the dementia had fully reversed 6 months 
after implantation of the pacemaker. 
The association between a reduced CBF and cognitive impairment has received 
much more attention. In the Rotterdam Study, a large population-based cohort 
study, individuals with cognitive decline were found to have lower CBF than were 
those individuals who had stable cognitive function in the previous years63. Others 
have found that reduced CBF correlated with reduced cognitive functioning, 
regardless of the underlying brain disease64. The mechanism for this relationship is 
likely to be the increasing sensitivity of neurons to ischemia or hypoperfusion with 
age65. The evidence for the causal relationship between impairment in CBF, 
neuronal injury, and cognitive decline has recently been reviewed elsewhere17,66.
Cholinergic and Anticholinergic Drugs Influence CBF 
The effects of stimulation and inhibition of cholinergic neurons have also been 
assessed in pharmacological experiments. Scopolamine, an anticholinergic drug, 
blocks the binding of Ach to its muscarinic receptor. In young humans, scopolamine 
reduced frontal cerebral perfusion by 20% 34. An increase in CBF in various cortical 
regions was observed with cholinergic drugs (the ChEIs eptastigmine and 
physostigmine) in young and aged humans35. Moreover, physostigmine was able to 
restore CBF after it had been reduced by scopolamine36. In rats, rivastigmine 
reduced brain injury from hypoperfusion, indicating that autoregulation of CBF was 
improved37.
Effects of ChEI Treatment on CBF in AD 
Computed tomography using radionuclides has provided information on regional 
changes in CBF in Alzheimer patients. Two early studies, looking at the effects of a 
single ChEI dose on CBF, found an increase in posterior parietotemporal and 
superior frontal perfusion38,39. The longer-term outcome of treatment with ChEIs has 
been investigated extensively40–48. Prospective studies in untreated patients have 
found a strong correlation between clinical deterioration and progressive regional 
hypoperfusion. Consistently, patients who responded to treatment showed either 
improvement or stabilization of CBF49. In contrast, nonresponders (those patients 
who demonstrated progressive cognitive deterioration with neuropsychological 
evaluation) had a progressive decline of CBF50. Aside from AD, a rise in CBF after 
treatment with ChEIs was noted in patients with vascular dementia, dementia with 
Lewy bodies, and dementia of Parkinson’s disease, albeit in case reports and 
investigations in small numbers of patients50–53.
The Increase in CBF Is Not an Effect of Increased Metabolism 
An obvious thought is that the augmentation of CBF by ChEIs is a consequence of 
a regional increase in cerebral metabolism, which in turn is caused by cholinergic 
activation of cortical neurons. The available data, however, point toward a direct 
vascular effect. Blocking cortical neuronal activity did not prevent the increase in 
blood flow induced by cholinergic agonists54. Electrical stimulation of the rat NBM 
augmented cortical CBF (up to 300% in frontal areas) without an increase in 
metabolic activity28,29. Physostigmine increased CBF in both healthy young and 
aged humans, without a rise in cerebral glucose consumption35. Other studies have 
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Neurovascular Regulation 
The original cholinergic hypothesis and the new cholinergic–vascular hypothesis 
are not mutually exclusive. In contrast, they can coexist if we attribute a dual role to 
the cholinergic system: the coordination of neuronal activation and perfusion in 
cognitive tasks. This review has provided evidence that the cholinergic system is 
equipped to increase regional cerebral perfusion. Recent other reviews6,78 have 
summarized the large volume of evidence that this system also controls cognitive 
and attentional processes. Most experiments on this topic suggest that it acts as a 
central control system that shifts activity between cortical areas and regulates the 
process of attention, a prerequisite to perform cognitive tasks. Studies that explore 
patterns of cognitive activation use changes in cerebral hemodynamics as a 
surrogate measure for neuronal activity. For instance, functional magnetic resonance 
imaging (fMRI) measures the blood oxygen level dependent (or BOLD) signal, 
which depends on changes in deoxyhemoglobin. This practice is valid because 
changes in blood oxygenation occur almost instantaneously with neuronal 
activation79. The striking temporal and spatial association of neuronal activation and 
increased blood flow fuels a speculative hypothesis on the physiological role of the 
cholinergic system. This system has the unique capability to activate regional 
cortical neurons through its cortical projections from the NBM and, at the same 
time, to direct blood flow to these neurons by simultaneously dilating the 
corresponding cortical microvessels through its vascular projections from that 
same NBM. This mechanism ensures that adequate nutrients (oxygen and glucose) 
are directly available for activated neurons. This process of coupling of CBF with 
neuronal activation is described as functional hyperemia. Even though this 
mechanism is more complex than is suggested here, it is not unthinkable that the 
cholinergic system has a part in it. In AD, the cholinergic deficit will impair 
neurovascular regulation and lead to neuronal dysfunction and cognitive decline. 
Cerebrovascular disease and aß deposition further contribute to this uncoupling by 
delaying the hemodynamic response following neuronal activation73,74,80.
Future research 
The validity and clinical relevance of this hypothesis need further confirmation in 
future studies. More precisely, such research could investigate whether 
Clinical relevance
Interaction With the Vascular, Cholinergic, and Amyloid Hypotheses of AD 
The cholinergic–vascular hypothesis implies that the cholinergic deficit in AD not only 
affects cholinergic innervation of cortical neurons, but also leads to a loss of cholinergic 
innervation of cortical blood vessels. This vascular cholinergic deficit causes (regional) 
cerebral hypoperfusion, which in turn contributes to cognitive decline and 
neurodegeneration. Consequently, treatment with ChEIs may improve clinical functioning 
by augmenting cerebral perfusion. This mechanism offers an explanation for the 
intraindividual variation in response to treatment in AD. Recent research has focused 
on the vascular risk factors and the signs of overt vascular disease that are observed 
in many patients with AD17,66,67. Cholinergic augmentation can lead to an increase in 
CBF only if the cerebral vasculature is able to respond with vasodilatation. The 
presence of severe microvascular deformity that is found in certain AD patients18, as 
well as endothelial dysfunction from vascular disease or ischemia68,69, could reduce or 
obstruct cholinergic vasodilatation. This obstruction would explain the lack of clinical 
response in a large subgroup of AD patients. Theoretically, these patients might benefit 
from the addition of medication aimed at improving vascular endothelial function, such 
as statins and angiotensin-converting enzyme (ACE) inhibitors. 
Vasodilatation mediated by Ach is reduced by aß, and aß increases neuronal 
susceptibility to ischemia70–72. Vice versa, ischemia promotes vascular and neuronal 
aß deposition66,73. Therapeutic interventions aimed at reducing aß burden are thus 
likely to benefit from and be synergistic with strategies to improve cerebral perfusion 
[for review, see74]. 
Because hypoperfusion contributes to the neuropathology of AD, the (partial) 
restoration of perfusion by ChEIs may slow neurodegeneration and hence 
progression of disease. Because there is no reason to assume that ChEIs halt 
cholinergic degeneration itself, the positive effect on CBF is likely to wane with the 
progressive loss of cholinergic neurons. Indeed, ChEI treatment stabilizes disease 
for a short period of time and may slow disease progression, but it fails to halt it, as 
has been observed in all trials in AD and, more recently, in Mild Cognitive 
Impairment9,11,75. Combining ChEI therapy with strategies aimed at reducing 
cholinergic degeneration may hold promise to slow disease progression76,77.
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nonresponders (AD patients who do not benefit from ChEIs) have an impaired 
vasodilatory response to ChEIs in comparison with responders. If so, a next step is 
to evaluate whether adding vascular therapy can improve this response. Recent 
developments in monitoring cerebral hemodynamics, such as fMRI, transcranial 
Doppler sonography, and near infrared spectroscopy, facilitate the noninvasive 
registration of the vascular effects of cholinergic augmentation in patients with 
dementia. For instance, transcranial Doppler sonography measures changes in 
CBF velocity, and near infrared spectroscopy measures changes in cerebral 
cortical tissue oxygenation, both with excellent temporal resolution and a relatively 
low cost. Both high temporal and spatial resolutions for measuring CBF and brain 
tissue oxygenation are offered by fMRI81. Specifically, arterial spin labeling 
techniques allow dynamic monitoring of changes in regional CBF, whereas diffusion 
tensor imaging may identify subtle changes in white matter integrity, which could be 
used as sensitive outcome parameters to record the effects of vascular 
treatment82. 
Regarding the concept of neurovascular regulation, it can be hypothesized that 
ChEIs will augment functional hyperemia in AD. If such an effect can indeed be 
observed, for instance with fMRI or positron emission tomography using a cortical 
stimulation paradigm, this may prove a valuable parameter to measure the complex 
response to pharmacotherapy in AD.
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The emperor’s pointer (BMJ 2002;324:418)
At first I thought it was just me. I was attending my first scientific meeting, a young doctor eager 
to acquire new knowledge. It was clear that the first speaker had firmly embraced the concept of 
the PowerPoint presentation, and he was treating his audience to beautifully coloured slides. Like 
so many of us, he tended to put just a little too much information on each slide. One of his slides 
showed a comparison between groups, and we were promised that the third group would differ 
dramatically from the other two. I saw two lines cross the slide, one close to the other, but no third 
line. I looked at the key at the bottom of the graph and again saw no more than two groups. I was 
still waiting for a sudden and victorious appearance of the third group on the graph when the 
speaker turned to the next slide as if nothing had happened. At another point, he showed us a 
pictogram of a human cell that was engaging in complex metabolic activity, with multiple 
schematics of receptors, proton pumps, and mitochondrial pathways. A small detail of this cell's 
activity was apparently of great interest to the speaker, for he was enthusiastically aiming his laser 
pointer at it. I waited for the dot or arrow to appear on the slide, but nothing happened. “Turn it 
on,” I thought, but instead he went on to the next slide, leaving me in the dark about what had been 
so interesting in that cell. A similar thing occurred a few slides later, but no one in the audience 
seemed to bother to tell the speaker to turn on his magical pointing device. It had to be me, then. 
Apparently, his laser pointer was invisible to me, as were some of his wonderfully coloured lines 
and bars and legends. I couldn't see the emperor's clothes. And then it dawned on me: I was a 
man. And what are men, at least some men? Yes, they are colour blind. Presentation after 
presentation, I have failed to see the highlights in so many slides. And even the trusted journal BMJ 
joins in the conspiracy. For no particular reason, some issues appear without a date on the cover, 
such as the first issue in November 2001. Or is it that sometimes, some parts of this journal are 
invisible to me? But I can't be alone. Suppose I'm at a large international meeting with an audience 
of 1500 people, of whom 1000 are male. About 70 of them will be colour blind and therefore not 
able to see the little red dot or arrow being pointed at that interesting red line. There may be even 
more, because it seems that a lot of men who once had dreams of becoming a pilot but were 
turned down because of colour blindness have become doctors. 
What can we do about this? Using a big flashing yellow arrow might help; or, as in Wheel of Fortune, 
using a female assistant to point out the area of interest on a slide with a cane (she herself can be 
guided by the speaker using his pointer); or, perhaps, just putting less data on each slide.
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Abstract
Near infrared spectroscopy (NIRS) is a non-invasive method to monitor cerebral 
haemodynamics. Used either alone or in combination with other non-invasive 
methods such as transcranial Doppler sonography, this technique is well suited for 
use in cerebrovascular research in ageing. Reproducibility of NIRS, however, has 
only been determined in neonates and adults. We applied controlled desaturation 
(the O2-method) to measure the cerebral blood volume (CBV) with NIRS in 16 
healthy subjects aged 65 to 88. This method uses deoxygenated haemoglobin (the 
concentration of which is manipulated by desaturation) as an intravascular tracer for 
NIRS. We determined repeatability (between tests interval: 2 min), short-term 
reproducibility (intervals of 20 and 40 min) and long-term reproducibility (interval > 
2 weeks). We found a coefficient of variation (CV) of 12.5% for repeatability and a 
CV of 11.7% for short-term reproducibility. The CV for long-term reproducibility was 
15%. We conclude that NIRS can reproducibly measure CBV in subjects aged 65 
and older, using the O2-method. In this group of healthy subjects, this method was 
well tolerated.
Introduction
With advancing age, global cerebral blood flow declines.1 Moreover, there is an 
increasing prevalence of factors such as orthostatic hypotension and postprandial 
hypotension that could further impair perfusion of the brain.2-4 In clinical practice, 
these findings can lead to dizziness, loss of consciousness or syncope and 
cerebral ischaemia.3 Research in this field requires continuous haemodynamic 
monitoring of both systemic blood pressure and cerebral perfusion. Magnetic 
resonance imaging (MRI) and positron emission tomography (PET) are two 
important techniques to investigate cerebral haemodynamics, but these methods 
are limited to monitoring in the supine position, and may have limited availability. 
Near infrared spectroscopy (NIRS) offers non-invasive monitoring of cerebral 
haemodynamics with high temporal resolution at low cost.5 It can easily be adapted 
to allow continuous monitoring during a 90-min postprandial test, or during head-up 
tilt or active standing. NIRS can measure beat-to-beat variations in the concentrations 
of oxygenated (O2Hb) and deoxygenated (HHb) haemoglobin. We have previously 
shown that these measurements are reproducible in healthy elderly subjects.6 In 
addition, we have demonstrated that NIRS-recorded changes in O2Hb and HHb, 
brought about by finger tapping, correlated well with changes in BOLD-signal 
recorded by fMRI.7 
Techniques have been developed in neonatal research that enable NIRS to measure 
the more intuitive haemodynamic parameters, cerebral blood flow (CBF) and 
cerebral blood volume (CBV).8-12 In contrast with the situation in neonates, in adults 
only CBV can be measured reproducibly.9,10 CBV is affected by changes in 
cerebrovascular dilatation, arterial-to-venous-transit time and CBF.13 To measure 
CBV, O2Hb and HHb are used as an intravascular tracer, or ‘dye’. A gradual 
decrease in the fraction of inspired oxygen results in a slow desaturation of 
haemoglobin, hence its name ‘the O2-method’.11 The reproducibility of this method 
has been examined in neonates and adults, and its internal validity has been tested 
in an animal model, but no data are available for subjects above the age of 65.10,11,14 
Because ageing is associated with reduced cerebral blood flow, brain atrophy and 
changes in respiratory physiology, this method may be less reliable in older 
subjects. We designed this study to test the reproducibility of CBV measurements 
in subjects between 65 and 90 years old.
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waited 20 min before measuring CBV, to cancel out the effect that tilting itself has 
on CBV. Finally, long-term reproducibility was tested by repeating a CBV test after 
an interval of two or more weeks. All measurements were performed and analysed 
by the same researcher (JC).
This protocol was approved by the Ethics Committee of our institution.
Subjects
We recruited 16 healthy volunteers responding to a newspaper announcement, 12 men, 
4 women, mean age 73 years, range 68–87. All subjects were examined by a 
geriatrician. They were leading an active and independent life, had no history of 
cardiovascular or cerebrovascular disease, had a normal cognitive screening (mini 
mental state examination score >24 and normal clock drawing test), and used no 
medication. They had normal ECGs, and normal duplex examination of the carotid 
and vertebral arteries. All subjects gave their written informed consent.
CBV measurements
We used a continuous wave NIRS instrument (Oxymon, Artinis Medical Systems, 
The Netherlands). A detailed description of the materials and methods used to 
measure CBV has been published previously.10 The distance between the transmitter 
and the receivers was 5.5 cm to assure deep enough penetration of the infrared 
light into the brain to exclude substantial contamination from the extra-cerebral 
circulation. The probes were held in place by a custom-made elastic headband and 
were applied to the skin with light pressure. We applied a fixed differential path 
length factor of 6.6 (corresponding to age 50) in all subjects.15 This factor corrects 
for the distance that the light travels through the cerebral tissue. No data are 
available on the actual variation of the differential path length factor with age above 
the age of 50. For the purpose of this reproducibility study, however, this is of little 
significance.
All experiments were performed in the morning. Beat-to-beat arterial pressure was 
recorded using a finger plethysmograph (Finapres, Ohmeda 2300, USA). Arterial 
saturation (SaO2) was recorded with a pulse oximeter (N200 Nellcor Puritan Benett, 
Methods
Study design
CBV was measured in two cortical regions: the frontal and frontoparietal cortex. 
It has previously been demonstrated that the frontal cortex is susceptible to 
deoxygenation in orthostatic hypotension.3 The repeatability, short-term and 
long-term reproducibility were tested. Repeatability was assessed in three sets of 
repeated CBV measurements (see figure 1). Each set consisted of two identical 
desaturation periods with a normoxic interval of 1 min. Short-term reproducibility 
was assessed by inserting a 20 min interval between the first and the second set. 
During this interval, the subjects remained in a supine position. Between the second 
and the third set, we used a longer interval of 40 min. After 20 min, we performed 
an intervention that is likely to be used in future studies assessing CBV with NIRS. 
This intervention consisted of a 60° head-up tilt test for a period of 5 min. 
The purpose was to test the possible effect of a tilt-test procedure on optode 
position and fixation. Movement of the optodes due to tilting could have a negative 
effect on the reproducibility of the CBV measurements following this tilt test. We 
4
The bottom half shows the SaO2-curve, where the desaturation episodes can easily be identified. The upper half of  
the graph shows the parameters measured by NIRS. Oxygenated haemoglobin decreases during desaturation (peaks  
facing downwards); deoxygenated haemoglobin rises during desaturation (upward peaks); and total haemoglobin 
(which represents the sum of the previous parameters) should remain constant during desaturation (a straight line).
Figure 1  Graphical overview of the experiment.  
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or the pulse oximetry signal, mostly due to motion artefacts or disconnection of the 
probes leading to signal loss. These instances are reported as missing values or 
uninterpretable tests.
For repeatability, we compared the two measurements in each of the three sets. 
For reproducibility, we compared the average values for the three sets. 
We calculated coefficients of variation (CV) and two-tailed Pearson correlation 
coefficients. Differences were tested with a paired sample t-test.
The overall CBV for each subject was calculated as the mean of the three CBV sets. 
Because of the small size of the group and the unevenly spread ages, we did not 
investigate the correlation between age or gender and CBV.
We determined mean values for blood pressure and etCO2 measurements during 
3 min of baseline recording and during 1 min at the end of the first desaturation 
episode, and compared these values using a paired-sample t-test.
USA) with a reflectance sensor attached to the forehead, and end tidal CO2 (etCO2) 
was monitored using a capnograph (N1000, Nellcor Puritan Benett, USA). 
All analogue signals were synchronized and stored together with the NIRS data on 
a PC for off-line analysis.
During desaturation, the subjects were asked to breathe through a face mask, and 
hypoxia was induced using a stepwise computer controlled reduction of the inspired 
oxygen fraction (FiO2) by changing an O2/N2 gas mixture (Bronckhorst Hitec, 
Ruurlo, The Netherlands). We aimed for a gradual decrease in SaO2 of 10% below 
baseline within 3 to 5 min, after which FiO2 was immediately increased to 33%. 
As a result of this, SaO2 returned to normal values within 10 to 30 s.
CBV analysis
CBV analysis was performed off-line using a software application written inMatlab 
(Oxysoft, Artinis Medical Systems, The Netherlands). The start and end of each 
desaturation episode were visually identified from the graphic representation of the 
changes in [O2Hb], [HHb] and SaO2 (see figure 2). The theoretical explanation of 
CBV calculation from these data has been described in detail before.10-12 In short, 
the concentrations of [O2Hb] and [HHb] measured by NIRS vary with the 
concentration of cerebral haemoglobin [cHb] and its absorptive property, which 
depends on its oxygenation state (SaO2). Because total cerebral haemoglobin 
remains constant during desaturation, [O2Hb] and [HHb] will change equally but in 
opposite direction, and their average is used in the equation as the differential 
haemoglobin signal (Hbdiff = ([O2Hb] – [HHb])/2). [cHb] is then derived from the 
relationship of the change in Hbdiff and SaO2. This relationship can be calculated 
using the slope method, which applies linear regression (Hbdiff = slope * SaO2 + 
constant) to determine the slope, which equals [cHb]. CBV is derived from [cHb] by 
multiplying with a constant k that incorporates brain density, cerebral-to-large-
vessel haematocrit ratio and unit conversion, and this result is divided by the 
subjects haemoglobin [Hb] concentration:
CBV(mL 100 g–1) = k * [cHb]/[Hb]
Statistical analysis
All CBV tests were processed regardless of their quality, except for those instances 
where CBV could not be calculated due to a disturbance in either the NIRS signal 
4
The lower part of the graph shows the saturation curve, identifying the period of desaturation. The upper part shows 
the effect of desaturation on the parameters measured by NIRS, oxygenated and deoxygenated haemoglobin.  
The dotted lines mark the manually chosen points for the calculation of CBV using the slope method (see the text  
for details).
Figure 2  Example of a CBV measurement.  
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The results for repeatability are demonstrated in table 2. We found no difference in 
repeatability between the three sets, or between the two measurement sites, and 
therefore all measurements were pooled. The CV for these pooled data was 12.5% 
(95% CI: 9.3–15.8%). A Bland–Altman plot is presented in figure 3. 
Results
Group values (mean ± SD) for cHb were 28.3 ± 9 μmol L–1. The results of the CBV 
measurements are summarized in table 1. The CBV for the whole group was 0.98 ± 
0.38 mL 100 g–1. There was a small and non-significant difference between the CBV 
in the first and last set (–0.1 mL 100 g–1, p = 0.2). Mean etCO2 was 34.7 ± 3.6 
mmHg during baseline and 34.8 ± 4.2 mmHg during desaturation. The average 
mean arterial pressure (MAP) was 75.7 ± 9.5 mmHg during baseline and 78.9 ± 9.9 
mmHg during desaturation (p = 0.034). 
4Table 1
Table 2
  Age  CBV (mL 100 g–1)
Subject Gender (years) Baseline 20 min 40 min ≥ 1 week 
 1 Female 70 0.52 0.56 0.51 0.52
 2 Female 68 1.28 0.96 1.11 0.47
 3 Female 70 0.64 0.86 0.81 0.61
 4 Female 73 0.77 0.80 0.77 0.89
 5 Male 69 1.20 1.06 1.05 1.17
 6 Male 70 Missing 0.63 0.54 1.04
 7 Male 68 1.06 1.25 1.39 1.23
 8 Male 75 0.84 0.77 0.80 1.00
 9 Male 69 1.17 1.29 1.11 1.00
 10 Male 82 1.21 1.08 0.91 1.03
 11 Male 74 0.87 0.64 0.50 Missing
 12 Male 70 1.30 1.32 1.10 1.47
 13 Male 73 1.76 1.27 1.56 1.33
 14 Male 75 1.16 1.46 1.42 1.35
 15 Male 75 0.65 0.68 0.58 1.17
 16 Male 87 0.84 0.68 0.59 0.88
  Mean 73 1.02 0.96 0.92 1.01
  SD 5.2 0.33 0.29 0.34 0.30
  Min 68 0.52 0.56 0.50 0.47
  Max 87 1.76 1.46 1.56 1.47
Summary of individual data for age, gender and CBV values. This table provides age and CBV values for all subjects, 
as well as mean values for the whole group. Three sets of two CBV measurements were performed with intervals of 
20 min, 40 min and more than 1 week. Each CBV value represents the average of the two CBV measurements in that 
particular set. Missing values are uninterpretable CBV measurements.
Optode  Missing  CBV-set 1 CV (%) CBV-set 2 CV (%) CBV-set 3 CV (%)
position values (95% CI) (95% CI) (95% CI)
Frontal 8 11.8 (5.9–17.6) 11.7 (7.4–16.1) 11.0 (5.2–16.8)
Parietal 15 10.9 (6.3–15.5) 14.3 (5–23.6) 17.3 (8.7–25.9) 
Coefficients of variation (CV) for repeated CBV tests, expressed as mean values with 95% confidence interval.  
The first pair of CBV tests (CBV-set 1) was recorded at the baseline, the second (CBV-set 2) was performed after  
20 min of supine rest, and the third (CBV-set 3) after 40 min of supine rest, interrupted midway by a tilt test for 5 min. 
Missing values are reported as the percentage of the total number of CBV-sets (48) that were collected.
Analysis as proposed by Bland and Altman of repeated CBV tests calculated using the slope method (see the text for 
details). In 16 subjects, six sets of two repeated (interval: 1 min) CBV measurements were performed. The average of 
these two measurements is plotted against their difference
Figure 3 Repeatability of CBV tests.   
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Discussion
The main finding of our study is that CBV measurements with NIRS can be 
performed with the same reliability in old subjects as they can in other age groups. 
Repeatability in our study resulted in a CV of 12.5%, which is almost equivalent to 
the CV of 11.7% that was found for this method in adults and the CV of 11.5% that 
was found in neonates.10,11 Of note, the study of Van de Ven et al was performed in 
our institution using identical equipment and methodology. These investigators 
have discussed the differences with reproducibility results from studies using other 
methodology.10 
An important new outcome of our study is that, even with a prolonged interval of 
several weeks, measurements of CBV with NIRS in this age group of healthy elderly 
subjects were reproducible with a CV of 15%, and showed an acceptable correlation. 
Over such a period, individual CBV is subject to considerable physiological change. 
The option to perform repeated measurements of CBV over time with a non-invasive 
method like NIRS offers an interesting perspective for cerebrovascular research.
The reproducibility of CBV measurements with NIRS in our study compares 
favourably to other methods. For example, PET measures CBV with a CV of 20% 16, 
and MRI measures CBV with a CV of 14% 17.
The fact that we did not validate our NIRS measurements with a second method to 
determine CBV is a limitation in the design of this study. However, even though there 
are several methods available to measure CBV, none of these can actually serve as 
a gold standard. Haemodynamic measurements with NIRS in animals, neonates 
and adults have been compared with MRI, immunolabelling, jugular venous 
occlusion plethysmography and PET.18-21 The correlation between the two methods 
studied varied from very poor to excellent. Only one of these studies, comparing 
NIRS with MRI, actually used the desaturation method to determine CBV. In this 
study, the group mean value for CBV obtained with NIRS was similar to that found 
with MRI, but intra-individual correlation between the two methods was poor.21 
We judged that validation with a second neuroimaging tool that cannot serve as 
a gold standard would yield little extra information for the purpose of our 
reproducibility study.
The mean CV for the third set of repeated CBV tests, which was obtained 20 min 
after a tilt table intervention, was not significantly different from that of previous CBV 
sets. Pearson’s correlation coefficient for the repeated tests was R = 0.81, p < 0.001. 
11 out of 96 sets (11%) could not be analysed because either or both CBV tests were 
uninterpretable. 
For short-term reproducibility, we found a good correlation between the three CBV 
values (R > 0.8, p = 0.01), and the CV was 11.7% (95% CI: 8.3–15%). For the 
CBV values obtained on different days (with an interval of two or more weeks), 
correlation was acceptable (R=0.5, p=0.05) and the CV was 15% (95% CI 5–25%). 
A Bland–Altman plot for long-term reproducibility is presented in figure 4.
The quality of a measurement using the slope method can be expressed by the 
linear correlation coefficient (r2) of the relationship between the changes in Hbdiff 
and SaO2. Mean r2 for our measurements was 0.92 ± 0.05. We found a correlation 
between the goodness of fit (a high value for r2) and the CV (R = 0.3, p = 0.05). 
All CBV values with r2 > 0.95 had a CV of 10% or less.
4
Analysis as proposed by Bland and Altman. In 16 subjects, CBV was determined twice with an interval of more than  
2 weeks. The average of the two CBV values is plotted against their difference.
Figure 4 Long-term reproducibility of CBV measurements.   
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(±15.1) years.16 The study of Van de Ven et al, using NIRS, found a mean CBV value 
of 3.66 ± 0.82 mL 100 g–1 in a group of adults with a mean age of 31 ± 10 years. 
Future studies are needed to further investigate the low CBV values we found in our 
age group. Despite similar brain geometry in young and ageing subjects, a 
reduction with ageing in the deoxyhaemoglobin response to cortical activation was 
apparent both with NIRS and fMRI in a previous study.7 One of many possible 
explanations for this finding is a reduced cortical haemoglobin content with ageing. 
A future study using different source-detector distances and measuring brain 
geometrics with MRI may serve to confirm in a larger group that there is no evidence 
for reduced brain tissue sample due to brain atrophy. In addition, a study 
investigating a larger, intermediate age group may demonstrate if a true reduction 
of CBV measured by NIRS age occurs with advancing age.
Conclusion
The O2-method to measure changes in CBV with NIRS can be applied in subjects 
aged 65 years and older. Despite many possible sources of variation in older 
subjects, including reduced global cerebral perfusion, brain atrophy and altered 
respiratory physiology, we found that reproducibility in our study was comparable 
to investigations in younger subjects. We conclude that NIRS is a safe and reliable 
tool to monitor changes in CBV in cerebrovascular research in the ageing 
population.
A potential problem with the desaturation method is that it could influence CBV. 
Prolonged hypoxia, especially around or below a SaO2 of 80%, can induce 
vasodilatation and increase CBF and CBV. On the other hand, desaturation could 
produce compensatory hyperventilation, which causes vasoconstriction and 
reduces CBF. In our study, we found no evidence for hyperventilation during 
desaturation, as etCO2 remained stable. Blood pressure rose slightly during 
desaturation, which is consistent with previous investigations. Because we performed 
paired CBV measurements with a short interval, any substantial effect of the 
desaturation procedure itself on CBV would result in the second CBV measurement 
being systematically higher or lower than the first. We did not find such an effect in 
our study. In addition, we constantly monitored the total haemoglobin concentration 
measured by NIRS, which did not change during our desaturation procedures.
We did not investigate the possible effects of altered brain geometry with ageing on 
the outcome of CBV measurements. For instance, brain atrophy with ageing would 
increase the depth of the cerebral tissue relative to the probes. This could 
unfavourably affect the relative contribution of extracerebral tissue to the NIRS 
signal. In order to investigate this, a method comparing different source-detector 
distances would be needed. Kohri et al.22 for example demonstrated that with 
source-detector distances of 3 cm, the cerebral tissue contributed to 55% of the 
signal, versus 69% when using a 4 cm distance. We did not investigate these 
aspects in this study for several reasons. First, we wished to compare results 
directly with the previous study by Van de Ven et al in younger subjects, using an 
identical technique. Second, the source-detector distance used with the 
Oxymon-device is 5.5 cm, which is larger than is generally available in other NIRS 
devices, and represents the optimal distance for this device to minimize noise from 
extra-cerebral tissues. Third, a previous study in our laboratory has measured the 
depth between NIRS optodes and cerebral cortical tissue using MRI in a small 
group of young (35 ± 9 years) and ageing (73 ± 3 years) subjects, and found no 
evidence for an increase with ageing.7 
Possibly related to this matter is the finding of low CBV values in our group. 
Even though estimation of individual values for CBV was not the primary focus of 
this study, this finding merits further discussion. For comparison, mean CBV 
determined by PET was 3.8 ± 0.7 mL 100 g–1 in a group with a mean age of 51.8 
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Chapter 5
Transcranial Doppler estimation of cerebral 
blood flow and cerebrovascular conductance 
during modified rebreathing
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Abstract
Clinical transcranial Doppler assessment of cerebral vasomotor reactivity (CVMR) 
uses linear regression of cerebral blood flow velocity (CBFV) vs. end-tidal CO2 
(PETCO2) under steady-state conditions. However, the cerebral blood flow (CBF)-
PETCO2 relationship is nonlinear, even for moderate changes in CO2. Moreover, 
CBF is increased by increases in arterial blood pressure (ABP) during hypercapnia. 
We used a modified rebreathing protocol to estimate CVMR during transient breath-
by-breath changes in CBFV and PETCO2. Ten healthy subjects (6 men) performed 
15 s of hyperventilation followed by 5 min of rebreathing, with supplemental O2 to 
maintain arterial oxygen saturation constant. To minimize effects of changes in ABP 
on CVMR estimation, cerebrovascular conductance index (CVCi) was calculated. 
CBFV-PETCO2 and CVCi-PETCO2 relationships were quantified by both linear and 
nonlinear logistic regression. In three subjects, muscle sympathetic nerve activity 
was recorded. From hyperventilation to rebreathing, robust changes occurred in 
PETCO2 (20–61 Torr), CBFV (-44 to +104% of baseline), CVCi (-39 to +64%), and 
ABP (-19 to +23%) (all P < 0.01). Muscle sympathetic nerve activity increased by 
446% during hypercapnia. The linear regression slope of CVCi vs. PETCO2 was less 
steep than that of CBFV (3 vs. 5%/Torr; P = 0.01). Logistic regression of CBF-PETCO2 
(r2 = 0.97) and CVCi-PETCO2 (r2 = 0.93) was superior to linear regression (r2 = 0.91, 
r2 = 0.85; P = 0.01). CVMR was maximal (6–8%/Torr) for PETCO2 of 40–50 Torr. 
In conclusion, CBFV and CVCi responses to transient changes in PETCO2 can be 
described by a nonlinear logistic function, indicating that CVMR estimation varies 
within the range from hypocapnia to hypercapnia. Furthermore, quantification of the 
CVCi-PETCO2 relationship may minimize the effects of changes in ABP on the 
estimation of CVMR. The method developed provides insight into CVMR under 
transient breath-by-breath changes in CO2.
Introduction
The prominent cerebral blood flow (CBF) responses to changes in arterial CO2 are 
a unique characteristic of the cerebral vasculature.1,2 These responses have been 
quantified to reflect cerebral vasomotor reactivity (CVMR)3, even though the 
underlying mechanisms are still not completely understood.4 With the advent of 
transcranial Doppler (TCD) for measurement of CBF velocity (CBFV) with high 
temporal resolution, the Doppler-CO2 test of CVMR has become a widely adopted 
method in research and clinical practice practice. Research exploring the 
physiological characteristics of CVMR has demonstrated that the relationship 
between arterial CO2 and CBF is nonlinear and that this relationship is affected by 
CO2-induced changes in arterial blood pressure (ABP).3,5-12 In addition, the control 
mechanisms that govern the responses of CBF and ABP to CO2 have dynamic 
properties.5,9,11 Despite these complexities associated with the CBF-CO2 relationship, 
measurement of CVMR has been widely applied in clinical practice to evaluate 
cerebral vascular function, e.g., in patients with carotid artery stenosis or 
hypertension.3,13-15 These clinical studies have quantified CVMR using linear 
regression of steady-state responses of CBF to changes in CO2, without incorporation 
of the effects of ABP. The likely reason for this simplicity is that well-controlled 
experiments and complex modeling methods may not be practical for clinical 
use.9,16 In this regard, development of a new method that is clinically applicable and 
may assess CVMR reliably under conditions of breath-by-breath changes in 
end-tidal CO2 (PETCO2) is warranted. 
We used a modified rebreathing protocol, consisting of a period of voluntary 
hyperventilation, followed by rebreathing, to obtain a wide range of changes in 
PETCO2 to assess CVMR under breath-by-breath conditions.17 We hypothesized that 
the CBF-PETCO2 relationship is nonlinear during transient changes in PETCO2. 
In addition, we speculated that measurement of cerebrovascular conductance 
index (CVCi) during this process may reveal direct effects of changes in ABP on 
CBF, leading to a more precise estimation of CVMR based on the CVCi-PETCO2 
relationship. Finally, to explore the underlying mechanisms of increases in ABP 
during hypercapnia, we recorded muscle sympathetic nerve activity (MSNA) in 
three subjects in this study.
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Instrumentation and data acquisition. The middle cerebral artery (MCA) was 
insonated with a 2-MHz pulsed Doppler ultrasound system (Multi-Dope X2; DWL). 
The probe was securely attached to the cranium by a mold that was cast individually 
to fit the facial bone structure.21 In this way, the exact position and angle of the 
probe were preserved during the repeat tests.
Throughout the test, ABP was monitored noninvasively using a Finapres (Ohmeda 
2300) and was corroborated by concurrent electrosphygmomanometry (SunTech 
Medical) with measurements at intervals of 1 min. PETCO2 was recorded using a 
capnograph (POET TE; Criticare Systems), SaO2 was measured using a pulse 
oximeter (Biox 3700; Ohmeda), and heart rate (HR) was monitored with a three-lead 
ECG connected to a cardiotachometer (Quinton Instruments).
MSNA was recorded in three participants. MSNA signals were obtained by the 
microneurographic technique.22 Sympathetic bursts were identified by a computer 
program and then were confirmed by an experienced microneurographer. The 
number of bursts per minute (burst frequency) and the sum of the integrated burst 
area per minute (total activity) were used as quantitative indexes. Specifically, total 
activity was normalized to the baseline value (set at 100%) to reflect changes in 
sympathetic activity during CO2 stimuli. 
Data analysis. Off-line data analysis was performed with commercially available 
software (Acknowledge; BIOPAC Systems). For hyperventilation, the time delay 
between the onset of hyperventilation and the onset of changes in CBFV and ABP 
was measured. Similarly, at the end of rebreathing, the time delays for recovery 
between PETCO2, CBFV, and ABP were measured. Values for CBFV, ABP, and 
PETCO2 at the last minute of recovery were compared with their pretest baseline. 
Breathing cycles were identified from the respiratory CO2 signal. For each cycle, the 
corresponding value for PETCO2 and mean values for CBFV, ABP, and HR were 
measured. Averaging the number of cardiac cycles (usually 6) has been applied 
previously in an attempt to reduce respiratory hemodynamic variability.23 
We preferred to identify each respiratory cycle24 to derive the breath-to-breath 
CBFV-PETCO2 relationship. During the short breathing cycles in hyperventilation, an 
average of data from two cycles was used. Because CBFV is affected directly by 
changes in ABP2,5,6,10, CVCi was calculated by dividing mean CBFV by mean ABP 
Methods
Ten healthy subjects (4 women) with a mean age of 37 yr (SD 8), height 177 cm 
(SD 10), and weight 84 kg (SD 18) voluntarily participated in the study. Participants 
were nonsmokers, were not on any medication, and were normotensive. Participants 
were free of known cardiovascular, cerebrovascular, or respiratory disease. Each 
subject was informed of the experimental procedures and signed a consent form, 
approved by the Institutional Review Boards of the University of Texas Southwestern 
Medical Center and Presbyterian Hospital of Dallas. 
Protocol. Each participant visited the laboratory twice, 3–4 wk apart (in three 
participants, the time interval was 3–4 mo). All experiments took place in a quiet 
laboratory with a room temperature of 22°C. The subjects refrained from heavy 
exercise and caffeinated or alcoholic beverages at least 12 h before the tests. 
The study was conducted with the subjects in the supine position. Therefore, 
assessment of CVMR would be comparable with those obtained with other imaging 
technology.16 Participants wore a nose clip and breathed through a mouthpiece with 
a Y-valve, with one end connected to a 5-liter rubber bag and the other end open to 
room air. This system was held in place by an adjustable cable, rendering it 
practically weightless to avoid any discomfort for the subject. After at least 20 min 
of stabilization, 2 min of baseline data during spontaneous breathing were recorded 
on room air. A modified Read rebreathing protocol was used.17,18,19 The procedure 
contains a period of voluntary hyperventilation preceding rebreathing to obtain a 
wider range of CO2 changes. Specifically, a short period of 15 s of hyperventilation 
with a duty cycle of 1 s and maximal voluntary deep breaths were used. This short 
period of hyperventilation reduced PETCO2 to ~20 Torr but did not cause respiratory 
muscle fatigue or central hypoxia possibly associated with a prolonged 
hyperventilation as employed in the other rebreathing methods.18,19 At the end of a 
deep inspiration, the respiratory valve was switched to the empty bag and then the 
bag was filled with the subjects’ own breathing gas during expiration (with a PETCO2 
of ~20 Torr, comparable to a gas mixture with 2.6% CO2). Rebreathing was 
continued for 5 min, before returning to room air for recovery (4 min). During 
rebreathing, a small amount of oxygen was bled into the rebreathing bag at the 
subject’s basal metabolic rate (estimated using the Harris-Benedict formula) to 
maintain arterial oxygen saturation (SaO2) constant.20
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CBFV-CVMR0 and CVCi-CVMR0, respectively. In addition, to complement the 
assessment of CVMRmax with the derivative method, CVMR was estimated by the 
linear regressions in the steep part of the sigmoidal curves, and these results were 
defined as CBFV-CVMR1 and CVCi-CVMR1, respectively.
Statistics. The results of curve fitting were examined by the correlation coefficients 
(r 2) and by model residual analysis of individual data (SigmaPlot 8.02; SPSS). Thus 
individual data for r 2 as well as mean sum of squares were available for both linear 
and logistic curve fits, allowing comparisons of both methods using paired t-tests 
(SigmaStat 3.11; Systat Software). Comparisons of cerebral hemodynamics at 
baseline, during hyperventilation, and during rebreathing were made with one-way 
repeated-measures ANOVA. Comparisons between the estimates of CVMR by 
different methods were made with paired t-tests. Test-retest reproducibilities for 
curvefitting parameters and for CVMR estimation were examined by the analysis of 
typical error (the SD of the differences between the two tests divided by square root 
of 2), which was expressed as a coefficient of variation.26 Data are presented as 
means and SD, and a P < 0.05 was considered to be statistically significant.
within each breath cycle to reveal intrinsic vascular responses to changes in CO2. 
Furthermore, percent changes from baseline CBFV and CVCi values were calculated 
for data analysis. Data ranging from the nadir of PETCO2 during hyperventilation to 
the end of rebreathing were utilized for curve fitting to quantify the CBFV-PETCO2 
and CVCi-PETCO2 relationship.
A four-parameter logistic function was used for curve fitting25:
f(x) = y0 - 
a
  (1)
 
1+e[bx (x-x0)]
 
where f(x) represents percent changes in CBFV or CVCi (x representing PETCO2). 
The model parameter a represents the range of change in CBFV or CVCi, y0 is the 
maximum value of CBFV or CVCi during hypercapnia, x0 is the level of PETCO2 
where the first-order derivative of the logistic function (the slope of the curve) is 
maximal, and b is related to the overall curvilinear properties of the sigmoidal curve 
(Fig. 1). Nonlinear curve fitting was performed with a Marquardt-Levenberg 
algorithm for model parameter identification (SigmaPlot 8.02; SPSS). The selection 
of this model was based on the feature of curvilinear distribution of breath-by-breath 
changes in CBFV or CVCi vs. PETCO2 (Fig. 2) and the fact that model parameters of 
the selected logistic function have clear physiological implications, as shown in Fig. 1.25
The first-order derivative of the logistic function was calculated with the following 
equation:
f’(x) =  
a x b x e[bx (x-x0)]
 (2)
 {1+e[bx (x-x0)]}2 
This derivative function yields the specific CO2 sensitivity (or CVMR) for each 
PETCO2. At x = x0, CVMR becomes maximal (CVMRmax), and Eq. 2 becomes 
(a x b)/4. Of note, CVMRmax derived from the CBFV-PETCO2 relationship was 
denoted as CBFVCVMRmax and CVMRmax derived from the CVCi-PETCO2 
relationship was denoted as CVCi-CVMRmax.
For comparison, linear regressions of changes in CBFV and CVCi vs. PETCO2 were 
conducted for the entire range of changes in PETCO2, from the nadir of hyperventilation 
to the end of rebreathing. The slopes of these linear regressions were defined as 
5
a Total range of changes in cerebrovascular conductance index (CVCi) or cerebral blood flow velocity (CBFV); y0, 
maximum value; x0, level of end-tidal CO2 (PETCO2) that exhibits highest CO2 sensitivity; b curvilinear properties of  
the sigmoidal curve.
Figure 1  Schematic representation of a logistic function with 4 parameters  
to be identified.   
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Results
Changes in cerebral and systemic hemodynamics. All 10 participants completed 
the experimental protocol, so that 20 data sets were collected. Data from one test 
could not be used because of poor signal quality; hence, reproducibility results 
were available only for nine subjects. Representative changes in CBFV, ABP, 
PETCO2, HR, and MSNA are shown in Fig. 2. Individual values for SaO2 varied within 
the range of 96–100% during baseline breathing of room air and remained 
unchanged during rebreathing, owing to the supplementation of oxygen. There was 
a delayed response of CBFV (mean: 7 s, range 6 –10) and ABP (mean: 14 s, range 
5
ABP, arterial blood pressure; HR, heart rate; MSNA, muscle sympathetic nerve activity. Note the significant increases 
in ABP and MSNA, concurrent with the increase in CBFV during rebreathing. Arrows indicate start and end of  
hyperventilation and rebreathing periods.
Figure 2  A typical recording of baseline, hyperventilation, rebreathing, and 
recovery in 1 subject.   
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The group-averaged data of changes in CBFV and CVCi as well as logistic 
regression of pooled data for all subjects are shown in Fig. 4. Because there were 
no significant differences between results from the first and second tests, all data 
were used in the pooled data analysis. Logistic regression of individual data 
demonstrated an excellent curve-fitting result (mean r 2 = 0.95, SD 0.04; average of 
mean sum of squares = 37, SD 19), superior to the use of linear regression (mean 
r 2 = 0.88, SD 0.06; average of mean sum of squares = 85, SD 51; P<0.01) for both 
the CBFV-PETCO2 and the CVCi-PETCO2 relationships. Specifically, logistic 
regression was performed well in all 18 tests for changes in CBFV (r 2 = 0.97, SD 
0.02) and in 16 of 18 tests for CVCi (r 2 = 0.93, SD 0.06). In those two cases of CVCi 
for which logistic regressions could not be performed reliably, linear regressions 
yielded an r 2 of 0.71 and 0.76 for CBFV and CVCi, respectively. 
 
Table 2 shows the group-averaged model parameters and the calculated CVMR 
indexes derived, respectively, from the logistic and linear regressions. Over the 
entire range of changes in PETCO2, the linear regression slope of changes in CVCi 
(CVCi-CVMR0) was significantly smaller than that of CBFV (CBFV-CVMR0). The 
12–16) to changes in PETCO2 during hyperventilation. Correction for the time delay 
did not significantly alter the result of data analysis. Because the physiological 
validity of applying a time correction for CVMR estimation was uncertain, analysis 
of the raw (uncorrected) data is presented. After the rapid return of PETCO2 to the 
pretest baseline level at the onset of recovery, a considerable time delay was 
observed for the ensuing recovery of CBFV (mean: 21 s, range 14–35) and of ABP 
(mean: 22 s, range 12–30). However, this delay did not influence the data analysis 
because the recovery period was not included in the models used to assess CVMR 
in this study. Whereas ABP gradually returned to the pretest baseline after 
rebreathing, CBFV displayed an undershoot and then gradually returned to a 
sustained level, which was below the pretest baseline level (mean: 81% of baseline, 
range 65–90), even at the end of the 4 min of recovery. On average, PETCO2 was 
reduced by 22 Torr during hyperventilation and increased by 20 Torr during 
rebreathing from the pretest baseline (P < 0.001). 
These changes in PETCO2 resulted in a respective reduction of CBFV by 46% and 
an increase by 104% relative to the baseline (P<0.001). CVCi fell by 39% during 
hyperventilation and increased by 64% during rebreathing (P < 0.001). Of note, ABP 
was reduced by 19% during hyperventilation and augmented by 23% during 
rebreathing (P<0.01). During rebreathing, increases in ABP appeared to be 
proportional to increases in PETCO2 but leveled off at high levels of PETCO2 (Fig. 2). 
HR increased by 29% during hyperventilation and by 14% during rebreathing 
(P<0.01) (Fig. 2, Table 1).
In the three subjects that underwent recording of MSNA, averaged burst frequency 
increased from 24 at baseline to 30 bursts/min during hyperventilation, and total 
nerve activity increased by 166% (P=0.01). MSNA returned rapidly to baseline after 
cessation of hyperventilation and subsequently increased to 41 bursts/min and 
446% for total nerve activity during the last minute of rebreathing (P=0.01; Fig. 2). 
Changes in MSNA were similar in all three subjects.
Curve-fitting and model parameters. Figure 3 depicts the representative results 
of sigmoidal curve fitting of the CBFV/CVCi-PETCO2 relationship in one subject. 
The specific CVMR derived from the first-order derivative of the logistic function is 
also plotted. 
5
Sigmoidal curve represents the result of logistic regression; the dotted bell-shaped curve is the first-order derivative of 
the identified logistic function. Linear regression was performed in the steep portion of the sigmoidal curve to estimate 
cerebral vasomotor reactivity (CVMR), using CBFV and CVCi as the dependent variables, respectively.
Figure 3  Typical data of logistic regression of %changes in CBFV and CVCi to 
changes in end-tidal CO2 (PETCO2) in 1 subject.   
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wide range of breath-by-breath changes in PETCO2 (~20–61 Torr) and corresponding 
changes in CBFV, CVCi, and ABP. 
The main findings of this study are twofold. First, consistent with our hypothesis, 
transient, breath-by-breath responses of both CBFV and CVCi to changes in PETCO2 
demonstrate nonlinear properties that can be quantified by a logistic function. 
Second, the magnitude of increases in CBFV during hypercapnic rebreathing 
exceeded CVCi (104% vs. 64%) because of the presence of significant increases in 
ABP by 23%. Consistently, during hypocapnic hyperventilation, the reduction in CBFV 
(46%) surpassed CVCi (39%), whereas ABP fell by 19%. These observations suggest 
that changes in ABP during CO2 stimuli have direct effects on CBF.
Study limitations. The reproducibility of model parameters and estimates of CVMR 
are comparable with other Doppler-CO2 tests.3,27,28 Nonetheless, the coefficient of 
variation of the model parameter b was relatively large compared with the other 
parameters (Table 2). Parameter b reflects the overall curvilinear properties of the 
sigmoidal curve. Therefore, estimation of parameter b may have been affected by 
the lack of precise control of levels of PETCO2 reached during voluntary 
hyperventilation between the tests. The technique of dynamic end-tidal forcing may 
steep ranges of the sigmoidal curves were found to lie between 40 and 50 Torr 
PETCO2 for most subjects (Figs. 3 and 4). As expected, in the steep ranges of the 
sigmoidal curves, linear regression slopes of changes in CBFV (CBFV-CVMR1) and 
CVCi (CVCi-CVMR1) were similar to those obtained from the first-order derivatives 
of the identified logistic function (CBFV-CVMRmax and CVCi-CVMRmax, 
respectively). Of note, both CVMRmax and CVMR1 were higher than the estimates 
of CVMR from the linear regressions over the entire range of changes in PETCO2 
(CVMR0). Finally, for test-retest reproducibility, coefficients of variation for 
curve-fitting parameters and for estimates of CVMR are presented in Table 2.
Discussion
We have developed a clinically applicable method to assess CVMR that addresses 
the nonlinear relationship and interactions between transient changes in CO2, 
CBFV, and ABP. Based on a modified rebreathing method, we have observed a 
5
Sigmoidal curve represents the result of logistic regression of pooled group data from all subjects (parameters for 
CBFV: a = 140%, y0 = 198%, x0 = 47 Torr, b = 0.20 Torr -1; parameters for CVCi: a = 102%, y0 = 169%, x0 = 47 Torr, 
b = 0.16 Torr -1; note that these values are similar to the parameters obtained by averaging the individual curve fitting 
results as listed in Table 2). Dots and error bars, Group averages and SDs, respectively, for CBFV (%) and CVCi (%) 
within 5-Torr ranges of PETCO2 (e.g., 20–25 25–30, etc.).
Figure 4  Group (n = 10) averaged results for logistic regression of percent 
changes in CBFV and CVCi to changes in PETCO2.   
Table 2  Estimation of Logistic Function Parameters and CVMR.
 CBFV-PETCO2 CV,% CVCi-PETCO2 CV,%
 a, %    149 ± 34 17 99 ± 29* 26
 y0, % 202 ± 35 10 166 ± 30* 11
 x0, Torr 47 ± 2 6 46 ± 2 4
 b, Torr-1 0.22 ± 0.06 36 0.28 ± 0.09 58
 CVMRmax, %/Torr 8 ± 2† 23 6 ± 2† 31
 CVMR0 , %/Torr 5 ± 1 18 3  ± 1* 18
 CVMR1, %/Torr 7 ± 1† 9 6 ± 1*† 26
Values are mean ± SD, from 10 subjects. CV: coefficient of variation. CBFV: cerebral blood flow velocity; a, y0, x0, 
and b, identified logistic function parameters (Fig 1). CVMRmax: maximal cerebral vasomotor reactivity (CVMR), 
peak value of the first-order derivative of the identified logistic function. CVMR0: linear regression slope  
of  percentage changes in CBFV over the entire range of changes in PETCO2. CVMR1: linear regression slope of 
CBFV vs. PETCO2 in the steep portion of the sigmoidal curve.
* p < 0.01 for difference in parameters between CBFV-PETCO2 and CVCi-PETCO2. 
† p < 0.01 for CVMR0 vs. CVMRmax and CVMR1.
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In the present study, we found that estimates of CVMR based on CBFV (during either 
hyper- or hypocapnia) exceeded those based on CVCi. For example, model parameters 
a and y0 (which reflect the range and maximal changes in CBFV and CVCi, respectively) 
derived from the CBFV-PETCO2 relationship were significantly higher than those 
obtained from the CVCi-PETCO2 relationship. Likewise, linear regressions resulted in 
higher values for CVMR when derived from CBFV instead of CVCi. 
According to Ohm’s law, the much higher increases in CBFV (104%) during 
hypercapnia relative to the increases in CVCi (64%) could be attributed to the 23% 
increase in ABP. Consequently, increases in ABP led to an overestimation of CVMR 
based on the linear regression of changes in CBFV vs. PETCO2 (CBFV-CVMR0) 
(Table 2).6 Together, these findings suggest that the net CBF responses to acute 
hypercapnia in humans are dominated by an overwhelming vasodilatory effect of 
CO2, which impairs cerebral autoregulation and thereby enhances the effects of 
ABP on CBFV.
Estimation of CVCi. This study applies changes in cerebrovascular conductance 
to assess CVMR during transient changes in PETCO2. The use of CVCi, in contrast 
to changes in CBFV, may better reflect the physiological process of cerebral 
vasodilatation during hypercapnia and cerebral vasoconstriction during hypocapnia. 
When an index of cerebrovascular resistance (the inverse of conductance) is used 
rather than CBFV to assess CVMR, the outcome was less influenced by changes in 
ABP.6 However, the use of resistance, rather then its inverse conductance, to assess 
CVMR may lead to difficulties in data interpretation, especially under conditions with 
increased CBF.49 Because of their reciprocal relationship, in a condition where 
resistance is low and blood flow is high, a large increase in conductance 
(vasodilatation) leads to only a small (further) decrease in resistance. Therefore, if 
vasomotor responses are estimated from changes in resistance, such a small 
decrease in resistance could be falsely interpreted to represent a small increase in 
vasodilatation. Because CVMR testing generates high blood flow, conductance 
rather than resistance was used in this study. 
Alternatively, studies have analyzed the ABP-CBFV relationship within each cardiac 
cycle and used linear extrapolations to calculate the zero-flow pressure (also known 
as critical closing pressure) or resistance-area product indexes.24,50,51 Hypocapnia 
provide much better control of PETCO2 to improve the reproducibility of model 
parameter’s estimation.29 An additional limitation, inherent to the use of TCD, is that 
CBFV was measured to reflect changes in CBF. The TCD method has been well 
validated against other modalities used to measure CBF.30-32 However, changes in 
CBFV reflect changes in CBF only if the diameter of the insonated MCA remains 
constant. Direct and indirect measurements of the MCA diameters and comparisons 
of changes in CBFV with changes in CBF measured by different modalities during 
either hypo- or hypercapnia suggest the validity of using TCD.33,34 We cannot 
exclude the possibility that a vasodilatation in the MCA may occur at high levels of 
CO2.35 If this were the case, the magnitude of maximal changes in CBF may have 
been underestimated by the measurement of CBFV during hypercapnia. However, 
the maximum changes in CBFV at a PETCO2 level of 60 Torr (~100% above baseline) 
are consistent with results of direct measurements of CBF in other studies with a 
similar level of changes in CO2.2,7
Magnitude of changes in CBFV and ABP. We found marked changes in CBFV 
with a range of nearly 150% from hyperventilation to rebreathing, with rebreathing 
accounting for an estimated doubling of baseline CBF. This range of changes in 
CBF is comparable with those found in other studies using TCD or other techniques 
to measure CBF.2,7,19,29,36,37 Prominent CBF responses to arterial CO2 are well 
established.2-4,12 These changes in CBF have been attributed mainly to cerebral 
vasodilatation during hypercapnia and vasoconstriction during hypocapnia.38,39
However, changes in arterial CO2 elicit complicated autonomic reflexes and exert 
vascular effects not only in the cerebral but also in the systemic circulation.40,41 ABP 
increases substantially even during moderate increases in arterial CO2, due largely 
to sympathetic activation5,10,42,43, which clearly occurred in our study as well. 
This chemoreflexmediated sympathetic activation may have confounding and 
opposing effects for the cerebral circulation, especially in the setting of CO2-induced 
cerebral vasodilatation. For example, systemic hypertension may increase CBF 
prominently when normal autoregulatory mechanisms are impaired by CO2.6,8,44 
Conversely, sympathetic activation in the brain may restrain CO2-induced 
vasodilatation39,45-47, although it is less certain whether such effects occur consistently 
in humans.48 Both of these opposing effects will influence the measurement of 
CVMR during rebreathing. 
5
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have reached its maximal levels at or greater than a PETCO2 of 60 Torr.3,12 Second, 
substantial sympathetic activation may constrain the magnitude of the CBFV 
responses.39,45,48
With the onset of recovery, PETCO2 returned rapidly to the pretest baseline level 
within ~1–2 breaths of room air (<10 s). However, there was a substantial time delay 
of ~20 s for CBFV to reach a new sustained level, which was lower than the pretest 
baseline value. Of note, ABP returned to the pretest baseline level without a similar 
undershoot. These data suggest a sustained cerebral vasoconstriction during 
recovery from prolonged acute hypercapnia. In addition, these data confirm that 
adaptive processes modify the response in both ABP and CBF to CO2, leading to 
limitations in the use of steady-state data to estimate CVMR.7,52 However, the time 
delay in the recovery of CBFV appears to be much longer than that reported with a 
step change in CO2 (6 s).29 These discrepancies might be related to the differences 
in the duration as well as the intensities of CO2 stimuli used.
Assessment of CVMR. A sigmoidal distribution of data was present in most 
subjects when breath-by-breath changes in CBFV were plotted against PETCO2. 
Furthermore, similar distributions were observed for changes in CVCi, indicating the 
presence of threshold and saturation properties of cerebrovascular changes in 
response to transient changes in PETCO2, providing further evidence for the 
nonlinear properties of CBF responses to changes in CO2.3,12,29,52,53 However, the 
specific physiological mechanisms underlying the nonlinear CBF-CO2 relationship 
cannot be determined in the present study.
Data with a sigmoidal distribution could be fitted equally well with several nonlinear 
functions based on the norm of least-square curve-fitting procedures.12 A modified 
logistic function was employed for curve fitting.25 Compared with other curve-fitting 
methods, one advantage of the logistic function used in this study is that the model 
parameters identified have clear physiological meanings (Fig. 1). In addition, the 
first-order derivative of the identified logistic function readily provides an estimation 
of CVMR for each level of PETCO2.
The linear regression slope of the CBFV-PETCO2 relationship (CVMR0, 5%/Torr) over 
the entire range of changes in PETCO2 is consistent with previous findings. 2,7,29,54 
increases and hypercapnia reduces zero-flow pressure; therefore, changes in these 
indexes may serve as alternative measures to assess cerebrovascular responses to 
CO2.23,24 Whereas the clinical relevance of assessment of CVMR has been 
demonstrated in follow-up studies in patients at risk for cerebrovascular events14,15, 
similar findings have not been reported for zero-flow pressure or resistance-area 
product parameters.
Temporal characteristics of changes in CBFV and ABP. The CBF response to 
transient changes in CO2 has a time delay of ~5–7 s.9,52 It is therefore of interest to 
consider whether this factor could affect the estimation of CVMR using the proposed 
modeling. Identification of the time delay between transient changes in CBF and 
PETCO2, as performed in these studies, requires complex and stringent control of 
respiration and CO2 levels. However, in the present study, we are able to approximate 
the time delay between changes in PETCO2, CBFV, and ABP based on the individual 
data from each subject. The average time delay of the reduction in CBFV in 
response to the reduction in PETCO2 during hyperventilation was ~7 s, consistent 
with the reported time delay after a negative step change in PETCO2 (6.8 s) 52 and 
with a time delay of ~5 s found when spontaneous CO2 oscillations were analyzed.11 
This time delay is possibly explained by CO2 transportation time.53 The identification 
of a similar time delay during hypercapnic rebreathing is less evident because, as 
can be seen in Fig. 2, rebreathing caused a ramplike increase in PETCO2. Despite 
the time delay between transient changes in CBFV and CO2, it had little effect on 
the estimation of CVMR. With a total duration of hyperventilation of 15 s, a (short) 
plateau phase with minimum and stable CO2 and CBFV values was reached in all 
individuals. Values at the end of hyperventilation (i.e., in this plateau phase) were 
used as a starting point for calculation of CVMR. Therefore, “correction” for the time 
delay did not affect the modeling and data outcome. Similarly, the observed 
reduction in ABP during hyperventilation also showed a time delay, lagging behind 
the changes in CBFV by an additional 7 s. This delayed response in ABP may partly 
explain why there was a smaller difference between changes in CVCi and CBFV 
during hyperventilation when compared with hypercapnic rebreathing.
During rebreathing, CBFV increased steadily, associated with a continuous increase 
in PETCO2, and then appeared to level off at high levels of PETCO2. Two mechanisms 
may have contributed to the saturation of CBFV. First, cerebral vasodilatation may 
5
120 121
References
 1.  Ainslie PN, Ashmead JC, Ide K, Morgan BJ, Poulin MJ. Differential responses to CO2 and 
sympathetic stimulation in the cerebral and femoral circulations in humans.  
J Physiol 2005;566:613–624.
 2.  Kety S, Schmidt C. The effects of altered arterial tensions of carbon dioxide and oxygen on 
cerebral blood flow and cerebral oxygen consumption of normal young man.  
J Clin Invest 1948;27:484–492.
 3.  Ringelstein EB, Sievers C, Ecker S, Schneider PA, Otis SM. Noninvasive assessment of 
CO2-induced cerebral vasomotor response in normal individuals and patients with internal 
carotid artery occlusions. Stroke 1988;19:963–969.
 4.  Hurn P, Traystman RJ. Changes in arterial gas tension. In: Edvinsson L, Krause D (eds). 
Cerebral Blood Flow and Metabolism.  
Philadelphia, PA: Lippincott Williams & Wilkins, 2002: 384–394.
 5. Dumville J, Panerai RB, Lennard NS, Naylor AR, Evans DH. Can cerebrovascular reactivity be 
assessed without measuring blood pressure in patients with carotid artery disease?  
Stroke 1998;29: 968–974.
 6. Edwards MR, Topor ZL, Hughson RL. A new two-breath technique for extracting the 
cerebrovascular response to arterial carbon dioxide. Am J Physiol Regul Integr Comp 
Physiol 2003;284: R853–R859.
 7.  Ellingsen I, Hauge A, Nicolaysen G, Thoresen M, Walloe L. Changes in human cerebral blood 
flow due to step changes in PaO2 and PaCO2. Acta Physiol Scand 1987;129:157–163.
 8.  Harper AM, Glass HI. Effect of alterations in the arterial carbon dioxide tension on the blood 
flow through the cerebral cortex at normal and low arterial blood pressures.  
J Neurol Neurosurg Psychiatry 1965;28:449–452.
 9. Mitsis GD, Ainslie PN, Poulin MJ, Robbins PA, Marmarelis VZ. Nonlinear modeling of the 
dynamic effects of arterial pressure and blood gas variations on cerebral blood flow in 
healthy humans. Adv Exp Med Biol 2004;551:259–265.
 10. Panerai RB, Evans DH, Naylor AR. Influence of arterial blood pressure on cerebrovascular 
reactivity. Stroke 1999;30:1293–1295.
 11. Panerai RB, Simpson DM, Deverson ST, Mahony P, Hayes P, Evans DH. Multivariate dynamic 
analysis of cerebral blood flow regulation in humans.  
IEEE Trans Biomed Eng 2000;47:419-423.
 12. Reivich M. Arterial PCO2 and cerebral hemodynamics. Am J Physiol 1964;206:25–35.
 
However, this method of analysis, although practical, evidently underestimates the 
maximal cerebral vasodilatory effect of CO2, as indicated by the estimates of 
CVMRmax using either the first-order derivatives of the identified logistic function 
(8%/Torr) or the specific linear regressions in the steep portion of sigmoidal curves 
(7%/Torr) (Table 2).
The inflection point of the logistic function (parameter x0), which corresponds to the 
maximal rate of changes in CBFV or CVCi to CO2 (CVMRmax), was almost identical 
for both the CBFV-PETCO2 and CVCi-PETCO2 relationships (Table 2). This 
demonstrates that CVMRmax occurs during moderate hypercapnia, slightly above 
the baseline level of PETCO2, consistent with previous studies suggesting that 
estimation of CVMR is lower during hypocapnia than during hypercapnia.6,19,29,36
Previous studies have used similar rebreathing methods to estimate CVMR.19,37,54,55 
However, these studies investigated only the hypercapnic stimuli and used linear 
regressions to derive a CVMR from 2.8 to 5.2%/Torr.37,54,55 Only one study included 
the hypocapnic range using hyperventilation before rebreathing and applied a 
bilinear model, resulting in a smaller CVMR in the hypocapnic range than in the 
hypercapnic range (1.6 vs. 2.8 cm·s -1·Torr -1).19 Direct comparisons to these previous 
findings are difficult because hypoxic and/or hyperoxic conditions were also 
employed in these studies.
In conclusion, a clinically applicable rebreathing method was developed to assess 
CVMR during transient changes in PETCO2. We found that both CBFV and CVCi 
responses to transient changes in PETCO2 are nonlinear and that these responses 
can be quantified well by a modified logistic function. Furthermore, we found that 
the magnitude of change in CBFV during CO2 rebreathing (and hyperventilation) is 
higher than that of CVCi, suggesting direct effects of increases (and decreases) in 
ABP on changes in CBFV. For assessment of CVMR, the range of changes in CO2 
to be studied and the confounding influence of changes in ABP on CBFV must be 
considered for application of an appropriate modeling method to quantify CBFV or 
CVCi responses.
5
122 123
 28. Totaro R, Marini C, Baldassarre M, Carolei A. Cerebrovascular reactivity evaluated by 
transcranial Doppler: reproducibility of different methods. Cerebrovasc Dis 1999;9:142–145.
 29. Poulin MJ, Liang PJ, Robbins PA. Dynamics of the cerebral blood flow response to step 
changes in end-tidal PCO2 and PO2 in humans. J Appl Physiol 1996;81:1084–1095.
 30. Bishop CC, Powell S, Rutt D, Browse NL. Transcranial Doppler measurement of middle 
cerebral artery blood flow velocity: a validation study. Stroke 1986;17:913–915.
 31. Dahl A, Lindegaard KF, Russell D, Nyberg-Hansen R, Rootwelt K, Sorteberg W, Nornes H. A 
comparison of transcranial Doppler and cerebral blood flow studies to assess cerebral 
vasoreactivity. Stroke 1992;23:15–19.
 32. Lindegaard KF, Lundar T, Wiberg J, Sjoberg D, Aaslid R, Nornes H. Variations in middle 
cerebral artery blood flow investigated with noninvasive transcranial blood velocity 
measurements. Stroke 1987;18:1025–1030.
 33. Giller CA, Bowman G, Dyer H, Mootz L, Krippner W. Cerebral arterial diameters during 
changes in blood pressure and carbon dioxide during craniotomy.  
Neurosurgery 1993;32:737–741.
 34. Serrador JM, Picot PA, Rutt BK, Shoemaker JK, Bondar RL. MRI measures of middle cerebral 
artery diameter in conscious humans during simulated orthostasis.  
Stroke 2000;31:1672–1678.
 35. Valdueza JM, Draganski B, Hoffmann O, Dirnagl U, Einhaupl KM. Analysis of CO2 vasomotor 
reactivity and vessel diameter changes by simultaneous venous and arterial Doppler 
recordings. Stroke 1999;30:81–86.
 36. Ide K, Eliasziw M, Poulin MJ. The relationship between middle cerebral artery blood velocity 
and end-tidal PCO2 in the hypocapnic-hypercapnic range in humans.  
J Appl Physiol 2003;95:129–137.
 37. Pandit JJ, Mohan RM, Paterson ND, Poulin MJ. Cerebral blood flow sensitivity to CO2 
measured with steady-state and Read’s rebreathing methods.  
Respir Physiol Neurobiol 2003;137:1–10.
 38. Atkinson JL, Anderson RE, Sundt TM Jr. The effect of carbon dioxide on the diameter of brain 
capillaries. Brain Res 1990;517:333–340.
 39. Wei EP, Kontos HA, Patterson JL Jr. Dependence of pial arteriolar response to hypercapnia 
on vessel size. Am J Physiol Heart Circ Physiol 1980;238:H697–H703.
 40. Kontos HA, Richardson DW, Patterson JL Jr. Effects of hypercapnia on human forearm blood 
vessels. Am J Physiol 1967;212:1070–1080.
 41. Richardson DW, Wasserman AJ, Patterson JL Jr. General and regional circulatory responses 
to change in blood pH and carbon dioxide tension. J Clin Invest 1961;40:31–43.
 13. Blaser T, Hofmann K, Buerger T, Effenberger O, Wallesch CW, Goertler M. Risk of stroke, 
transient ischemic attack, and vessel occlusion before endarterectomy in patients with 
symptomatic severe carotid stenosis. Stroke 2002;33:1057–1062.
 14. Kleiser B, Widder B. Course of carotid artery occlusions with impaired cerebrovascular 
reactivity. Stroke 1992;23:171–174.
 15. Widder B, Kleiser B, Krapf H. Course of cerebrovascular reactivity in patients with carotid 
artery occlusions. Stroke 1994;25:1963–1967.
 16. Mitsis GD, Zhang R, Levine BD, Marmarelis VZ. Cerebral hemodynamics during orthostatic 
stress assessed by nonlinear modeling. J Appl Physiol 2006;101:354–366.
 17. Duffin J, McAvoy GV. The peripheral-chemoreceptor threshold to carbon dioxide in man.  
J Physiol 1988;406:15–26.
 18. Mohan R, Duffin J. The effect of hypoxia on the ventilatory response to carbon dioxide in 
man. Respir Physiol 1997;108:101–115.
 19. Vovk A, Cunningham DA, Kowalchuk JM, Paterson DH, Duffin J. Cerebral blood flow 
responses to changes in oxygen and carbon dioxide in humans.  
Can J Physiol Pharmacol 2002;80:819–827.
 20. Harris J, Benedict F. A biometric study of human basal metabolism.  
Proc Natl Acad Sci USA 1918;4: 370–373.
 21. Giller CA, Giller AM. A new method for fixation of probes for transcranial Doppler ultrasound. 
J Neuroimaging 1997;7:103–105.
 22. Vallbo AB, Hagbarth KE, Torebjork HE, Wallin BG. Somatosensory, proprioceptive, and 
sympathetic activity in human peripheral nerves. Physiol Rev 1979;59:919–957.
 23. Hancock SM, Mahajan RP, Athanassiou L. Noninvasive estimation of cerebral perfusion 
pressure and zero flow pressure in healthy volunteers: the effects of changes in end-tidal 
carbon dioxide. Anesth Analg 2003;96:847–851.
 24. Hsu HY, Chern CM, Kuo JS, Kuo TB, Chen YT, Hu HH. Correlations among critical closing 
pressure, pulsatility index and cerebrovascular resistance.  
Ultrasound Med Biol 2004;30:1329–1335.
 25. Kent BB, Drane JW, Blumenstein B, Manning JW. A mathematical model to assess changes 
in the baroreceptor reflex. Cardiology 1972;57:295–310.
 26. Hopkins WG. Measures of reliability in sports medicine and science.  
Sports Med 2000;30:1–15.
 27. Rohrberg M, Brodhun R. Measurement of vasomotor reserve in the transcranial Doppler-CO2 
test using an ultrasound contrast agent (Levovist). Stroke 2001;32:1298–1303.
 
5
124 125
Epidemiology: friend or foe? (BMJ 2004;329:467)  
Geriatric research is rapidly growing. Twenty years ago it was nearly impossible to find a trial that 
included old people. The major subject heading (MeSH) term "aged, 80 and over" wasn't 
introduced until 1986. But in the past 10 years more than 10,000 randomised controlled trials were 
published that included this age group. Alzheimer's disease is a good example of a geriatric 
disease that has long been ignored. It took us a while to realise that this devastating and incurable 
disease is about to become a pandemic. In the past decade we started a frantic search for clues 
that might lead to its cure. Since no one really knew where to start, we asked our friend 
epidemiology for help. Large cohorts of elderly people were studied. Epidemiologists looked for 
correlations, hoping to identify factors associated with a reduced risk of dementia. And with 
success. They gave us, among others, hormone replacement therapy in women and two groups 
of drugs, statins and non-steroidal anti-inflammatory drugs (NSAIDs). People using either of these 
types of drug were less likely to have Alzheimer's disease, they said. These hopeful findings were 
welcomed like a drop of water in the desert, and they were published in high ranking journals. All 
this inspired more research. The gold standard of evidence based medicine, the randomised 
controlled trial, was applied to confirm the data in a prospective setting. And in laboratories 
worldwide sophisticated in vitro and in vivo studies were designed to discover the pathophysiological 
mechanisms by which oestrogen, statins, and NSAIDs protect against Alzheimer's disease. To our 
surprise, the randomised controlled trials gave us bad news. The drugs had no effect at all on 
Alzheimer's disease. How can we explain this? It seems that the original observational studies 
suffered from the epidemiologist's biggest enemy: bias. Even worse, with hindsight this bias could 
and should have been easily identified. Doctors do not readily prescribe cholesterol lowering 
agents to patients with dementia. Likewise, patients with cognitive impairment are not likely to see 
their doctor to have their cholesterol checked. This explains why patients without dementia are 
more likely to use a statin than patients with dementia. The same holds for the use of hormone 
replacement therapy in women. In the case of the NSAIDs it was chance that played a trick on us. 
Chance findings are a recognised risk of doing multiple regression analysis on large volumes of 
variables in population studies: you can end up finding that patients born on a Monday are more 
likely to develop dementia than patients born on other days of the week. When we think about 
these events it seems that epidemiology—or rather its careless use—provided us with false clues. 
This led to a waste of valuable time and money. When scientists are so eager to find results, 
epidemiology can present as a friend but behave as our foe. What came next is puzzling. The 
laboratories started to publish their data. They had discovered that inflammatory processes are 
involved in the pathogenesis of Alzheimer's and that NSAIDs can modify these. They also 
identified several mechanisms of action for statins. For example, statins reduce the formation of 
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amyloid, one of the hallmarks of Alzheimer's. These data were enough to indicate that both drugs 
do have the potential to reduce the risk of the disease in certain patients. So, where does this leave 
us? Were the epidemiological findings true associations after all? This would mean that the 
randomised controlled trials have led us astray. This is troubling news for a gold standard. It is, 
however, not inconceivable that the design of these trials was inadequate. The process resulting 
in Alzheimer's disease probably starts many years before clinical symptoms present. If the 
therapeutic effect of statins and NSAIDs lies at a point 10 to 20 years before the onset of 
symptoms, any trial that starts at a much later stage will never find an effect. The alternative 
explanation is that the problem lies in the interpretation of the data. Maybe the inflammatory 
response seen in Alzheimer's is a non-specific reactive process and modifying it with NSAIDs has 
no true benefit. And maybe the  amyloid that is reduced by statins is merely an innocent bystander 
and not a factor contributing to the disease. I think we're simply not clever enough at this point to 
have the broad view needed to solve the puzzle of Alzheimer's. It is like trying to describe a 
painting when your view is limited to a corner of it. We started out looking for clues to a cure for 
Alzheimer's disease. With the help of epidemiology we found several. Unfortunately, not one of 
them has turned out to be useful, despite lots of research effort. What we are left with is a number 
of new hypotheses. So how should we judge epidemiology in this case: friend or foe? I still vote 
for friend. Friends aren't always right, but  they do make life much more interesting. 
5
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Chapter 6
Dynamic cerebral autoregulation 
during repeated squat-stand maneuvers
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Introduction
Continuous measurements of cerebral blood flow velocity (CBFV) using transcranial 
Doppler (TCD) have shown that CBFV is affected by dynamic perturbations in blood 
pressure (BP) considered to lie within the “autoregulatory range”.1,2 Transfer function 
analysis of spontaneous oscillations in BP and CBFV quantifies this dynamic 
pressure-flow relationship of the cerebral circulation, and has suggested that cerebral 
autoregulation is more effective at low compared to high frequencies (the “high pass 
filter” effect).1,3-5 However, this method may be limited by the relatively small magnitude 
of spontaneous oscillations. Also, assessment of dynamic cerebral autoregulation 
based on spontaneous changes in blood pressure and CBFV exhibits substantial 
individual variability under most experimental conditions.4,6 In addition, coherence 
between these oscillations at low frequencies (<0. 07Hz) generally is low (<0.5), and 
thus it is uncertain whether the quantification of the transfer function is statistically 
reliable5 and whether oscillations in CBFV simply may not be causally related to 
changes in BP at low frequencies.7 In practice, most studies exclude data with 
coherence <0.5 for analysis, which can amount to a third of all collected 
measurements.8,9 
Squatting followed by standing produces dramatic changes in BP.10 In daily life 
comparable maneuvers occur frequently, e.g. when standing up after tying shoelaces 
or picking something from the floor, and these maneuvers are often accompanied by 
symptoms of light-headedness suggestive of cerebral hypoperfusion. Previous studies 
demonstrated that when such squat-stand maneuvers are performed repeatedly, large 
and periodic changes in BP and CBFV are created.11 Thus, the magnitude of these 
changes is representative of daily life challenges for cerebral autoregulation.
We conducted this study to address the following hypotheses: 
1)  Oscillatory changes in BP and CBFV at specific low frequencies (0.025, 0.05 and 
0.1 Hz) can be induced with repeated squat-stand maneuvers, thus creating relatively 
narrow band, but high amplitude signals. 
2)  With increased correlation between BP and CBFV, and reduced signal to noise, 
transfer function assessment of dynamic cerebral autoregulation at the low and very 
low frequencies would be improved, associated with reduced variability in phase and 
gain estimates. 
Abstract
Transfer function analysis of spontaneous oscillations in blood pressure (BP) and 
cerebral blood flow (CBF) can quantify the dynamic relationship between BP and 
CBF. However, such oscillation amplitudes are often small and of questionable 
clinical significance, vary substantially, and cannot be controlled. At the very low 
frequencies (< 0.07 Hz) coherence between BP and CBF often is low (< 0.50) and 
their causal relationship is debated. How these factors affect transfer function 
analysis is not clear. Eight healthy subjects performed repeated squat-stand 
maneuvers to induce large oscillations in BP at frequencies of 0.025 and 0.05 (very 
low frequency) and 0.1 Hz (low frequency) respectively. BP (Finapres), CBF velocity 
(CBFV, TCD), and end-tidal CO2 (capnography) were monitored.  Spectral analysis 
was used to quantify oscillations in BP and CBFV and to estimate transfer function 
phase, gain and coherence. Compared with spontaneous oscillations, induced 
oscillations had higher coherence (mean 0.8 SD 0.11, > 0.5 in all subjects at all 
frequencies) and lower variability in phase estimates. However, gain estimates 
remained unchanged. Under both conditions, the “high-pass filter” characteristics 
of dynamic autoregulation were observed. In conclusion, using repeated squat-stand 
maneuvers, we were able to study dynamic cerebral autoregulation in the low 
frequencies under conditions of hemodynamically strong  and causally related 
oscillations in BP and CBFV. This enhances not only the confidence of transfer 
function analysis as indicated by high coherence and improved phase estimation, 
but strengthens also the clinical relevance of this method as induced oscillations in 
BP and CBFV mimic those associated with postural changes in daily life.
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were recorded during spontaneous respiration. These data were used for spectral 
analysis of spontaneous oscillations in BP and CBFV. Next, repeated squat-stand 
maneuvers were performed. After careful instruction and practice, participants were 
coached into performing these maneuvers at a frequency of 0.025 Hz (20 s squat 
followed by 20 s standing up), 0.05 Hz (10 s squat, 10 s stand) and 0.1 Hz (5 s squat, 
5 s stand) for 5 min each, separated by 10 min of recovery between the maneuvers. 
During these maneuvers, subjects were instructed to keep normal breathing and to 
avoid performing a Valsalva maneuver.
Data processing. The analog finger BP and Doppler CBFV signals were sampled 
simultaneously at 100 Hz (Multi-Dop X2, DWL). Real time beat-to-beat mean values 
of pressure and velocity were calculated as waveform integration of the sampled 
pressure and velocity signal within each cardiac cycle, divided by the corresponding 
pulse interval and stored for off-line analysis. Beat-to-beat changes in mean BP and 
CBFV were aligned with the time of R wave peaks of the ECG and linearly 
interpolated, then resampled at 2 Hz to convert the unequally spaced beat-to-beat 
time series to a uniformly spaced time series for spectral and transfer function 
analysis. The time series were detrended with third-order polynomial fitting and then 
subdivided into 128-point segments (64 s) with 50% overlap for spectral estimation. 
This process resulted in eight segments of data for the segment periodogram 
average, with a spectral resolution of ~0.0156 Hz. In this way, each segment 
contains at least one full period of oscillations at the lowest frequency (0.025 Hz) 
and up to 6 full periods of oscillations at the frequency of 0.1 Hz. Fast Fourier 
transforms were implemented with each Hanning-windowed segment and averaged 
to calculate the autospectrum of BP and CBFV. This analysis was repeated after 
adjustment of the window length to the cycle length of the squat-stand maneuvers, 
to the effect that each window contained 3 cycles. Because this did not alter transfer 
function estimates, the described standard window-lengths were used for both 
spontaneous and induced oscillations. Breath-to-breath values for ETCO2 were 
linearly interpolated and resampled at 2Hz and spectral analysis was performed to 
estimate the variability in ETCO2. Respiratory frequency was obtained form spectral 
analysis of continuous recording of CO2 waveforms.
Transfer function estimation. Estimation of transfer function gain, phase and coherence 
function was based on the cross-spectral method which has been described in detail 
Methods
Subjects. We studied eight healthy young subjects, four males, age 30 (SD 4) years, 
weight 72 (SD 18) kg, systolic/diastolic BP 114 (SD 5.4)/70 (SD 8.7) mmHg. These 
subjects were free of known disease, used no medication, and did not smoke. 
Ethical approval. The study complies with the standards set by the latest revision 
of the Declaration of Helsinki and was approved by the Institutional Review Boards 
of the University of Texas Southwestern Medical Center and Presbyterian Hospital 
of Dallas. All participants provided informed consent in writing.
Instrumentation. BP was measured in the finger by photoplethysmography 
(Finapres, Ohmeda). We and others have shown previously that this method reliably 
assesses dynamic changes in beat-to-beat BP that correlate well with intra-arterial 
recordings and can be used to quantify to the dynamic pressure-flow relationship 
of the cerebral circulation.5,12,13 The servo-reset mechanism was turned off during 
data collection for a maximum of 5 min to allow uninterrupted data recording.14 
Intermittent BP was also measured in the arm by electrosphygmomanometry 
(Suntech), with a microphone placed over the brachial artery and the Korotkoff 
sounds gated to the electrocardiogram (ECG). The arm pressure was used to verify 
the accuracy of the finger pressure recordings throughout the experiment. 
CBFV was obtained in the middle cerebral artery (MCA) by transcranial Doppler 
ultrasonography. This technique allows non-invasive and repeatable estimates of 
changes in CBF on a beat-to-beat basis. A 2-MHz Doppler probe (DWL Elektronische 
Systeme, Germany) was placed over the temporal window and fixed at a constant 
angle and position with a custom made individually shaped mould. End-tidal CO2 
(ETCO2) was monitored with a nasal cannula using capnography (Criticare 
Systems). In addition, peripheral arterial saturation (pulse-oximetry) and 3-lead 
ECG were registered. 
Experimental Procedures. All experiments were performed in the morning, at least 
2 h after a light breakfast and 12 h after the last caffeinated beverage or alcohol, in 
a quiet, environmentally controlled laboratory with an ambient temperature of 22°C. 
After at least 10 min rest in sitting position, 5-min segments of BP and CBFV data 
6
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Results
Hemodynamics effects of squat-stand maneuvers. Large oscillations in BP and 
CBFV were observed at all three frequencies of repeated squat-stand maneuvers 
(figures 1 and 2). There was a low inter-subject variability in the frequency induced 
by the repeated squat-stand maneuvers, determined from the peak of the BP and 
CBFV power spectra: maneuvers at 0.1 Hz induced a peak at 0.11 Hz in 7 and 0.14 
Hz in 1 subject; maneuvers at 0.05 Hz and 0.025 Hz induced peaks respectively at 
0.047 and 0.031 Hz in all 8 subjects. 
previously.5 Transfer gain quantifies how changes in BP are transmitted into CBFV; a 
lower gain suggests that oscillations in CBFV in response to changes in BP are either 
buffered by active changes in cerebrovascular resistance out of phase with changes in 
BP (dynamic autoregulation)8,15,16 and/or by increases in steady-state cerebrovascular 
resistance.17 The phase spectrum describes the temporal relationship between changes 
in BP and CBFV at different frequencies.3,8,18 Finally, estimates of coherence function 
quantify to what extent changes in CBFV are linearly correlated with changes in BP. 
Based on our previous studies5, transfer function analysis for spontaneous 
oscillations was carried out in the three frequency domains: very low frequency 
(0.02–0.07 Hz), low frequency (0.07–0.2 Hz) and high frequency (0.2–0.35 Hz). 
Because we wished to make comparisons, the oscillations induced by repeated 
squat-stand maneuvers were analyzed in the same frequency domains as used for 
spontaneous oscillations: squat-stand maneuvers at 0.025 Hz and 0.05 Hz were 
analyzed in the very low frequency domain (0.02–0.07 Hz); 0.1 Hz maneuvers were 
analyzed in the low frequency domain (0.07–0.14 Hz). 
For induced oscillations, we also performed the analysis around each of the three 
evoked frequencies. Thus, 0.025 Hz maneuvers were analyzed in the range 
0.02–0.06 Hz and 0.05 Hz maneuvers were analyzed in the range 0.03–0.08 Hz in 
all subjects. 0.1 Hz maneuvers were analyzed in the range 0.08–0.14 Hz in 7 
subjects and 0.11-0.17 Hz in 1 subject with the peak at 0.14 Hz (see results). Transfer 
function gain, phase and coherence did not differ significantly between the choices 
of the frequency bands. Therefore, we will only report the results based on the same 
frequency ranges as used for spontaneous oscillations. 
Statistical analysis. Comparisons between baseline and squat-stand maneuvers 
and between different frequencies were performed using analysis of variance for 
repeated measures. The data for BP, CBFV, HR, and CO2 had a normal distribution 
(Kolmogorov-Smirnov test), and repeated measures ANOVA with Bonferroni 
post-test for multiple comparisons if p < 0.05 was applied. Normal distribution 
could not be assumed for the data for spectral power, transfer function gain, phase 
and coherence. Therefore, the nonparametric Friedman test with Dunn post-test 
was applied. Statistical significance was set at p < 0.05. Data are presented as 
mean and standard deviation (SD). 
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Data from one subject, showing beat-to-beat variability in blood pressure (BP) and cerebral blood flow-velocity 
(CVBFV) (top panel), and results of spectral analysis of these data (bottom panel). A: resting condition (spontaneous 
oscillations), B: oscillations induced by squat-stand maneuvers at 0.025 Hz, C: oscillations induced at 0.05 Hz, D:  
oscillations induced at 0.1 Hz.
Figure 1  Spectral analysis of hemodynamic changes in rest and during 
squatting maneuvers.   
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Figure 3 summarizes transfer function gain, phase and coherence in the frequency 
domains of VLF, LF and HF for spontaneous oscillations, and for oscillations induced 
at 0.025, 0.05 and 0.1Hz by the repeated squat-stand maneuvers. For comparison, 
these parameters are superimposed on the frequency plots of transfer function gain, 
phase and coherence for spontaneous oscillations. Despite the poor coherence at the 
very low frequencies for spontaneous oscillations there was a remarkable consistency 
between estimates of gain from spontaneous and induced oscillations: no significant 
differences were observed at the VLF and LF ranges between spontaneous and 
induced oscillations, and the variability of the estimates was comparable (see size of 
the standard errors in Fig 3). However, findings for phase were different. As seen in Fig 
3, phase estimates from induced oscillations were lower. Moreover, estimation of VLF 
phase from the induced oscillations (0.025 and 0.05 Hz) showed much less inter-
individual variability (mean 0.5 radians, range 0.3-0.7, associated with a coherence of 
0.8) than VLF phase estimated from spontaneous oscillations (mean 0.8 radians, range 
0.1–1.9, associated with a coherence of 0.4). 
Table 1 shows that the mean values of the main hemodynamics variables BP, HR, 
ETCO2 and respiratory frequency did not change significantly due to the repeated 
squat-stand maneuvers, despite the increased oscillation amplitude. Fluctuations in 
ETCO2 were slightly enhanced during these maneuvers (Table 2).
Magnitude of induced oscillations. The repeated squat-stand maneuvers at 0.025 
and 0.05 Hz resulted in respectively 15-fold and 40-fold increases in BP spectral 
power (compared to spontaneous VLF oscillations), while at 0.1Hz, a 100-fold 
increase occurred relative to spontaneous LF oscillations (figure 2 and table 2). 
These augmented oscillations in BP led to 10, 20 and 100-fold increases in CBFV spectral 
power at 0.025, 0.05 Hz and 0.1 Hz, respectively. Thus, increases in CBFV oscillations 
were relatively smaller than increases in BP oscillations at 0.025 and 0.05 Hz but not at 
0.1 Hz, indicating more effective damping at the lower frequencies (Fig 2B). As expected 
this was corroborated by lower gain in these frequencies (see below and Fig 3). 
Transfer Function Gain, Phase and Coherence. Coherence between BP and 
CBFV was much higher for repeated squat-stand maneuvers than for spontaneous 
oscillations, with values > 0. 6 for all subjects (range: 0.61-0.96).    
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Table 1  Main hemodynamic parameters during the different tests.
 Rest  Periodic squatting P value
  0.025 Hz 0.05 Hz 0.1 Hz
BP (mmHg) 84  (8) 90  (9) 86  (9) 90  (3) 0.18
CBFV (cm/s) 55 (13) 53  (8) 52  (9) 55 (11) 0.24
HR (bpm) 69 (15) 84 (17) 88 (17) 90 (17) 0.1
ETCO2 (mmHg) 38  (3) 38  (3) 38  (4) 40  (3) 0.08
Resp.freq. (Hz) 0.29 (0.07) 0.31 (0.07) 0.34 (0.05) 0.28 (0.07) 0.34
BP: blood pressure (Finapres). CBFV: cerebral blood flow-velocity (TCD). ETCO2: end-tidal CO2 (capnograph). 
Resp. freq: respiratory frequency (spectral analysis of the CO2 waveform). Values represent mean and standard 
deviation (SD) during each test. P values: repeated measures analysis of variance.
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A. Spectral power of spontaneous oscillations in blood pressure (BP, in mmHg2) and cerebral blood flow-velocity 
(CBFV, in (cm/s)2). Bars represent group mean and standard error. VLF: very low frequency band (0.02-0.07 Hz), LF: 
low frequency (0.07-0.2) HF: high frequency (0.2-0.35 Hz). P-values: results of Friedman Test. * significant post-hoc 
(Dunn) test for BP; ** for CBFV. B. Spectral power of BP and CBFV during oscillations induced by periodic squatting  
at three frequencies: 0.025 and 0.05 Hz (VLF range) and 0.1 Hz (LF range). Note the different Y-axis scale (factor 30)  
for spectral power compared with 2A. P-values and *,** as in 2A. Differences in spectral power between spontaneous 
and induced oscillations were highly significant (p < 0.0001).
Figure 2  Spectral power of BP and CBFV for spontaneous and induced  
oscillations.   
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Discussion
There are several new findings in this study. During repeated squat-stand maneuvers 
at three specific frequencies of 0.25 Hz, 0.05 Hz and 0.1 Hz, large oscillatory 
changes in BP and CBFV were generated around each of these frequencies. 
Increases in oscillations in BP and CBFV led to a significant increase in coherence 
in the very low frequency range and improved estimations of transfer function 
phase. Interestingly, estimation of transfer function gain yielded identical results 
with spontaneous and induced oscillations. The “high-pass filter” behavior of the 
dynamic pressure-flow relationship, deduced from these augmented and causally 
related oscillations in BP and CBFV, fits the model based on analysis of spontaneous 
oscillations. These findings show that the large oscillations in BP and CBFV induced 
during repeated squat-stand maneuvers not only provided strong and physiologically 
relevant hemodynamics perturbations, but also led to improved estimation of 
transfer function to assess dynamic cerebral autoregulation at the very low 
frequencies.
Previous methods to induce hemodynamics oscillations. Previous studies have 
induced oscillations in BP and CBFV in order to advance the understanding of 
dynamic pressure-flow relationship of the cerebral circulation.8,11,13,18-21 In one of the 
first studies describing the clinical application of the phase relationship between BP 
and CBF, Diehl et al. used periodic breathing to induce sinusoidal oscillations at 0.1 
Hz (6 breaths per min).18 Forced breathing carries the risk of altering arterial CO2, 
which affects CBF. For obvious reasons, this technique can not be used to induce 
oscillations at frequencies much lower than 0.1 Hz. Augmented oscillations have 
also been induced by repeated head-up tilt to 45° (< 2 s) with a period of 10 s.8 
The purpose of this study was to investigate the phase relationship between BP and 
cerebrovascular resistance, in order to explain the phase lead of CBFV to BP in 
studies of autoregulation. Compared with spontaneous oscillations, coherence 
between BP and CBFV was increased by these maneuvers. A disadvantage of this 
technique was the uncertain effect of the gravitational force on cerebral perfusion 
pressure when going from supine to tilt.8 Recently, a method of cyclic thigh cuff 
compression and release was used to induce oscillatory changes in BP and CBF at 
a single frequency of 0.033 Hz.19 On average, BP increased by ~10 mmHg during 
cuff compression, and decreased by ~6 mmHg during cuff release. However, 
Both for spontaneous and induced oscillations, it was clear that with increasing 
frequency, gain increased and phase decreased (Fig 3), in line with high-pass filter 
properties of the dynamic pressure-flow relationship of the cerebral circulation.   
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Group results of transfer function analysis of spontaneous oscillations (resting conditions) and oscillations induced by 
repeated squat-stand maneuvers at 3 different frequencies. The background plots are frequency distribution graphs, 
obtained from spontaneous oscillations, of mean (black line) and standard error (SE, gray area) phase, gain and 
 coherence plotted against oscillation frequency. Squared boxes represent mean (SE) phase, gain and coherence 
 within the three frequency bands VLF, LF and HF (see Fig 2). For comparison, results obtained from repeated 
 squat-stand maneuvers are plotted as black dots (mean and SE) at their respective frequencies (0.025, 0.05 and 0.1 Hz). 
Statistical comparisons were made using Friedman Test with Dunn post-test if p < 0.05;  *: significant difference within 
group and **: between groups   
Figure 3  Results of transfer function analysis of spontaneous and induced 
oscillations.   
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in BP at 0.05 and 0.1 Hz may be compounded by cardiovascular resonance in 
response to external perturbations to BP.25,26 In fact, the frequencies of 0.05 and 0.1 
Hz of repeated squat-stand maneuvers in this study are close to the baroreflex 
resonance frequencies observed in humans.25,26 
Low-frequency coherence. Low-frequency coherence (<0.07 Hz) was increased 
significantly in all subjects. Previous studies have suggested that low coherence 
may indicate that changes in CBFV are relatively independent of changes in BP, and 
thus may reflect an intact cerebral autoregulation. Conversely, increases in 
coherence have been interpreted to reflect impairment of autoregulation.1 Could the 
higher coherence indicate that autoregulation was less efficient for the large 
hemodynamics changes during the repeated squat-stand maneuvers? Given the 
fact that transfer function gain was not different from spontaneous oscillations, 
indicating a similar degree of damping for the much stronger induced oscillations 
in BP, this is very unlikely.15 Furthermore, phase shifts for induced oscillations were 
within the normal range and showed a pattern similar to spontaneous oscillations, 
indicating intact autoregulation. Therefore, we propose that the increased coherence 
reflects improved “signal to noise ratio” for induced oscillations. Finally, it can be 
speculated that the high coherence for induced oscillations may reflect nonlinear 
synchronization or entrainment of the two oscillatory systems (BP and CBFV) with 
periodic external stimuli, similar to what has been observed in other biological 
regulator systems.27
Transfer function phase and gain. Phase estimates at the VLF frequencies from 
spontaneous oscillations had large inter-individual variability (observe the high 
standard error in figure 3); this most likely results from the low coherence, since 
phase for augmented oscillations in BP and CBFV, associated with higher 
coherence, showed considerably less inter-individual variability (Fig 3). Decreases 
in phase with increases in frequency confirmed previous observations based on 
spontaneous oscillations under resting conditions that phase shift is larger at the 
VLF than the LF frequencies. Phase in induced oscillations (0.6 radians, SD 0.23) 
was slightly lower than, but consistent with, observations in previous studies using 
enhanced oscillations. These studies found a phase lead of CBFV of 0.6–0.8 
radians in the very low frequency region < 0.07 Hz.11,20,21 Since the magnitude of 
enhanced BP and CBFV oscillations in this study is significantly higher than in those 
continuous recordings did not reveal clearly discernible sinusoidal changes in BP 
and CBFV in response to cyclic changes in cuff pressure.19 Finally, oscillatory lower 
body negative pressure (OLBNP) has been applied to create oscillations in BP and 
CBFV.13,20,21 This technique has important limitations in that changes in pressure of 
LBNP chambers may not transfer immediately and effectively into changes in BP 
with increases in oscillatory frequencies.21 In addition, LBNP pressures that were 
high enough to be effective in generating large BP and CBFV oscillations are poorly 
tolerated by subjects.20 Despite these technical difficulties, Hamner et al. have 
applied OLBNP to induce oscillations in BP and CBFV at the frequencies of 0.03, 
0.05 and 0.1 Hz, with the purpose of increasing low frequency coherence.21 Even at 
a maximum change of LBNP pressure from zero to -40 mmHg and at the most 
effective frequency of 0.05 Hz, spectral power of BP and CBFV increased only by a 
factor of 10 and 5 respectively.21 Of note, 14 out of 36 LBNP trials in nine subjects 
still had coherence < 0.3 at the frequencies of 0.03 and 0.05 Hz, indicating the 
limitations of using oscillatory LBNP to generate large and coherent low frequency 
changes in BP and CBFV.21
Rationale for using repeated squat-stand maneuvers. More than half a century 
ago, Sharpey-Schafer described the strong hemodynamics changes provoked by a 
squat-stand maneuver.10 Briefly, squatting induces a rapid but transient rise in BP 
with its peak after about 2 to 3 seconds. The increase in BP has been attributed 
mainly to a sudden increase in cardiac output from increased venous return from 
the lower limbs.22 The reduction in BP during standing up has been attributed to a 
combination of reduction in peripheral vascular resistance and a reduction in 
cardiac output due to rapid translocation of central blood volume to the lower 
limbs.23 Here, we observed large and coherent oscillations in BP and CBFV, induced 
by repeated squat-stand maneuvers at three distinct frequencies. These results 
clearly demonstrated that low frequency, transient changes in CBFV occur in 
response to dynamic changes in arterial pressure that should lie within the 
“autoregulatory range”.
Different frequencies induced oscillations with different magnitude. Oscillations 
in BP at 0.05 and 0.1 Hz were much larger than at 0.025 Hz. A likely explanation is 
that at 0.025 Hz, baroreflex sympathetic control of BP would have sufficient 
response time to counteract dynamic changes in BP.24 Conversely, large oscillations 
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rate and ETCO2 between resting conditions and repeated squat-stand maneuvers 
(Table 1) argues against significant hemodynamics exercise effects. 
The number of subjects in this study is relatively small. However, the increases in 
spectral power and coherence were robust and statistically significant.
Finally, flow-velocity in the MCA is determined by CBF and by the diameter of the 
MCA. Therefore, changes in CBFV reflect changes in CBF only if the MCA diameter 
is constant. During acute, moderate changes in BP, MCA diameter showed less 
than 4% change.30,31 This suggests that in our study, small changes in MCA diameter 
can not be excluded. In theory, this would have the following effects on our data. 
Vasoconstriction during an increase in BP overestimates the associated rise in CBF. 
Conversely, vasodilatation induced by a decrease in BP overestimates the reduction 
in CBF. Collectively, these effects, if they did occur, would overestimate transfer 
function gain, but would not affect phase, as this parameter is not affected by the 
amplitude but by the timing of the oscillations. In a similar vein, pressure-induced 
passive changes in diameter would underestimate changes in CBFV and thus 
transfer function gain, but not phase. 
Clinical significance. In clinical practice, the consequences of sudden changes in 
BP are frequently encountered in patients complaining of feeling light headed or 
dizzy when standing up, and in patients evaluated for unexplained falls or syncope. 
Diagnostic evaluation generally focuses on BP measurements, with the inexplicit 
assumption that a reduction beyond a certain defined cut-off value (e.g. 20 mmHg 
systolic) induces cerebral hypoperfusion. However, dynamic cerebral autoregulation 
mediates the consequences of BP changes on CBF, and therefore plays an 
important role in determining the clinical consequence of hemodynamic instability. 
Quantification of dynamic cerebral autoregulation has provided insight in these 
syndromes32 as well as in other important clinical conditions such as stroke32,33, 
hypertension9,34, and will be important to investigate in Alzheimer disease.35,36
previous studies, these data suggest that estimation of phase also may be 
influenced by the magnitude of oscillations in BP and CBFV. 
Transfer function gain was similar for spontaneous and induced oscillations even 
though coherence was low for spontaneous oscillations (0.4, SD 0.13) at frequencies 
below 0.07 Hz. These findings suggest that, compared with phase, estimation of 
gain is less affected by the magnitude of BP and CBFV oscillations and by low 
coherence. 
The characteristics of transfer function gain and phase in the present study, under 
conditions of augmented oscillations in BP and CBFV, extend previous observations 
of the “high-pass filter” characteristics of dynamic cerebral autoregulation.21 The 
consistency of transfer function gain and phase estimates between spontaneous 
and augmented changes in BP and CBFV suggests that for each specific frequency, 
CBFV changed in proportion with changes in BP, revealing linear dynamic system 
properties.28 These observations are interesting given the fact that BP and CBFV 
spectral power during repeated squat-stand maneuvers was substantially higher 
than for spontaneous oscillations (10 to 100 fold), suggesting that linear transfer 
function analysis can be applied in a wide range of changes in BP and CBFV. 
ETCO2 during repeated maneuvers. Fluctuations in ETCO2 were enhanced 
slightly during repeated squat-stand maneuvers (Table 2). Considering that CBF 
changes 3% for each mmHg change in ETCO2, the spectral power of these 
fluctuations translates into fluctuations in CBFV with a maximum of 2.5%, which is 
small relative to the > 20% of change induced by BP. Moreover, the repeated body 
movements may introduce artifacts in capnography registration of the CO2 
waveform, which do not affect mean ETCO2 estimation, but could cause 
overestimation of fluctuations. We did not find a temporal relationship between 
fluctuations in ETCO2 and oscillations in BP or CBFV.
Study limitations. Repeated squat-stand maneuvers can be considered as aerobic 
exercise. Thus, these maneuvers per se may modulate the dynamic pressure-flow 
relationship of the cerebral circulation. However, previous studies have shown that 
moderate to high intensity aerobic exercise did not alter dynamic cerebral 
autoregulation.29 Moreover, the absence of changes in mean blood pressure, heart 
6
144 145
References
 1.  Giller CA. The frequency-dependent behavior of cerebral autoregulation.  
Neurosurgery 1990;27:362-368.
 2.  Zhang R, Zuckerman JH, Levine BD. Spontaneous fluctuations in cerebral blood flow: 
insights from extended-duration recordings in humans.  
Am J Physiol Heart Circ Physiol 2000;278:H1848-H1855.
 3. Diehl RR, Linden D, Lucke D, Berlit P. Spontaneous blood pressure oscillations and cerebral 
autoregulation. Clin Auton Res 1998;8:7-12.
 4. Panerai RB, White RP, Markus HS, Evans DH. Grading of cerebral dynamic autoregulation 
from spontaneous fluctuations in arterial blood pressure. Stroke 1998;29:2341-2346.
 5.  Zhang R, Zuckerman JH, Giller CA, Levine BD. Transfer function analysis of dynamic cerebral 
autoregulation in humans. Am J Physiol 1998;274:H233-H241.
 6.  Taylor JA, Carr DL, Myers CW, Eckberg DL. Mechanisms underlying very-low-frequency 
RR-interval oscillations in humans. Circulation 1998;98:547-555.
 7.  Giller CA, Hatab MR, Giller AM. Oscillations in cerebral blood flow detected with a 
transcranial Doppler index. J Cereb Blood Flow Metab 1999;19:452-459.
 8.  Hughson RL, Edwards MR, O'Leary DD, Shoemaker JK. Critical analysis of cerebrovascular 
autoregulation during repeated head-up tilt. Stroke 2001;32:2403-2408.
 9.  Lipsitz LA, Mukai S, Hamner J, Gagnon M, Babikian V. Dynamic regulation of middle cerebral 
artery blood flow velocity in aging and hypertension. Stroke 2000;31:1897-1903.
 10.  Sharpey-Schafer EP. Effects of squatting on the normal and failing circulation.  
BMJ 1956;1:1072-1074.
 11.  Birch AA, Dirnhuber MJ, Hartley-Davies R, Iannotti F, Neil-Dwyer G. Assessment of 
autoregulation by means of periodic changes in blood pressure. Stroke 1995;26:834-837.
 12.  Sammons EL, Samani NJ, Smith SM, Rathbone WE, Bentley S, Potter JF, Panerai RB. 
Influence of noninvasive peripheral arterial blood pressure measurements on assessment 
of dynamic cerebral autoregulation. J Appl Physiol 2007;103:369-375.
 13.  Zhang R, Zuckerman JH, Iwasaki K, Wilson TE, Crandall CG, Levine BD. Autonomic neural 
control of dynamic cerebral autoregulation in humans. Circulation 2002;106:1814-1820.
 14.  Omboni S, Parati G, Frattola A, Mutti E, Di RM, Castiglioni P, Mancia G. Spectral and 
sequence analysis of finger blood pressure variability. Comparison with analysis of 
intra-arterial recordings. Hypertension 1993;22:26-33.
 15.  Kolb B, Rotella DL, Stauss HM. Frequency response characteristics of cerebral blood flow 
autoregulation in rats. Am J Physiol Heart Circ Physiol 2007;292:H432-H438.
Conclusions
We have demonstrated that large and coherent oscillations in BP and CBFV at the 
low frequencies of 0.025, 0.05 and 0.1 Hz can be induced by repeated squat-stand 
maneuvers. This study is the first to succeed in inducing high amplitude oscillations 
in the low frequencies, in combination with high coherence, thereby allowing 
confident comparisons of the behavior of dynamic cerebral autoregulation in low 
versus high frequencies. The magnitude of these hemodynamics changes as well 
as the maneuvers through which they are induced arguably are representative of 
the daily physiological challenges put to cerebral autoregulation, such as orthostatic 
hypotension. Phase estimates at the low frequencies below 0.07 Hz were 
substantially improved by the augmented BP and CBFV oscillations. Therefore, we 
conclude that addition of these maneuvers to an analysis based solely on 
spontaneous oscillations enhances the information obtained from transfer function 
analysis and may be an important step towards its translation and implementation 
in clinical medicine. 
 
6
146 147
 30.  Giller CA, Bowman G, Dyer H, Mootz L, Krippner W. Cerebral arterial diameters during 
changes in blood pressure and carbon dioxide during craniotomy.  
Neurosurgery 1993;32:737-741.
 31.  Serrador JM, Picot PA, Rutt BK, Shoemaker JK, Bondar RL. MRI measures of middle 
cerebral artery diameter in conscious humans during simulated orthostasis.  
Stroke 2000;31:1672-1678.
 32.  van Beek AH, Claassen JA, Rikkert MG, Jansen RW. Cerebral autoregulation: an overview 
of current concepts and methodology with special focus on the elderly.  
J Cereb Blood Flow Metab 2008;28: 1071-1085.
 33. Immink RV, van Montfrans GA, Stam J, Karemaker JM, Diamant M, van Lieshout JJ. Dynamic 
cerebral autoregulation in acute lacunar and middle cerebral artery territory ischemic 
stroke. Stroke 2005;36: 2595-2600.
 34. Immink RV, van den Born BJ, van Montfrans GA, Koopmans RP, Karemaker JM, van Lieshout 
JJ. Impaired cerebral autoregulation in patients with malignant hypertension.  
Circulation 2004;110:2241-2245.
 35.  Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral perfusion in 
Alzheimer's disease and related cognitive disorders: the cholinergic-vascular hypothesis.  
J Gerontol A Biol Sci Med Sci 2006;61:267-271.
 36.  Suter OC, Sunthorn T, Kraftsik R, Straubel J, Darekar P, Khalili K, Miklossy J. Cerebral 
hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease.  
Stroke 2002;33:1986-1992.
 16.  Kontos HA, Wei EP, Navari RM, Levasseur JE, Rosenblum WI, Patterson JL, Jr. Responses 
of cerebral arteries and arterioles to acute hypotension and hypertension.  
Am J Physiol 1978;234:H371-H383.
 17.  Zhang R, Witkowski S, Fu Q, Claassen JA, Levine BD. Cerebral hemodynamics after short- 
and long-term reduction in blood pressure in mild and moderate hypertension. 
Hypertension 2007;49:1149-1155.
 18.  Diehl RR, Linden D, Lucke D, Berlit P. Phase relationship between cerebral blood flow 
velocity and blood pressure. A clinical test of autoregulation. Stroke 1995;26:1801-1804.
 19.  Aaslid R, Blaha M, Sviri G, Douville CM, Newell DW. Asymmetric dynamic cerebral 
autoregulatory response to cyclic stimuli. Stroke 2007;38:1465-1469.
 20.  Birch AA, Neil-Dwyer G, Murrills AJ. The repeatability of cerebral autoregulation 
assessment using sinusoidal lower body negative pressure. Physiol Meas 2002;23:73-83.
 21.  Hamner JW, Cohen MA, Mukai S, Lipsitz LA, Taylor JA. Spectral indices of human cerebral 
blood flow control: responses to augmented blood pressure oscillations.  
J Physiol 2004;559:965-973.
 22.  Krediet CT, de B, I, Ganzeboom KS, Linzer M, van Lieshout JJ, Wieling W. Leg crossing, 
muscle tensing, squatting, and the crash position are effective against vasovagal reactions 
solely through increases in cardiac output. J Appl Physiol 2005;99:1697-1703.
 23.  Wieling W, Krediet CT, van DN, Linzer M, Tschakovsky ME. Initial orthostatic hypotension: 
review of a forgotten condition. Clin Sci (Lond) 2007;112:157-165.
 24.  Eckberg DL and Sleight P. Human Baroreflexes in Health and Disease.  
Oxford: Clarendon Press, 1992.
 25.  Hammer PE, Saul JP. Resonance in a mathematical model of baroreflex control: arterial 
blood pressure waves accompanying postural stress.  
Am J Physiol Regul Integr Comp Physiol 2005;288: R1637-R1648.
 26.  van de Vooren H, Gademan MG, Swenne CA, TenVoorde BJ, Schalij MJ, van der Wall EE. 
Baroreflex sensitivity, blood pressure buffering, and resonance: what are the links? 
Computer simulation of healthy subjects and heart failure patients.  
J Appl Physiol 2007;102:1348-1356.
 27.  Matsugu M, Duffin J, Poon CS. Entrainment, instability, quasi-periodicity, and chaos in a 
compound neural oscillator. J Comput Neurosci 1998;5:35-51.
 28.  Van de Vegte J. Feedback control systems. Englewood Cliffs, NJ: Prentice Hall, 1994.
 29.  Ogoh S, Dalsgaard MK, Secher NH, Raven PB. Dynamic blood pressure control and middle 
cerebral artery mean blood velocity variability at rest and during exercise in humans.  
Acta Physiol (Oxf) 2007; 191:3-14.
6
148 149
Tellymedicine (BMJ 2005;331:1185)
In the past, doctors had to see a patient before they could make a diagnosis. Doctors were also 
restricted in whom they could tell about this diagnosis -the patient and his or her trusted next of 
kin, the nurse, and perhaps the odd interested colleague. Recent advances in technology first 
brought us telemedicine, where doctors can assist other doctors in making a diagnosis, guide 
surgical procedures, or even perform surgery themselves, without being physically near the 
patient. More recently, we have seen tellymedicine. This enables us to make a diagnosis in 
patients for whom we have no responsibility. We don't need to examine them, nor do we need a 
formal invitation to become involved in their medical care. In fact, we may only know of these 
patients from watching them on television or from reading about them in a newspaper. One of the 
most accomplished tellydoctors is Dr Gupta, a neurosurgeon who is also a senior medical 
correspondent for the US Cable News Network (CNN) (www.cnn.com/2005/HEALTH/03/30/otsc.
gupta/). Dr Gupta diagnosed coronary artery disease in former US president Bill Clinton almost 
before his cardiologist did. Another recent triumph of tellymedicine was recorded during the death 
of the late pope. The reluctance of the pontiff's doctors to release information threatened to turn 
things into a private Vatican matter. Fortunately, tellydoctors in several countries used their skills 
in remote diagnostics to provide the international media with detailed information on the pope's 
medical condition during his last days. Forensic medicine is one particular field that can benefit 
from tellymedicine. For instance, Volkert van der Graaf, the assassin of Dutch politician Pim 
Fortuyn, was admitted to a clinic for forensic psychiatry so that a single expert witness could 
report to the court. Because Volkert refused cooperation, this psychiatric evaluation was extremely 
lengthy. Fortunately, several "Tele" psychiatrists, after studying the media, were able to conclude 
that Volkert suffered from Asperger's syndrome, and informed the court and public of this through 
the media long before his trial. In the UK, Professor David Southall sought a child protection 
investigation after watching a television programme. He claimed to see what others had not but 
for his pains was found guilty of serious professional misconduct by the General Medical Council. 
Tellymedicine implies that an insightful diagnosis can be made through careful observation alone, 
and that modern physicians have lost this gift and have come to rely too much on their tradition of 
diagnostic tests and procedures, requiring the physical presence of the patient. Tellymedicine 
obviates all these costly and time consuming tests. Patients are spared pointless visits to our 
clinics. As an additional benefit, they can read their diagnosis in the newspapers or watch it on 
television in the comfort of their home.
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Abstract
In hypertension, cerebral vasomotor reactivity to CO2 may be reduced as a 
consequence of cerebrovascular remodelling and endothelial dysfunction. In 
untreated patients, BP (blood pressure) reduction may further impair CO2 reactivity 
as cerebral pressure autoregulation will cause compensatory cerebral vasodilatation. 
Treatment with an AT (angiotensin) II receptor blocking agent may modulate CO2 
reactivity under these conditions as AT II mediates vascular remodelling and 
endothelial function. 11 patients with newly diagnosed, untreated mild to moderate 
hypertension, 9 men, 2 women, age (mean (SD)) 52 (9) years, and 8 controls, 
7 men, 1 woman, age 46 (10) years were studied. Patients received losartan/
hydrochlorothiazide (50/12.5 or 100/25 mg) to reduce BP to < 140/<90 mmHg 
within 1-2 weeks. BP, heart rate, CBFV (cerebral blood flow-velocity), cerebrovascular 
resistance, and CO2 reactivity were measured at baseline, after the rapid BP 
reduction, and after long- term treatment (3-4 months). At baseline, hypertension 
was not associated with reduced CO2 reactivity. Treatment effectively lowered BP 
from 148(12)/ 89(7) to 130(15)/80(9) after 1-2 weeks and 125(10)/ 77(7) mmHg after 
3-4 months (p=0.003). Cerebrovascular resistance was reduced (indicating 
vasodilatation) and CBFV remained stable, however, CO2 reactivity was not 
affected. In conclusion, in this small sample, neither elevated BP nor rapid BP 
lowering affected CO2 reactivity. In addition, no effect was observed of prolonged 
inhibition of AT II with losartan.
Introduction
Hypertension is the major risk factor for stroke1, and large epidemiological studies 
have demonstrated that high blood pressure (BP) in midlife is also a major risk 
factor for Alzheimer’s disease and vascular dementia.2 These important clinical 
associations are supported by the profound disruptive effects of hypertension on 
the brain’s circulation. Prolonged hypertension leads to  remodelling of cerebral 
arteries with an increase in wall thickness/lumen ratio.3 In addition, hypertension 
impairs endothelium-mediated cerebral vasodilatation.4 
Substantial evidence suggests that angiotensin II is implicated in cerebral vascular 
remodelling and endothelial dysfunction in hypertension.4 Specifically, angiotensin 
II, via AT1 receptor binding, attenuates endothelium-dependent responses of the 
cerebral circulation.4 Thus, antihypertensive treatment with ACE inhibitors or AT1 
receptor blockers may reverse cerebrovascular changes not only through the 
lowering of BP, but also through direct vascular effects of these agents acting on 
the vascular renin-angiotensin system.2,5
Two major regulatory mechanisms for the cerebrovascular effects of hypertension 
are implicated that can both be evaluated clinically: 1) pressure autoregulation 
(cerebral autoregulation), describing the cerebral vasomotor responses to changes 
in perfusion pressure6, and 2) CO2 reactivity, describing cerebral vasomotor 
responses to changes in arterial CO2 (CVMR).7 These two mechanisms differ 
importantly in that most evidence suggests that CVMR is, and cerebral autoregulation 
is not, affected by endothelial dysfunction.6,8,9 Moreover, angiotensin II may exert 
differential effects on CVMR and cerebral autoregulation.4
Recently, we have reported that dynamic cerebral autoregulation and cerebral 
vasodilatatory response to BP reduction were preserved in hypertensive patients 
receiving treatment with the AT1 receptor blocker losartan combined with 
hydrochlorothiazide (Hyzaar).6 These findings support the notion that angiotensin 
receptor blockade causes a leftward shift of the lower limit of static cerebral 
autoregulation (to lower pressures), thus protecting the brain against hypoperfusion 
when BP is lowered.10
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The study was conducted in accordance with the guidelines set by the Declaration 
of Helsinki, and the Institutional Review Boards of the University of Texas 
Southwestern Medical Center and Presbyterian Hospital of Dallas approved the 
study. All participants provided informed consent in writing.
Instrumentation
Finger photoplethysmography (Finapres, Ohmeda) was used to measure 
beat-to-beat changes in BP. Intermittent cuff BP was measured at the upper arm 
using electrosphygmomanometry (SunTech). CBF-velocity (CBFV) was recorded in 
the middle cerebral artery (MCA) using transcranial Doppler (TCD, Multiflow, DWL). 
The Doppler probe was placed over the subject’s temporal window and fixed at a 
constant angle with a probe holder that was custom made to fit each subject’s facial 
bone structure. This technique allowed CBFV to be measured precisely at the same 
acoustic window and at the same angle for repeated studies.7 Heart rate was 
monitored using ECG. End-tidal CO2 (ETCO2) was monitored via a nasal cannula 
using a capnograph (Criticare Systems Inc.).
Protocol
All experiments were performed in the morning at least two hours after a light 
breakfast. The subjects refrained from heavy exercise and caffeinated or alcoholic 
beverages at least 24 hours before the tests. Baseline measurements, consisting of 
six min of beat-to-beat BP and CBFV during spontaneous breathing, were recorded 
after at least 30 min of supine rest. 
We used a previously described protocol to estimate CVMR using breath-by-breath 
changes in ETCO2, CBFV and BP.7 The study was conducted with the subjects in 
the supine position to allow comparison with studies using other imaging technology 
such as MRI or PET.11,12 To obtain a wide range of CO2 changes (from ~20 to 60 
mmHg ETCO2), a modified rebreathing protocol was used with a period of voluntary 
hyperventilation preceding rebreathing. Rebreathing was continued for 5 min, 
before returning to room air for recovery (4 min). During rebreathing, a small amount 
of oxygen was bled into the rebreathing bag at the subject’s basal metabolic rate 
(estimated using the Harris-Benedict formula) to maintain arterial oxygen saturation 
(SaO2) constant.7
However, it is not clear whether hypertension-induced cerebrovascular changes 
may impair vascular reactivity to CO2. Moreover, pressure autoregulation may 
interact in the way that the vasodilatation required to buffer BP reduction may 
attenuate or exhaust any further vasodilatatory response to CO2. Furthermore, 
whereas blockade of the effects of angiotensin II may improve pressure 
autoregulation, its effects on CVMR are insufficiently known. The present study was 
performed to test the hypothesis that CVMR is reduced in untreated mild to 
moderate hypertension, and that these changes are exacerbated after acute 
reduction in BP associated with autoregulatory vasodilatation. In addition, we 
hypothesized that prolonged treatment with losartan, through a beneficial effect on 
vascular remodelling or endothelial function may restore CVMR.  
Materials and Methods
Subjects
This study was conducted in a subgroup of subjects who participated in research 
to determine the effects of short and long-term reduction in BP on dynamic cerebral 
autoregulation in patients with mild and moderate hypertension.6 11 patients with 
newly diagnosed mild to moderate hypertension (9 men, 2 women) with a mean age 
of 52 (SD 9) years (range, 39–66), and 8 healthy subjects (7 men, 1 woman) with a 
mean age of 46 (SD 10) years (range, 38-66) participated in this study (Table 1). 
Based on the variance of he method used to measure CVRM, obtained in a previous 
study7, this study had 90 % power to detect a 10 % change in total CVMR, or a 
difference in CVMR equal to or greater than 1.5 %/Torr.
None of the patients had received prior antihypertensive treatment. Classification of 
hypertension (JNC 7 and ESC/ESH 2007; mild to moderate, grade 1-2) was based 
on the average of awake recordings from 24-h ambulatory BP.1 All participants 
underwent a thorough medical history and physical examination, as well as blood 
chemistry evaluation and echocardiography to exclude angina pectoris, myocardial 
infarction, heart failure, diabetes, renal disease, lung disease, or history of stroke. 
None were current smokers. During the screening process, patients with severe 
hypertension (Grade 3; systolic pressure > 180 or diastolic pressure > 110 mmHg) 
were referred to emergency medical care and were not included in this study. 
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described in detail previously.7 In short, a 4 parameter logistic function was used for 
sigmoidal curve fitting, where model parameter a represents the total range of 
change in CBFV or CVCi; y0 is the maximum value of CBFV or CVCI during 
hypercapnia; x0 is the level of ETCO2 where vascular reactivity to changes in CO2 
is maximal; and b is a constant that determines the sigmoidal shape of the curve 
(low values for b result in an almost flat curve) (Fig. 1). Finally, linear regression of 
changes in CBFV and CVCI in the range of ETCO2 between 40-50 Torr was 
performed. We have shown previously that the slope of this regression is a robust 
method to estimate maximum vascular reactivity for each individual subject.7 This 
maximum vascular reactivity is expected to be very sensitive to altered myogenic 
and structural cerebrovascular properties, associated with hypertension.3,15,16
Statistics
T-tests and analysis of variance were used to compare the differences and 
interactions between the subject groups and the effects of antihypertensive 
treatment on baseline hemodynamics and CVMR (SigmaStat, version 3.11 Systat 
Software Inc.). Data are presented as mean (SD), with their associated P values. 
Results
Reduction in BP and changes in CBFV
24 h ambulatory BP was reduced significantly within 1-2 weeks of treatment. 
Reductions in BP in patients with hypertension were well maintained over the period 
of 3-4 months with the same dose of drugs used to reduce BP acutely (Table 1). For 
brevity, nocturnal BP data are not shown, however, all participants were “normal 
dippers”, and treatment affected nocturnal BP similarly as awake BP.
Before treatment, no differences in CBFV were observed between control subjects 
and patients with hypertension. CBFV did not change after short and long-term 
reductions in BP.
Estimation of CVMR 
Before treatment, maximum (plateau) changes in CBFV and CVCI with hyperventilation 
and rebreathing were similar in control subjects and patients with hypertension. 
In patients, neither short-term nor long-term treatment affected these values (Table 2).
Antihypertensive treatment 
After the baseline test, patients received low dose losartan/hydrochlorothiazide 
(50/12.5 mg once daily) for one week. If the reduction in BP was not below a prior 
determined level of systolic pressure < 140 mmHg and diastolic pressure < 90 
mmHg the dose was increased to 100/25 mg. The short-term test (one to two weeks 
after start of treatment) was performed when this goal of BP control was reached. 
The long-term test was scheduled after three to four months of continued treatment. 
In patients, 24-h ambulatory BP (Accutracker II, SunTech) was measured before 
treatment and repeated on the days before the short and long-term tests. In healthy 
subjects, 24-h BP was measured once at baseline and once before the long-term 
test. The patients took their losartan/hydrochlorothiazide in the morning 2-3 h 
before the study to ensure its optimal BP lowering effects.
Data analysis
Off-line data analysis was performed using commercially available software 
(Acknowledge, BIOPAC systems). Baseline BP, HR and CBFV were obtained from the 
average of beat-to-beat data; ETCO2 was derived from the breath-to-breath data. 
Cerebrovascular conductance index (CVCI) was calculated as mean CBFV divided by 
mean BP for all beat-to-beat data.7 Since CBFV may be affected directly by changes 
in BP13,14, estimations of CVMR based on CVCI may reveal intrinsic vascular responses 
to changes in CO2. During hyperventilation and rebreathing, breath-to-breath values 
of mean CBFV, BP, CVCI, HR and ETCO2 were obtained. Towards the end of 
rebreathing, CBFV reached a plateau-phase; a similar plateau was observed for 
hypoventilation, indicating that a steady-state had been reached. To allow comparison 
with previous studies that have only measured steady-state conditions, the first part of 
data analysis was performed using these plateau values. Thus, maximum hypocapnic 
(~20 mmHg below baseline ETCO2) reduction in CBFV and CVCI (in %), maximum 
hypercapnic (~20 mmHg above baseline) increase in CBFV and CVCI (in %), and total 
range of change in CBFV and CVCI (hypocapnic + hypercapnic, in %) were derived. 
Next, CVMR was expressed as the ratio of % change in CBFV or CVCI over the whole 
range of changes in ETCO2 (hypocapnic + hypercapnic). 
The second part of data-analysis focused on the dynamic responses of CBFV to the 
transient changes in ETCO2. Here, during hyperventilation and rebreathing, CVMR 
was estimated nonlinearly for breath-to-breath changes in CBFV as well as CVCI, as 
7
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increased by 25 (SD 8) mmHg, without a change in HR. Neither short-term nor 
long-term treatment altered the BP and HR response to CO2.
Discussion
This study assessed cerebral vasomotor reactivity to CO2 in patients with newly 
diagnosed mild to moderate hypertension, using a modified rebreathing method 
recently developed in our laboratory.7 In these untreated patients, there was no 
evidence that the elevated BP caused impairment in CVMR. Acute lowering of BP 
within 1-2 weeks with losartan/hydrochlorothiazide led to compensatory cerebral 
vasodilatation (reduction in resistance) and therefore did not lower CBFV, consistent 
Examples of sigmoidal curve fitting of changes in CBFV and CVCI vs. ETCO2 are 
presented in Fig 1 and 2 respectively. The results of non-linear parameter identification 
are summarized in Table 2. Before treatment, no differences in the model parameters 
were observed between control subjects and patients with hypertension. Model 
parameters did not change after reductions in BP in patients. The steep portion of 
changes in CBFV or CVCI to ETCO2 was identified in the range between 40-50 Torr 
(Fig 1, 2). Estimation of CVMRmax in this range of ETCO2 also did not differ between 
patients and controls nor was it influenced by treatment (Table 2). 
Effects of CO2 on BP and HR
Patients and controls had similar changes in ETCO2 during hyperventilation and 
rebreathing (Fig 1, 2). In controls, hyperventilation decreased BP by 16 (SD 3) 
mmHg and increased HR by 17 (SD 11) bpm. Rebreathing increased BP by 27 (SD 
14) mmHg without a change in HR. In patients, hyperventilation lowered BP by 21 
(SD 12) mmHg and increased HR by 14 (SD 10) bpm. During rebreathing, BP 
7
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Results of the modified rebreathing test and sigmoidal curve-fitting, displaying the changes in cerebral blood flow 
velocity (CBFV, left) and cerebrovascular conductance index (CVCI, right) in response to end-tidal CO2 (ETCO2) in  
a healthy control subject. The black dots represent data averaged over the period of one breath, during hyper-
ventilation (data points below 100 %) and CO2-rebreathing (data points above 100%). The sigmoid line is the result 
of 4-parameter exponential curve fitting of these data points (see text and7 for more details). The left graph offers a 
graphic representation of these 4 identified parameters. “a” is the total range of changes in CVCi or CBFV, “Y0” is  
the maximum value, “X0” is the level of ETCO2 that exhibits highest CO2 sensitivity, and “b” is a factor that determines 
the shape of the regression curve.
Results of the modified rebreathing test and sigmoidal curve-fitting in a hypertensive patient. Representation of black 
dots and sigmoid curve as in figure 1. Top: Changes in cerebral blood flow velocity (CBFV) in response to end-tidal 
CO2 (ETCO2) at baseline (A), and after 1-2 weeks (B) and 3 months (C) of treatment with losartan/hydrochlorothiazide. 
Bottom: Changes in cerebrovascular conductance index (CVCI) in response to ETCO2 at baseline (D), and after 1-2 
weeks (E) and 3 months (F) of treatment.
Figure 1  Example of the analysis of vasomotor reactivity in a healthy subjects. 
Figure 2  Example of vasomotor reactivity analysis in a hypertensive patient.   
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in ETCO2 or BP, the parameters that determine the increase in CBFV and thus are 
essential to evaluate CVMR. Serrador et al. also reported reduced CVMR in subjects 
with both controlled and uncontrolled hypertension without co-morbidity.23 Breath-
by-breath changes in CVCI were obtained to estimate CVMR during hypercapnic 
rebreathing. Their CVCI data were derived after subtraction of a hypothetical 
component induced by changes in BP, assuming that cerebral autoregulation was 
unaltered in hypercapnic states. Interestingly, when CVMR was estimated from the 
unmodified CVCI data, there was no difference between patients and control 
subjects.23 Maeda et al. found a reduced CVMR in hypertension using linear 
regression analysis of CBFV in the hypocapnic to hypercapnic range and estimated 
CVMR from the regression slope of these data. However, CVMR was reduced only 
in a subgroup with advanced cerebrovascular disease. Kario et al. used perfusion 
MRI, with acetazolamide infusion to assess CVMR20. Only patients with both 
hypertension and diabetes had reduced reactivity. Tominaga et al. found normal 
CVMR, using the Xenon clearance method, in hypertensive patients who did not 
manifest cerebrovascular disease.24 Oku et al. found normal CVMR with PET in 
patients with mild to moderate hypertension with minimal or no cerebrovascular 
disease.12 None of these studies accounted for changes in BP during assessment 
of CVMR. Our study adds to these earlier reports by exploring a wider range of 
changes in CO2, and by investigating transient changes in CO2, CBFV and CVCI, 
therefore accounting for alterations in BP during CO2 stimuli.  
In all these studies, it was unknown how long hypertension had already been present 
at the time of study. Also, presence or absence of cerebrovascular disease in subjects 
was mostly judged on clinical history. Only subjects with signs or symptoms of 
cerebrovascular disease, and/or diabetes had reduced CVMR.20,25,26 Therefore, our 
observation of normal CVMR in hypertensive patients without evidence of cerebrovascular 
disease and without diabetes seems consistent with careful analysis of previous 
reports. Consistent with this interpretation is that in spontaneously hypertensive rats, 
CVMR remains normal, whereas CVMR is impaired in the stroke-prone genetic variant, 
at advanced age when cerebrovascular disease has developed.27
Normal CVMR after BP lowering
CVMR is reduced in patients with carotid artery stenosis, who have reduced 
perfusion pressure and compensatory cerebral vasodilatation.28 Reduction in 
with intact pressure autoregulation. These hemodynamic changes also did not 
impair CVMR. Furthermore, long-term antihypertensive treatment with the inhibition 
of angiotensin II, which in theory would cause beneficial cerebrovascular remodelling 
and/or improved endothelial function, did not further change cerebrovascular 
resistance nor did it augment CVMR. Finally, there was no difference in the BP and 
HR responses to CO2 stimuli between patients and controls, and these responses 
were not influenced by antihypertensive treatment.
The findings that CVMR was not altered in untreated hypertension and was not 
reduced by acute reduction in BP were in contrast with our hypothesis. Below, we 
will further discuss these findings in relation with the existent literature. 
CVMR in hypertension
It has been demonstrated repeatedly that CBF in patients with hypertension, 
measured directly or estimated from measurements of CBF-velocity, is similar to 
that observed in age and sex matched normotensive controls.6,17,18 According to 
Ohm’s law, this implies that cerebrovascular resistance is elevated in patients with 
hypertension, most likely due to cerebral vasoconstriction.17 Therefore, 
cerebrovascular capacity for further vasoconstriction may be reduced.19 Furthermore, 
cerebrovascular remodelling and/or endothelial dysfunction associated with 
prolonged hypertension may reduce the capacity for vasodilatation as demonstrated 
in animal studies.3 In the present study, however, patients with mild to moderate 
hypertension had vasoconstrictive and vasodilatatory responses to changes in 
arterial pressure and CO2 that were similar to normal controls. Specifically, the 
estimates of CVMR using traditional linear regression methods, as well as the 
recently developed and more sensitive transient estimates of CVMR did not differ 
between hypertensive patients and controls.
The findings in this study appear to be in contrast with previous reports of a reduced 
CVMR in patients with hypertension.20-22 Troisi et al. estimated CVMR with TCD in 
young subjects, free from cerebrovascular disease or diabetes, using a breath hold 
index, obtained during 30 s voluntary breath hold.22 This index was lower in subjects 
with hypertension (aged 34 (SD 7) y), and was partially restored following treatment 
with atenolol. Unfortunately, the breath hold index describes vascular reactivity only 
in a small hypercapnic range. Moreover, it does not provide information on changes 
7
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contention. First, Lipsitz et al. found a preserved CVMR following BP reduction with 
a wide range of antihypertensive drugs, which strongly argues against a specific 
drug class effect.33 Second, we observed these effects already after 1-2 weeks of 
treatment, which would mean that effects of angiotensin II inhibition on remodelling 
and endothelial function should have taken place within this short time frame.
Careful analysis of the studies that have reported an improvement of CVMR with 
long-term antihypertensive treatment, demonstrates that this effect was observed 
only in patients with known cerebrovascular disease and with diabetes.20
BP response to CO2
Hypercapnia, through central chemoreceptors, causes sympathetic activation 
which in turn results in elevated BP due to the combined effects of an increase in 
cardiac output and peripheral vascular resistance.7,34,35 Hypertension is associated 
with increased sympathetic activity.36,37 Thus far, the issue whether this increased 
baseline sympathetic activity leads to an enhanced effect of hypercapnia on BP in 
hypertensive patients had not been addressed specifically. There was no difference 
in BP and HR response between untreated patients with hypertension and controls. 
The few available studies on CVMR in hypertension that have measured the BP 
response to CO2 support these findings.12,23,24,33 One explanation is that despite the 
difference in baseline activity, sympathetic responses are similar in hypertension 
and controls, as has been observed for example in tilt-table testing.36 A second 
explanation is that the magnitude of CO2 induced sympathetic activation obscures 
the much smaller difference in baseline activity.35-37
Antihypertensive treatment did not alter the BP and HR responses to CO2. Previous 
research regarding interactions between baroreflex activation by changes in BP and 
central chemoreflex activation by changes in CO2 are inconsistent.34,35 Our findings 
suggest that baroreflex resetting after BP lowering does not alter the BP response 
to hypercapnia.   
The observed hypotensive response to hyperventilation, with an associated 
increase in HR, has been described previously.7 This response, too, was not 
influenced by hypertension or antihypertensive treatment. 
CVMR also was observed after acute reduction in BP in animal experiments29 and 
in human subjects.19 In contrast with these observations, we found no effect of either 
short or long-term BP lowering on CVMR, despite clear indications that cerebral 
vasodilatation occurred. Four factors may explain these observations.
First, the reduction in BP was smaller than in the acute hypotension experiments, 
where BP was reduced below the normal autoregulation range.19 The reduction in 
BP is also not likely to approximate the reduction in perfusion pressure caused by 
a severe carotid artery stenosis.
Second, the magnitude of vasodilatation induced by CO2 exceeds the magnitude of 
vasodilatation induced by pressure autoregulation. For example, for a 20% reduction 
in perfusion pressure, CBF can be maintained constant by an increase in cerebral 
blood vessel diameter of ≈6%. However, maximum hypercapnia, associated with a 
100% increase in flow, brings about a 20% increase in diameter, assuming that BP 
is unchanged.
Third, CVMR is largely determined by the properties of smaller cerebral arteries, 
arterioles and capillaries30, whereas hypertension has major effects on large 
cerebral arteries.31 Under normal conditions, large arteries (diameter >200 mm) 
account for ≈40% of total cerebral vascular resistance, but their relative contribution 
increases in chronic hypertension.31 In hypertensive rats with a mean aortic BP ≈160 
mmHg (controls: 98 mmHg), the nearly doubled large artery resistance resulted in 
a pial arteriolar pressure of only ≈80 mmHg (control 60 mmHg).32 Thus, microvessels 
may retain normal vascular reactivity to CO2 as they are protected by the resistance 
changes in larger arteries31; alternatively, the adaptations that take place in larger 
arteries as a result of either hypertension or BP lowering are not reflected in CVMR.
Fourth, losartan, an AT1 receptor antagonist that blocks the deleterious effects of 
angiotensin II, may have beneficial cerebrovascular effects that are independent of 
its BP lowering effects.5 Specifically, effects of losartan on cerebral remodelling and 
endothelial function may have augmented the vasomotor response to CO2, thus 
compensating for the effects of blood pressure reduction on CVMR. Indeed, Oku et 
al. similarly found no change in CVMR after follow-up of 8-22 weeks with losartan 
monotherapy.12 However, we caution that there are several arguments against this 
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Finally, because we only investigated losartan-hydrochlorothiazide, we can not tell 
whether our observations are specific for this drug class, or whether they will also 
apply to other antihypertensive drugs, as is suggested by the study of Lipsitz et al.33
In summary, we have studied patients with mild to moderate hypertension of 
unknown duration, in the absence of diabetes or cerebrovascular disease, and have 
shown that CVMR is not affected. As discussed above, we conclude that previous 
reports of impaired CVMR with hypertension were based on inclusion of hypertensive 
subjects with co-morbid severe cerebrovascular disease and/or diabetes.
We have also shown that despite significant hemodynamic alterations induced by 
the initiation of antihypertensive treatment, CVMR remained unaffected. These 
findings add to our previous observation that cerebral autoregulation was not 
altered after short-term and long-term antihypertensive treatment.6 Together these 
observations suggest that the cerebrovascular adaptations to a reduction in 
perfusion pressure are not associated with exhaustion of cerebrovascular reserve, 
with the caveat that these were patients with mild to moderate hypertension. 
 
Limitations of this study
The limitations imposed by the measurement of CBF using TCD, as well as the 
limitations specific to the method used to estimate CVMR have been discussed 
previously.7,38-40 The flow-velocity in the MCA measured by TCD is determined by 
CBF and by the diameter of the MCA. Therefore, changes in CBFV reflect changes 
in CBF only if the MCA diameter is constant. During hypotension, as well as during 
hypocapnia and hypercapnia, MCA diameter was unchanged or showed less than 
4% change.39,40 These studies were performed in healthy subjects and neurosurgical 
patients. Studies in hypertensive patients are lacking. Measurements of isolated 
MCA from spontaneously hypertensive rats indicate a 10 % change in diameter for 
a large range of changes in mean BP from 40 to 140 mmHg.41 This suggests that in 
our study, small changes in MCA diameter cannot be excluded. In theory, this would 
have the following effects on our data. Under conditions of equivalent CBF, the 
relatively narrower MCA lumen in hypertensive patients41 would increase CBFV and 
lead to overestimation of CBF, whereas a lumen increase in MCA following 
normalization of BP would lower CBFV and underestimate CBF. This then would 
have led to a reduction in measured CBFV following treatment. In summary, our 
finding of unaltered CBFV represent unaltered CBF is MCA diameter was constant, 
or increased CBF should MCA diameter have been affected by BP changes. 
Similarly, should hypocapnia cause MCA vasoconstriction, this would augment 
CBFV and underestimate the hypocapnic reduction in CBF, and vice versa for a 
vasodilatatory effect of hypercapnia. 
Nevertheless, our results are concordant with results obtained with other modalities 
(such as MRI and PET) to measure CBF during hypo- and hypercapnia 12,20,24, which 
suggests that  possible confounding effects of changes in MCA diameter in our 
study had minimal effect on outcome or interpretation. 
This is a study in a small number of subjects. We previously found good 
reproducibility of our method, in line with other methods to estimate CVMR.7 It has 
been shown that a clinically significant reduction in CVMR can be identified even 
with this small number of subjects.28 Indeed, this study was adequately powered to 
detect small differences in CVMR. 
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Abstract
Background and Purpose - Cerebrovascular disease may contribute to the 
development and progression of Alzheimer’s disease (AD). This study determined 
whether impairments in cerebral hemodynamics can be observed in early-stage AD.
Methods - 9 patients with mild AD and 8 cognitively normal controls matched for 
age underwent brain MRI and neuropsychological evaluation, followed by 
assessment of steady-state cerebral blood flow velocity (CBFV, transcranial 
Doppler), blood pressure (BP, Finapres) and cerebrovascular resistance index (BP/
CBFV). To detect changes in cerebral hemodynamics and to quantify the dynamic 
pressure-flow relation of the cerebral circulation, spectral and transfer function 
analysis of beat-to-beat variability in BP and CBFV under resting conditions and 
during repeated squat-stand maneuvers were measured. 
Results - Alzheimer patients had lower CBFV and higher cerebrovascular resistance 
index, even when normalized for total brain volume. Low-frequency variability of BP 
was enhanced in AD patients, suggesting impaired arterial baroreflex function. CBFV 
variability was reduced despite enhanced BP variability in AD. Consistent with this 
finding, transfer function gain at frequencies of 0.1 and 0.05 Hz during squat-stand 
maneuvers was significantly reduced by 40% in patients with AD (p < 0.01), indicating 
enhanced cerebral vasoconstriction in damping of CBFV to BP fluctuations.   
Conclusions - Patients had a distinct pattern of altered cerebral hemodynamics, 
including reduced CBFV and increased cerebrovascular resistance. Induced BP 
fluctuations were exaggerated, suggesting baroreflex impairment. Cerebral blood 
flow was severely compromised during dynamic standing, demonstrating impaired 
vasomotor reserve in patients with early AD. 
Introduction
Vascular pathology is likely to play an important role in the development and 
progression of Alzheimer’s disease (AD).1-5 Epidemiological studies have shown 
that vascular risk factors increase the risk of developing AD.6 In addition, brain 
autopsy studies have observed that both large and small-vessel disease are 
extensively present in AD.1,3 Furthermore, in animal models of AD, cerebrovascular 
disease is found not only in the form of anatomical (e.g. luminal obstruction and 
microvascular deformation),7 but also as functional (endothelium-related)8 alterations, 
linked to early vascular deposition of amyloid-beta peptide, which may precede 
overt AD neuropathology.7,8 Additionally, independent of the presence of 
amyloid-beta, brain vascular smooth muscle cells in AD patients display 
hypercontractile properties, and brain endothelial cells have reduced expression of 
genes regulating vascular differentiation, leading to enhanced cerebral 
vasoconstriction and possibly reduced capillary density.9,10
These vascular changes may contribute to the neuronal degeneration in AD5 and 
are even considered responsible for the initiation and progression of AD 
neuropathology.1 Indeed, in vivo measurements of CBF in patients with AD, using 
imaging modalities such as MRI and PET, have consistently identified reduced 
global and regional CBF associated with AD severity.5 A point of discussion 
remains, however, that the reduced CBF may equally be secondary to the loss of 
neuronal function (reduced metabolic demand) and/or brain atrophy. Therefore, 
further studies of cerebral hemodynamics in patients presenting with early AD are 
warranted to elucidate the role of vascular disease in AD. 
Transcranial Doppler ultrasonography (TCD) allows measurements of cerebral 
blood flow velocity (CBFV) in the major cerebral arteries with high temporal 
resolution. When registered together with blood pressure (BP), synchronized data 
of beat-to-beat variability in BP and CBFV are obtained, providing important 
information on the regulation of the cerebral circulation.11,12 Transfer function 
analysis, a method based on spectral analysis of these beat-to-beat data, can then 
be used to quantify the dynamic pressure-flow relationship of the cerebral 
circulation.11,12 We hypothesized that vascular abnormalities in AD at an early stage 
alter cerebral hemodynamics, which can be measured via beat-to-beat changes in 
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After at least 10 min rest in sitting position, 5-min segments of BP and CBFV data 
were recorded during spontaneous respiration. These data were used for spectral 
analysis of spontaneous oscillations in BP and CBFV.
To enhance the magnitude of alterations in BP and CBF – and to mimic such 
changes in daily life associated with changes in body posture- oscillations in BP 
and CBFV were induced by repeated squat-stand maneuvers. After careful 
instruction and practice, participants were coached into performing these maneuvers 
at a frequency of 0.025 Hz (20 s squat followed by 20 s standing up) for 5 min, 0.05 
Hz (10 s squat, 10 s stand) for 4 min and at 0.1 Hz (5 s squat, 5 s stand) for 3 min, 
separated by 10 min of recovery. Physical assistance during standing up from squat 
was provided to aid the performance of these maneuvers.
Transfer Function Analysis of the Dynamic Pressure-Flow Relationship of the 
Cerebral Circulation
The method of transfer function analysis, which provides the parameters of gain, 
phase and coherence, has been described in detail previously.11 
Transfer gain quantifies how the amplitudes of the changes (oscillations) in BP at 
different frequencies are transmitted to CBFV; a lower gain implies that these 
oscillations are reduced (damped) either by dynamic cerebral autoregulation or 
increases in the cerebrovascular impedance.14 In this study, transfer function gain is 
expressed not only as changes in CBFV per mmHg changes in BP, but also as the 
percentage change in CBFV per mmHg change in BP to reduce the potential effects 
of individual differences in MCA diameter on the gain estimate. Transfer function 
phase reflects the time relationship between oscillations in BP and CBFV. Coherence 
can be compared to a linear correlation coefficient, and quantifies to what extent 
changes in CBFV are linearly associated with changes in BP. 
MRI Measurements
T2-weighted and Fluid-Attenuated Inversion Recovery (FLAIR) images were 
obtained using a Philips Intera 1.5T scanner. Images were converted from DICOM 
to ANALYZE format to facilitate analysis. Segmentation of skull and connective 
tissue was conducted using the skull strip function in the DICOM image editor 
MRIcro. Leukoaraiosis volume (LV) and whole brain volume (WBV) were measured 
BP and CBFV using TCD. We proposed that changes in cerebral hemodynamics 
identified using this method potentially can be used for selection of patients at risk 
for vascular pathology in AD and as a biomarker for clinical trials of therapies aimed 
at reducing vascular risk in AD.
Materials and Methods
Subjects
We included 9 patients with a diagnosis of probable AD according to NINCDS-ADRDA 
criteria, with a clinical dementia rating scale of 0.5 (n=3) or 1.0 (n=6), and 8 
controls, matched for age and level of education, recruited from the Alzheimer 
Disease Center at UT Southwestern Medical Center, Dallas. Participants were 
selected from 11 patients and 12 controls who were screened. Subjects with acute 
or chronic knee or hip conditions which would prevent them from performing 
squat-stand maneuvers (2 controls) and subjects without an adequate acoustic 
window, preventing high quality TCD signal detection (1 control, 1 AD) were 
excluded during the initial screening process. Subsequently, 2 subjects (1 control, 
1 AD) were excluded because of poor finger BP and TCD signal quality during 
measurements. The study was approved by the Institutional Review Boards of the 
University of Texas Southwestern Medical Center and Presbyterian Hospital of 
Dallas. All participants signed an informed consent form. In AD patients, additional 
informed consent was obtained by proxy. AD patients and their controls underwent 
a comprehensive clinical-neuropsychological evaluation and brain imaging using 
MRI. Characteristics of the study participants are listed in Table 1. 
Hemodynamic Measurements
BP was measured in the finger by photoplethysmography (Finapres, Ohmeda). 
Finger arterial pressure waves measured with this technique were validated against 
central aortic root measurements and can be used reliably to quantify cerebral 
hemodynamics.13 CBFV was obtained in the middle cerebral artery (MCA) on one 
side by transcranial Doppler ultrasonography (DWL Elektronische Systeme, 
Germany).11 End-tidal CO2 was monitored with a nasal cannula using capnography 
(Criticare Systems). In addition, peripheral arterial saturation (pulse-oximetry) and 
3-lead ECG were recorded.
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studied in 6 AD patients and 5 aging controls.16 During hyperventilation and 
rebreathing, breath-to-breath changes in mean CBFV and BP were recorded and 
cerebrovascular conductance index (CVCi) was calculated (CBFV/BP). Total 
cerebral vasomotor reactivity (CVMR) is expressed as the range of percentage 
changes in CVCi during hyperventilation plus those during rebreathing. In addition, 
maximum CVMR index was obtained as the linear regression slope of percentage 
changes in CVCi in response to end-tidal CO2 between 40 - 50 mm Hg.16 
Statistical Analysis
Comparisons were made between AD and healthy aging. For normally distributed 
data, two-tailed Student t-test was used. Not all data resulting from transfer function 
analysis were normally distributed. Here, Student t-test was repeated after log-
transformation of the data, and in addition non-parametric testing was used 
(Wilcoxon rank test). Because of the small number of subjects, in addition to 
accepting a statistical significance at p < 0.05, p < 0.1 was interpreted to represent 
a relevant trend that warrants further exploration. Data are presented as mean and 
standard deviation (SD). 
Results
Patient characteristics
Alzheimer patients had relatively mild cognitive deficits consistent with early stage of 
the disease (Table 1), but were clearly impaired in episodic memory (only a summary 
of neuropsychological test results is presented here for brevity). Volumetric analysis 
of brain MRI’s revealed a trend towards higher white matter lesion volumes in AD. 
Global brain volume was not significantly different as can be expected due to large 
inter-individual variance in brain volume and the small sample size in this study.
Baseline hemodynamics are presented in Table 2. Ambulatory BP recordings revealed 
mean (SD) awake blood pressure of 136 (15)/75 (7) mmHg in AD and 124 (13)/71 (8) in 
aged controls (p=0.19 for systolic BP). Participants diagnosed with hypertension were 
well controlled (mean awake BP < 140/85 mmHg). Two AD patients and one control, 
who had not previously been diagnosed with hypertension, met criteria for systolic 
hypertension (mean awake systolic BP of 148, 156 and 146 mmHg respectively).
using an image processing tool developed with MATLAB (The MathWorks, Inc., 
Natick, MA, USA).15
24 hr Ambulatory Blood Pressure Monitoring
In 5 aging controls and 6 AD patients, 24 hr ambulatory BP recordings (Accutracker 
II, Sun Tech) were measured. Mean values for systolic and diastolic BP and heart 
rate were collected during awake hours and during sleep. 
Standing Up Following a Singe Squat
In these same 5 aging controls and 6 AD patients, we measured the hemodynamic 
effects of a single squat (60 s) followed by standing up to investigate the effect of a 
single hypotensive challenge to cerebral perfusion.
Cerebral Vasomotor Reactivity (CVMR)
Using a previously described method, hypocapnic vasoconstriction and hypercapnic 
vasodilatation –induced by hyperventilation and rebreathing respectively- were 
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Table 1  Overview of the various dynamic quantifications of cerebral  
autoregulation in the time domain.
 Alzheimer’s Disease Aging Controls  P Value
 (N= 9) (N= 8)
Age-yrs 67.9 (5.5) 64.5 (4.0) 0.17 
Gender -male:female  3:6 4:4 
MMSE 25 (3.2) 29 (0.5) 0.03
Word list recall- no. of words 2 (1.9) 8 (1.3) 0.0001
CDR- sum of boxes 4 (1.2) 0.1 (0.2) 0.0001
Total brain volume-ml 1081 (65) 1108 (79) 0.53
White matter lesions-ml 14.3 (10.4) 7.5 (5.8) 0.25 
Vascular risk factors (no. of subjects)
Hypertension 4 3
Hypercholesterolemia 6 1
Diabetes 0 0
Smoking 0 0 
Medication
Antihypertensive drugs 4 3
lipid-lowering drugs 4 2
cholinesterase-inhibitor 8 - 
NMDA-receptor antagonist 8 -
MMSE: Mini mental state examination. CDR: Clinical dementia rating scale
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explained by a higher or lower baseline BP, nor by a history of hypertension. The 
enhanced oscillations in BP suggest that baroreflex function is impaired in patients 
with AD. Estimates of transfer function gain, phase and coherence are depicted in 
figure 3. Transfer function gain for induced oscillations at the frequencies of 0.05 
and 0.1 Hz was reduced by ~30 % in AD relative to normal controls (p=0.01). 
However, for spontaneous oscillations this difference was not significant (p=0.18).
The hemodynamic effects of standing up after a single squat (60 s) are depicted in 
Figure 4. Whereas BP returned to baseline in controls after the initial rise at the 
onset of squatting, BP was not stable in AD. The reduction in BP upon standing up 
after squat was slightly larger (39 mm Hg (SD 16)) in AD than in controls (26 mm Hg 
(SD 11)), or, expressed as relative change, a reduction of 33 vs. 26 % (p=0.2). It is 
Despite the early stage of disease, AD patients had a substantially lower CBFV and 
higher cerebrovascular resistance compared with the controls (Table 1). Normalized 
for global brain volume, CBFV was 3.6 (0.7) cm/s per 100 ml brain volume in AD 
versus 5.7 (2.4) cm/s /100 ml in controls (p = 0.03).
Cerebral hemodynamics
Figure 1 shows an example of spontaneous oscillations in BP and CBFV, as well as 
the oscillations that were induced by repeated squat-stand maneuvers, in one 
patient with AD and one control subject. Note that oscillations are larger in AD for 
BP, but smaller for CBFV, compared to the healthy control.
Figure 2 displays the results of spectral analysis of oscillations in BP and CBFV. 
Note the larger spectral power in AD for BP oscillations, but not for CBFV.
Indeed, spectral analysis of spontaneous oscillations in BP revealed increased 
spectral power in the very low frequency range (VLF) in AD (Table 3).
BP oscillations induced by the repeated squat-stand maneuvers were consistently 
higher in AD in the VLF range (0.025 and 0.05 Hz), and in the LF range (0.1 Hz) 
(Table 3). Individual differences in the magnitude of BP oscillations could not be 
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Table 2  Baseline Hemodynamic Parameters.
 Alzheimer’s Disease Aging Controls  P Value
 (N= 9) (N= 8)
Systolic blood pressure-mmHg  140.1 (19.8) 125.6 (26.5) 0.23
Diastolic blood pressure-mmHg 73.7 (9.0) 73.1 (9.8) 0.91
Mean arterial pressure-mmHg  101.0 (12.4) 94.7 (15.8) 0.39
Mean arterial pressure-mmHg  98.4 (12.4) 94.4 (10.9)  0.39
(from Finapres)
Cerebral blood flow-velocity-cm/s 38.4 (7.1) 54.5 (19.0) 0.05
Cerebrovascular resistance-mmHg/cm/s 2.7 (0.7) 1.9 (0.6) 0.03
End-tidal CO2-mmHg 37.3 (3.0) 37.3 (4.2) 0.96
Total CVMR -% 58 (19) 76 (28) 0.26
Maximum CVMR index-%/mmHg 5.9 (2.6) 5.2(2.0) 0.66
CVMR: cerebral vasomotor reactivity
Example from two representative subjects, one with AD and one normal control, demonstrating spontaneous  
oscillations in blood pressure and cerebral blood flow-velocity over a period of 5 min (panel A). Panel B through D 
depict the effect of repeated squat-stand maneuvers at different intervals on these oscillations. Recording periods  
are 5, 4 and 3 min respectively. Panel B shows how repeated squat-stand intervals at 20 s lead to oscillations  
at 0.025 Hz. Panel C: 10 s intervals with oscillations at 0.05 Hz. Panel D: 5 s intervals with oscillations at 0.1 Hz.
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Figure 1  Spontaneous and Induced Oscillations in Blood Pressure and 
Cerebral Blood Flow Velocity.   
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clear in Figure 4 that baseline CBFV was substantially lower in AD (see also Table 
2). The orthostatic BP reduction following squat led to a reduction in CBFV of 12 (SD 
4) cm/s in AD vs. 21 (SD 26) cm/s in controls, or 26 % and 29 % (p=0.77). AD 
patients reached very low diastolic flow-velocity values during standing (12 (SD 7) 
vs. 24 (SD 11) cm/s in controls, p=0.1).
Finally, total cerebral vasomotor reactivity (CVMR) appeared to be lower in AD 
(Table 2), but this difference was not significant, because of the large individual 
variability in this small number of patients. Moreover, maximum reactivity index was 
similar in AD and controls. 
MRI and hemodynamics
We performed exploratory analysis of possible relationships between white matter 
lesion volume, brain volume and hemodynamic parameters. Although the 
interpretation is limited due to the small sample size, a larger volume of white matter 
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Individual power spectral density plots for aged controls and Alzheimer patients, for blood pressure (left pane) and 
cerebral blood flow-velocity (right pane). The Y-axis shows the magnitude of the observed oscillations, and the X –axis 
displays the frequency of these oscillations. Note the much stronger oscillations in blood pressure in the very low 
frequency range (0.02 – 0.07 Hz) in Alzheimer patients, with reduced oscillations in cerebral blood flow-velocity.
Group-averaged data showing results of transfer function analysis of spontaneous oscillations in blood pressure (BP) 
and cerebral blood flow-velocity  (CBFV) as well as of oscillations induced by repeated squat-stand maneuvers.  
 : Alzheimer  patients. • : normal controls.  Transfer function analysis describes how oscillations in BP are transformed 
into oscillations in CBFV. Gain is presented as both the absolute and percent changes in CBFV per mmHg change in 
BP.  *: p < 0.05; ** p < 0.01
Figure 2  Spectral Density Plots of Oscillations in Blood Pressure and Cerebral 
Blood Flow Velocity.   
Figure 3  Transfer Function Analysis of Spontaneous and Induced Oscillations 
in Blood Pressure and Cerebral Blood Flow Velocity.   
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lesions in this study was not associated with higher blood pressure or lower CBFV 
at baseline, nor with larger blood pressure variability, altered cerebral autoregulation 
or reduced vasomotor reactivity. 
Discussion
With non-invasive monitoring of blood pressure and cerebral blood flow-velocity 
using TCD, we observed a distinct pattern of changes in cerebral hemodynamics in 
patients with mild Alzheimer’s disease. In summary, these alterations consisted of a 
reduced CBFV with elevated cerebrovascular resistance that was not explained by 
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Table 3  Spectral Power of Spontaneous and Induced Oscillations in 
Blood Pressure and Cerebral Blood Flow Velocity.
 Alzheimer’s Disease Aging Controls  P Value
Spontaneous oscillations (N= 9) (N= 8)
PS BP - mmHg2   
VLF 9.6 (5.5) 5.6 (2.4) 0.08
LF 2.4 (1.4) 2.6 (3.1) 0.84
HF 0.5 (0.6) 0.6 (0.5) 0.69
PS CBFV – (cm/s)2   
VLF 3.0 (1.7) 5.5 (5.1) 0.18
LF 1.5 (1.4) 2.8 (4.2) 0.43
HF 0.4 (0.5) 0.5 (0.4) 0.68
Induced oscillations at 0.025 Hz N=4 N=4 
PS BP - mmHg2 239 (150.6) 86.3 (67.3) 0.11
PS CBFV - (cm/s)2 11.8 (7.3) 39.5 (42.9) 0.27
Induced oscillations at 0.05 Hz N= 9 N=8 
PS BP - mmHg2 460.9 (185.4) 306.8 (131.2) 0.06
PS CBFV - (cm/s)2 84.3 (55.5) 149.6 (109.1) 0.16
Induced oscillations at  0.1 Hz N=9 N=8 
PS BP - mmHg2 315 (117.8) 195.3 (90.8) 0.03
PS CBFV - (cm/s)2 77.8 (45.4) 126 (58.5) 0.08
BP: blood pressure. CBFV: cerebral blood flow-velocity. PS: power spectrum, indicating the magnitude of the  
observed oscillations within the specified frequency range. VLF: very low frequency oscillations, 0.02–0.07 Hz. LF: 
low frequency, 0.07-0.2 Hz. HF: high frequency, 0.2-0.35 Hz. Spontaneous oscillations were recorded during five 
minutes of rest in sitting position. Induced oscillations were provoked by repeated squat-stand maneuvers at 20/20, 
10/10 and 5/5 s intervals (0.025, 0.05 and 0.1 Hz respectively). 
Group-averaged beat-to-beat BP and CBFV in AD (solid line) and controls (dotted line) showing the response to a 
single squat (60 s) followed by standing (90 s). Top left: mean BP and CBFV. Top right: diastolic BP and diastolic CBFV. 
Bottom left: percentage changes in mean BP and CBFV.
Figure 4  Hemodynamic Effects of Standing after a Single Squat.   
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(Figure 4). In this study, we cannot determine the cause of these enhanced 
oscillations. Most likely, these data indicate that in early AD, alterations occur in BP 
regulation which may be related to  the central impairment of baroreflex function.22 
The right insular region has an important role in the regulation of autonomic 
function.23,24 As this region is affected by Alzheimer neuropathology early in the 
course of disease, it has been suggested that AD may be associated with autonomic 
dysfunction in baroreflex control of arterial pressure.23 In a similar vein, pathology of 
the insula and amygdala has been implicated in central autonomic disturbances 
including sudden cardiac death.24 
Reduced CBFV Variability and Dynamic Pressure-Flow Relationship
Our study expands the earlier observations of reduced CBF by showing that 
oscillations in CBFV are reduced in AD compared to age-matched controls. This 
finding is striking considering that, because of the stronger oscillations in BP, 
oscillations in CBFV were expected to be stronger, not weaker, in AD. As we will 
discuss below, these observations could point towards an enhanced cerebral 
vasoconstriction or other vascular abnormalities in AD, such as arteriolar luminal 
obstruction, microvascular deformation or alterations in endothelial function 
associated with amyloid angiopathy.7,9,10,25
It was demonstrated recently that vascular smooth muscle cells in small intracerebral 
and pial arteries of AD patients displayed hypercontractililty and enhanced 
vasoconstriction, and that these changes were associated with overexpression of 
serum response factor (a transcription factor that regulates neurovascular gene 
expression) and myocardin-regulated contractile proteins, independent of the 
vascular effects of amyloid-beta.10 Moreover, endothelial cells of cerebral blood 
vessels in AD were shown to have reduced expression of the MEOX2 homeobox 
gene, associated with a reduction in brain capillary density and reduced CBF.9 
Finally, vascular corrosion cast visualization of the brain vasculature in AD mice 
identified “holes” – areas of vessel elimination – with microvascular distortion, and 
deposits of amyloid-beta to the microvessels.7 
Conceivably, these vascular abnormalities may lead to significant increases in 
cerebrovascular resistance and/or vascular impedance to attenuate CBFV variability 
in response to oscillations in BP (of note, whereas vascular resistance describes the 
general brain atrophy; and reduced CBFV oscillations, despite increases in 
oscillations in BP, leading to a reduction in transfer function gain. Although the 
enhanced damping of flow oscillations in AD might seem beneficial, we found that 
actually, CBFV was profoundly reduced during an orthostatic challenge. This 
suggests that intact (or possibly enhanced) pressure autoregulation in AD fails to 
compensate for the combination of globally reduced cerebral blood flow and 
instability of blood pressure. 
Reduced CBFV in AD
Even when corrected for brain atrophy, baseline CBFV was reduced by 40 % in AD 
compared with age-matched controls, coupled with a 40% increase in cerebrovascular 
resistance. Although we measured CBFV only in the MCA (providing blood flow to 
~70% of the brain), our study is consistent with findings of a reduction in total CBF 
of ~20 % early in the disease process of AD,1,5,17-19 assuming that there were no 
group differences in the MCA diameters between patients with AD and their normal 
controls. It has been argued that reduction in CBF in AD could be explained by the 
loss of brain tissue due to the neurodegenerative process, or by a reduction in brain 
metabolic demand that parallels the cognitive decline.20 However, in this study, 
differences in individual whole brain volume between AD and controls could not 
explain the differences in CBFV, suggesting that changes in CBF may not be related 
exclusively to brain atrophy, consistent with previous perfusion studies using 
MRI.19,21 In addition, a reduction in brain metabolic demand in the mild stage of AD 
(CDR 0.5 - 1) is not likely to explain a 40 % reduction in CBF under resting 
conditions.17
Enhanced BP Oscillations in AD 
The finding of increased oscillations in BP in patients with AD was unexpected, and 
has not been reported previously. These oscillations were identified in the very low 
frequency range between 0.02 and 0.07 Hz. BP oscillations in this frequency range 
are characterized by periods of 14 -50 s, which translate into intervals of 
spontaneously elevated BP that last ~7 –25 s, alternated with intervals of reduced 
BP of that same approximate length. The high BP spectral power in AD patients 
signifies the magnitude of these changes in BP. The repeated squat-stand 
maneuvers induced oscillations in BP that were much stronger in AD patients. 
Instability in BP in AD was also observed in the single squat-stand maneuver 
8
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hypotension (Figure 4), where it was clear that cerebral autoregulation could not 
prevent a substantial and prolonged reduction in CBFV in AD. We therefore 
conclude that the reduced transfer function gain in AD reflects increased 
cerebrovascular resistance or impedance as discussed above, consistent with recent 
findings of reduced cerebrovascular compliance measured using perfusion MRI.19 
Study Limitations
Certain limitations of this study need to be addressed. First, this is an explorative 
study in a small number of subjects. Second, all patients with AD were treated with 
the cholinesterase-inhibitor donepezil and the NMDA-receptor antagonist 
memantine, and it cannot be excluded that either or both of these drugs was 
responsible for the increased oscillations in BP and the decreased oscillations in 
CBFV, although there is no evidence to suggest such an effect. On the contrary, 
there is evidence to suggest that cholinesterase-inhibitors may augment CBF and 
improve neurovascular function.29 If so, this could mean that either reduction in 
transfer gain and hence improved autoregulation reflects the drug effects or that the 
deleterious neurovascular effects of AD have been underestimated in this study. 
Third, some patients and controls were hypertensive or used antihypertensive 
drugs. Previous research has shown that neither mild to moderate hypertension per 
se, or the use of antihypertensive medication, affects dynamic cerebral 
autoregulation.14 Furthermore, exclusion of these patients would seriously hamper 
the generalizability of this study. Finally, TCD measures flow-velocity - in cm/s - in a 
(large) segment of the cerebral circulation, and can not directly be compared with 
CBF in the classic sense - expressed in ml/min per 100 gram of brain tissue. We 
have addressed this issue in part by expressing CBFV in cm/s per 100 ml of brain 
volume. Flow velocity will be affected by any change in the diameter of the insonated 
vessel. Previous studies have demonstrated that it is unlikely that changes in the 
MCA diameter will occur to the extent that they would influence the estimation of 
cerebral autoregulation using TCD.12
Summary
Patients with early AD had a distinct pattern of altered cerebral hemodynamics 
including reduced cerebral blood flow and increased cerebral vascular resistance. 
relationship between steady-state pressure and flow, impedance describes the total 
oppositions to oscillatory blood flow entering into a vascular bed and is determined 
by both vascular resistance and stiffness).26
This interpretation may be supported by observations in studies using functional 
magnetic resonance imaging (fMRI). FMRI measures neuronal activity indirectly 
through the blood oxygen level dependent (BOLD) hemodynamic response 
function, and it is interesting to note that the amplitude of this hemodynamic 
response is reduced in early AD during brain activation.27 Although this is usually 
taken to represent altered neural activity and/or neurovascular coupling, in the light 
of the present study it may well be driven primarily by increases in vascular 
resistance or impedance in AD.  
This is the first study to assess the dynamic pressure–flow relation of the cerebral 
circulation in patients with AD, and the observation of reduced transfer function gain 
needs to be further elaborated. Quantification of the dynamic pressure-flow relation 
of the cerebral circulation based on the transfer function analysis of beat-to-beat 
changes in BP and CBFV has been employed to assess dynamic cerebral 
autoregulation.11,28 It has been suggested that autoregulation effectively reduces the 
impact on CBF of slow (low frequency) changes in BP, but becomes progressively 
ineffective for more rapid changes in BP (high frequency), consistent with a 
“high-pass filter”. Consequently, reduction in transfer function gain (and increase in 
phase) at lower frequencies of BP oscillations is interpreted as normal autoregulation.12 
According to this model, dynamic autoregulation was not impaired in AD, as this 
would have resulted in an increased rather than decreased transfer function gain, 
as well as reductions in phase lead. This is in contrast with the findings in an AD 
animal model where cerebral autoregulation was impaired even before vascular 
deposition of amyloid-beta had occurred.8 However, direct comparisons between 
studies in humans and animals may be difficult. In addition, only static, not dynamic 
autoregulation was assessed in animal studies.8
Finally, the lower gain in AD vs. controls might also be interpreted to suggest that 
cerebral vasoconstrictive and/or vasodilatory responses to changes in BP were 
enhanced, thus leading to reductions in CBFV variability (enhanced autoregulation). 
This interpretation, however, is not supported by the observations during orthostatic 
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Induced blood pressure fluctuations such as might be encountered during daily life 
were markedly exaggerated, consistent with impaired baroreflex function. Although 
these BP fluctuations induced smaller changes in cerebral blood flow velocity in AD 
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cerebrovascular impedance), cerebral blood flow was severely compromised 
during dynamic standing, demonstrating impaired vasomotor reserve in patients 
with AD. 
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in its glory days, the monetary gold standard was never considered perfect. It was subject to 
endless debate, and in the end it was abandoned for a better system. Similarly, today’s gold 
standard tests will be replaced by better ones. As was eloquently stated by Versi: “It is the absolute 
truth that is never reached; gold standards are constantly challenged and superseded when 
appropriate”3
 1 Rudd P. In search of the gold standard for compliance measurement. Arch Intern Med 
1979;139:627-8.
 2 Duggan PF. Time to abolish “gold standard”. BMJ 1992;304:1568-9.
 3 Versi E. “Gold standard” is an appropriate term. BMJ 1992;305:187.
The gold standard: not a golden standard (BMJ 2005;329:1121)
Studies that evaluate a new diagnostic test, procedure, or method should do so by comparing it 
with a time honoured alternative that is considered to be the current standard in the field. In this 
context the meaning of the word standard is “authoritative or recognised exemplar of quality or 
correctness.” “Gold standard” is the popular term to describe this test; but “golden standard” is 
sometimes used as well. In fact, almost all medical publications in Dutch use the term “gouden 
standaard” which is a translation of “golden standard.” Apparently, medical scientists have 
become confused about the true meaning of the term gold standard.
Inspired by the Olympic Games, where the best athlete wins the gold medal, people who use 
“golden standard” think the term denotes the best standard in the world. Not bronze, not silver, but 
gold. Of course, this is incorrect. Gold standard is a historical term borrowed from economists. It 
signifies a monetary standard, under which the basic unit of currency was defined by a stated 
quantity of gold. The analogy should be clear: the value of each country’s method of payment 
(currency) was weighed against the gold standard, which made it possible to compare these 
different currencies for international trading. In a Medline search from 1955 onwards, the first 
emergence of the term -albeit in a different meaning- was in 1962, in an anonymous commentary 
in the Lancet. Entitled “Towards a gold standard,” it pleaded to set a standard for the use of gold 
salts in patients with rheumatoid arthritis. It may well have been Rudd who first introduced the 
“gold standard” in medicine in its current sense in 1979.1 In the following years, the number of 
publications that employed the term grew rapidly. This was much to the dismay of one biochemist, 
who thought the term was “presumptuous” for a biological test, since “the subject is in perpetual 
evolution [and] gold standards are by definition never reached.”2 He proposed abolishing the term 
“because the phrase smacks of dogma …After all, the financiers gave up on the idea of a gold 
standard decades ago.” He failed in his mission, however: since 1995, over 10 000 publications 
mentioned “gold standard.” So why is there also a “golden standard,” a term used in over 600 
publications since 1995 in English and in many more in foreign languages? I think this is because 
it is tempting to interpret the word “gold” in gold standard as an adjective, as in gold medal, and 
then to replace it with “golden,” which simply sounds better if English is not your first language. In 
addition, “golden standard” is a persuasive term that makes sense: if a standard is the one test by 
which all others are judged, then the golden standard must be perfect. Herein lies, I think, the 
importance of this discussion. The concept of a “golden standard” implies a level of perfection 
that can never be attained by any biological test, and will provoke criticism like that ventilated by 
Duggan.2 In contrast, a gold standard in its true meaning, derived from the monetary gold 
standard, merely denotes the best tool available at that time to compare different measures. Even 
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Introduction
Advances in measurement techniques have made it possible to study dynamic 
changes in brain blood flow. In this thesis, these techniques have been further 
explored, with specific attention for their potential use in elderly subjects. First, we 
have considered that measurements of cerebral perfusion, complimenting 
measurements of blood pressure, will provide valuable insight in disorders of blood 
pressure regulation. Second, we have proposed that measurements of blood 
pressure, cerebral blood flow, and their interaction, are important in dementia 
research.
This chapter will provide a summary of the findings in this thesis, followed by a 
general discussion.
Summary
Part 1. Clinical and methodological background
Chapter 2. This chapter introduces the concept of cerebral autoregulation. It 
provides a clinical background to indicate its relevance in several conditions that are 
prevalent in aging subjects. A comprehensive literature review in this chapter shows 
that there is relatively little information on the effects of aging on cerebral 
autoregulation, and that there are virtually no data available for subjects older than 
75 years. This chapter also describes several methods to analyze and quantify 
cerebral autoregulation. A suggestion is made for methods that would seem well 
suited for application in elderly subjects. One such method is the analysis of 
spontaneous oscillations in blood pressure and cerebral blood flow. These 
measurements can be performed under resting conditions, for example with the 
subject in seated position, and require little time (5-10 minutes). A disadvantage of 
this method is that spontaneous oscillations have small amplitudes, which may limit 
analysis and interpretation. As a solution, this chapter proposes methods to enhance 
oscillation amplitudes using repeated maneuvers such as sit-stand or squat-stand.
Chapter 3. In the third chapter we consider the interaction between dementia and 
cerebral perfusion. One of the hypotheses in Alzheimer’s disease is the cholinergic 
hypothesis, developed 30 years ago, when post mortem studies revealed a severe 
loss of cholinergic innervation in brains of Alzheimer patients, which was linked to 
the decline in memory. The treatment of Alzheimer's disease with cholinesterase 
inhibitors is based on this cholinergic hypothesis, however, this hypothesis fails to 
account for the lack of specificity of the clinical effects of cholinesterase inhibitors 
(e.g. improvements in other cognitive domains than memory, such as attention), for 
the replication of these effects in other dementias, and for the strong and 
unpredictable intra-individual variation in response to treatment. These findings 
may be better explained by the premise that cholinesterase inhibitors primarily act 
by augmenting cerebral perfusion: the cholinergic–vascular hypothesis. This 
chapter reviews the evidence from preclinical and clinical investigations on the 
vascular role of the cholinergic neural system. The clinical relevance of this 
hypothesis is discussed with respect to its interactions with the vascular and 
amyloid hypothesis of Alzheimer's disease. It is proposed that the role of the 
cholinergic system in neurovascular regulation and functional hyperemia may 
elucidate how the cholinergic deficit in Alzheimer's disease contributes to the 
clinical and pathological features of this disease. Dynamic measurements of 
cerebral perfusion will be important to further pursue this topic.
Part 2. Tools and methods to investigate cerebral hemodynamics
Chapter 4. This chapter evaluates near infrared spectroscopy (NIRS). NIRS is a 
non-invasive method to monitor cerebral hemodynamics. Used either alone or in 
combination with transcranial Doppler sonography, this technique would be well 
suited for use in cerebrovascular research in aging. Reproducibility of NIRS has 
primarily been determined in neonates and adults, and only limited information is 
available in aging subjects. In this chapter, controlled desaturation (the O2-method) 
was applied to measure the cerebral blood volume (CBV) with NIRS in 16 healthy 
subjects aged 65 to 88. This method uses deoxygenated hemoglobin (the 
concentration of which is manipulated by controlled desaturation) as an intravascular 
tracer for NIRS. Repeatability (between tests interval: 2 min), short-term reproducibility 
(intervals of 20 and 40 min) and long-term reproducibility (interval >2 weeks) were 
determined. We found a coefficient of variation (CV) of 12.5% for repeatability and 
a CV of 11.7% for short-term reproducibility. The CV for long-term reproducibility 
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frequencies of 0.025 and 0.05 (in the very low frequency range ) and 0.1 Hz (in the 
low frequency range). Indeed, large oscillations at these specific frequencies were 
induced. We conclude that using repeated squat-stand maneuvers, we are able to 
study dynamic cerebral autoregulation in the low frequencies under conditions of 
hemodynamically strong and causally related oscillations in pressure and flow. This 
improves the estimations of dynamic cerebral autoregulation, and strengthens the 
clinical relevance of this method since induced oscillations mimic hemodynamic 
changes associated with postural changes in daily life. 
Part 3. Application in clinical research
Chapter 7. In this chapter, we have applied the method described in chapter 5 to 
investigate cerebral vasomotor reactivity to CO2 in middle-aged patients with 
hypertension (mean age 52 years, range 40 -66). In hypertension, cerebral 
vasomotor reactivity to CO2 may be reduced as a consequence of cerebrovascular 
remodeling and endothelial dysfunction. In newly diagnosed untreated patients, 
blood pressure reduction following treatment may further impair CO2 reactivity, 
because compensatory cerebral vasodilatation will be induced by cerebral 
autoregulation. In this chapter, we studied 11 patients with newly diagnosed, 
untreated mild to moderate hypertension and 8 controls. At baseline, hypertension 
was not associated with reduced CO2 reactivity. In patients, treatment with losartan/
hydrochlorothiazide effectively lowered blood pressure. After 1-2 weeks of treatment, 
and after 3 months of treatment, cerebrovascular resistance was reduced (indicating 
vasodilatation) and cerebral blood flow velocity remained stable, however, CO2 
reactivity was not affected. In a previous study, we have shown that dynamic 
cerebral autoregulation was not affected by mild hypertension, nor by rapid or 
prolonged blood pressure reduction.1 This study adds to these findings by 
demonstrating that reactivity to CO2 is equally unaffected. Previous suggestions 
that hypertension is associated with impaired vasomotor reactivity appear to be 
explained by cerebrovascular and/or diabetic co-morbidity. 
 
Chapter 8. Here, the methods described in chapter 5 and chapter 6 have been 
employed to explore the cerebral hemodynamic characteristics in patients with mild 
Alzheimer’s disease compared with age-matched controls. In this chapter, the 
was 15%. We conclude that NIRS can reproducibly measure CBV in subjects aged 
65 and older, using the O2-method. In this group of healthy subjects, this method 
was well tolerated. 
Chapter 5. Cerebral blood vessels strongly respond to changes in CO2. This 
phenomenon is termed vasomotor reactivity, and has been used clinically and in 
research to evaluate cerebrovascular function. Often, transcranial Doppler 
ultrasonography (TCD) is used to measure changes in cerebral blood flow-velocity 
together with changes in end-tidal CO2 (the latter reflecting arterial CO2-pressure, 
pCO2. Blood pressure, however, is also affected by changes in CO2, and the 
independent effects of blood pressure on cerebral blood flow will confound 
interpretation of vasomotor reactivity to CO2. This chapter proposes a method to 
analyze vasomotor reactivity by looking at changes in conductance (flow divided by 
pressure), in addition to flow alone. Moreover, it is demonstrated that by using 
breath-by-breath analysis of changes in end-tidal CO2 and conductance, the 
non-linear dynamics of the relationship between CO2 and cerebral blood flow are 
revealed. This may provide a more sensitive method than previously used 
techniques that have assumed a linear relationship.
Chapter 6. This chapter further investigates how analysis of spontaneous 
oscillations in blood pressure and cerebral blood flow can be used to quantify the 
dynamic relationship between pressure and flow. As discussed in chapter 2, these 
measurements can be performed under resting conditions, and would therefore 
seem very suitable for application in elderly subjects. However, spontaneous 
oscillations often have small amplitudes, and therefore their clinical relevance may 
be questioned. Spontaneous oscillations have different frequencies or periods, 
ranging from the very low frequency range (< 0.07 Hz, which equals oscillation 
periods of 15 seconds or longer) to the high frequency range (0.2 - 0.35 Hz, or 
periods of 3-5 seconds). As described in chapter 2, cerebral autoregulation is 
particularly effective for very low frequency oscillations in pressure, making it 
important to study this frequency range. Unfortunately, it is often difficult to 
demonstrate beyond doubt that all observed very low frequency oscillations in 
cerebral blood flow are causally related to oscillations in blood pressure. In this 
chapter, we investigated if it would be possible and feasible to use repeated 
squat-stand maneuvers in order to induce large oscillations in blood pressure at 
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Overlooking these results, we will now address some relevant methodological 
issues regarding the techniques to measure cerebral perfusion. This will be followed 
by a discussion on the implications of these findings for future research. We will 
highlight what valuable insights in disorders of blood pressure regulation can be 
emphasis is on the method of transfer function analysis to quantify dynamic 
cerebral autoregulation. Transfer function analysis uses specific parameters (gain, 
phase shift and coherence) to quantify the relationship between blood pressure and 
cerebral perfusion. In this pilot study, we demonstrated that the application of these 
methods was feasible. Even though we studied a small number of subjects, and the 
Alzheimer patients were in an early stage of the disease, we noted remarkable 
alterations in blood pressure regulation and in cerebral perfusion in these patients. 
Cerebrovascular resistance was increased, and cerebral blood flow was reduced, 
even when corrected for differences in total brain volume. In addition, oscillatory 
changes in cerebral blood flow were reduced despite increased blood pressure 
oscillations in Alzheimer’s disease. These findings indicate that already in an early 
clinical stage, Alzheimer’s disease is associated with hemodynamic changes, 
which affect blood pressure and cerebral perfusion. Moreover, these changes could 
be described using the methods proposed in this thesis. 
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Table 1  Overview of instruments and main measurements used in this thesis. Table 2  Summary of the essential features of cerebral autoregulation and 
reactivity.
 Domain Sample frequency/ Main measures Optional additional
  Temporal resolution  measures  Cerebral autoregulation Vasomotor reactivity
Finapres
TCD
NIRS
Equipment used
Input measures
Physiological 
basis
Data preparation 
and analysis
Output measures
Interpretation
Normal 
obervations
Examples 
of abnormal 
findings
Blood 
pressure
Cerebral 
blood flow-
velocity
Tissue 
oxygenation
200 Hz, measures 
complete pressure 
wave within each 
cardiac cycle
200 Hz, measures 
complete flow-
velocity wave within 
each cardiac cycle
200 Hz, measures 
changes in 
concentration of 
hemoglobin (total, 
and oxygenated/
deoxygenated 
fractions) within each 
cardiac cycle
Beat-to-beat 
changes in systolic, 
diastolic, and mean 
blood pressure
Beat-to-beat 
changes in systolic, 
diastolic, and mean 
flow-velocity (MCA)
Beat-to-beat 
changes in oxyHb, 
HHb and tHb
Heart rate. Estimation 
of changes in a.o.: 
peripheral resistance, 
stroke volume
Pulsatility index, 
(micro)embolism 
detection
Estimation of cerebral 
blood volume (O2-
method).
Rapid detection of 
cortical activation 
(within msec) using 
oxyHb signal (cf fMRI 
BOLD).
Beat-to-beat BP, CBFV
Cerebrovascular adaptation to 
changes in perfusion pressure
-  Conversion to detrended time 
series
-  Spectral analysis BP and CBFV
  time series
- Transfer function analysis
Spectral power of oscillations in BP 
and CBFV
Transfer function phase, gain and 
coherence
Spectral power: magnitude of the 
hemodynamic oscillations
Gain: damping of BP oscillations 
to CBFV
Phase shift: adaptation of flow to 
pressure
Coherence: (linear) correlation 
between BP and CBFV oscillations
Lower gain and higher phase-shift 
for lower frequency oscillations, 
indicating that slower changes in 
BP are efficiently “filtered”.
Carotid stenosis, lacunar stroke, 
malignant hypertension, diabetes
Breath-to-breath BP, CBFV, etCO2
Hypocapnia causes vasoconstriction
Hypercapnia causes vasodilatation
-  Y-axis: % changes in BP, CBFV, 
CVC
- X-axis: etCO2
- linear regression
- exponential function
Total reactivity; separate hypocapnic 
and hypercapnic reactivity
Reactivity index
Reduced vasomotor reactivity 
indicates limited capacity for 
vasodilatation and / or constriction
Hypocapnia induces ~30% 
decrease, hypercapnia induces 
~70% increase in flow or 
conductance
Carotid artery stenosis, cerebral 
small-vessel disease
Finapres: finger arterial pressure measurement using photoplethysmography. TCD: tanscranial Doppler sonography. 
NIRS: near infrared spectroscopy. OxyHb: oxygenated hemoglobin.HHb: deoxygenated hemoglobin. tHb: total 
hemoglobin
BP: mean blood pressure CBFV: mean cerebral blood flow-velocity CVC: conductance-index (CBFV/BP) etCO2: 
end-tidal CO2 (partial pressure of CO2 in expired air)
Finapres, TCD, capnograph, ECG
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postural hypotension, and poses important limitations to the evaluation of vasomotor 
reactivity or hemodynamic responses to cognitive activation.3-5
Both TCD and near infrared spectroscopy (NIRS) provide an answer for these three 
limitations. Although at present, only a few centers world-wide combine these two 
techniques to measure cerebral hemodynamics in research settings, TCD alone is 
in fact widely available and is used in clinical practice and research. Both 
instruments have low cost for acquisition and operation. Temporal resolution is 
excellent (< 1 s), and as demonstrated in this thesis (chapter 6 and 8), and in 
previous work,6 body position and motion pose no limitations. Therefore, we have 
chosen to evaluate and further develop these techniques in our research into 
cerebral hemodynamics in aging.
TCD and NIRS have their own specific disadvantages that will be discussed below. For 
TCD, methodological issues are also discussed extensively in the literature review in 
chapter 2, and in chapters 5-8. For NIRS, a brief discussion is presented in chapter 4.
NIRS
NIRS measures changes in brain tissue hemoglobin oxygenation. The technique is 
limited to superficial areas of the brain, and it is not possible to know exactly the size 
and location of the tissue that is examined. This means that absolute values for 
hemoglobin concentrations cannot be obtained. In addition, it is possible that the 
signal is affected by extra-cranial sources (e.g. hemoglobin in scalp, muscle, or 
bone). With optimal inter-optode distance, the relative contribution of these sources 
can be minimized (chapter 4). Relative to the brain, perfusion in these extra-cranial 
tissues is small. Moreover, previous validation studies in our lab have included 
comparison with fMRI. The physiological constituent of the BOLD signal that is 
measured with fMRI is in fact the change in oxyhemoglobin that is measured by NIRS. 
It was shown in our lab that brain cortical oxygenation changes measured by NIRS 
correlated well with BOLD signal changes measured by fMRI.7 Since it is certain that 
the fMRI signal is purely composed of brain tissue oxygenation, this correlation 
suggests that extra-cranial contamination of the NIRS signal may be negligible.
Age-related changes in brain perfusion and brain atrophy may affect reliability of 
NIRS in research in elderly subjects. Therefore, we examined reproducibility of NIRS 
learned from the measurements of cerebral perfusion described in this thesis, and 
why measurements of blood pressure, cerebral blood flow, and their interaction, are 
important in dementia research. 
General discussion
Methodological considerations
Measurements of cerebral perfusion
In chapter 2 and 3, we have indicated that there is a need to enhance our knowledge 
of cerebral hemodynamics in many conditions and diseases that affect the aging 
population.
Over the past years, there have been important advances in techniques to evaluate 
cerebral perfusion.2 These include, but are not limited to, transcranial Doppler 
ultrasonography (TCD), near infrared spectroscopy, (functional) magnetic resonance 
imaging (MRI) and positron emission tomography (PET). MRI and PET have seen 
important improvements in spatial resolution (indicating in what detail regional 
perfusion differences can be separated) and temporal resolution (indicating in what 
detail changes in perfusion over time can be captured). For a detailed review 
comparing different techniques to measure cerebral perfusion, which is beyond the 
scope of this discussion, we refer to the excellent review of Wintermark et al. 2 
In short, at this moment, both MRI and PET have limitations and disadvantages, 
which reduce their potential usefulness in the field of research described in this 
thesis. First, availability is limited. For PET, this is determined by its high cost, but 
also depends on the speed of decay of the radio-active tracer, which means that 
the PET center must be in proximity to the tracer production site. Access to MRI for 
research purposes, especially to MRI machines with high magnetic field strength (3 
Tesla) is also limited due to factors including high clinical demand for MRI and 
budget limitations. Second, temporal resolution remains too low at this moment for 
both PET and MRI to capture fast changes in perfusion in response to rapid 
changes in perfusion pressure. Third and perhaps most importantly, MRI and PET 
scanning require that the subject is and remains as motionless as possible in the 
supine position. This makes it impossible to investigate the hemodynamic effects of 
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skull where the TCD signal can be obtained is known as the temporal window. 
Unfortunately, advancing age and female gender are associated with a higher risk 
of an “inadequate window”. This means that in older women, in up to 30% of 
subjects it will be impossible to obtain an adequate TCD signal.
Advantages of the combination of TCD and NIRS
In this thesis, TCD and NIRS have been evaluated separately. Because these 
techniques measure quite different aspects of cerebral hemodynamics, we propose 
that their combination will provide relevant complementary information. To exemplify 
this, we will briefly discuss which aspects of cerebral hemodynamics are addressed 
by TCD and NIRS.
Even though TCD provides an estimate of flow changes in the MCA, these changes 
reflect the dynamics of downstream, smaller vessels, rather than changes in larger 
caliber vessels such as the MCA itself (chapters 2 and 5-8).11-15 Thus, in a simplified 
depiction of complex hemodynamic physiology, the flow changes derived from TCD 
measurements are a reflection of downstream vasomotor changes (vasodilatation 
and vasoconstriction) in small vessels, in response to changes in CO2 (vasomotor 
reactivity) or changes in perfusion pressure (cerebral autoregulation).  
NIRS on the other hand can be regarded as an estimation of the “end result” of 
these hemodynamic changes at the level of the brain tissue. NIRS parameters 
indicate whether cortical total hemoglobin levels are stable, increase or decrease, 
and provide information on the supply of oxygen at the tissue level. For example, a 
reduction in oxygen-rich hemoglobin (O2Hb) measured using NIRS suggests that 
the balance between supply and demand for oxygen has shifted.7,16,17
In this way, combined measurements of TCD and NIRS together with Finapres or 
other devices that measure beat-to-beat blood pressure, will provide the following 
information, for example during orthostatic hypotension: the amount of blood 
pressure reduction, its effect on cerebral blood flow, and its effect on oxygen 
delivery at tissue level. 
Sample size- a matter of perspective
The studies in this thesis were performed in small numbers of subjects. In recent 
in aging (chapter 4). We examined short-term and long-term reproducibility of 
estimations of cerebral blood volume. This technique requires controlled 
deoxygenation (progressive hypoxia) to reduce in parallel peripheral oxygen 
saturation (SaO2) and cerebral oxygenation (oxyhemoglobin). Reproducibility was 
good, and comparable to other techniques to measure cerebral hemodynamics.8 
These results, together with previous reproducibility results for changes in cerebral 
oxygenation with orthostatic hypotension6,9 and correlation with fMRI7 (Mehagnoul-
Schipper, thesis 2003), all evidence of sufficient concurrent validity, indicate that 
NIRS can be confidently used in aging research.  
TCD
The limitations of TCD have been discussed in detail in chapter 2. In summary, it is 
important to realize that TCD provides an indirect measure of flow, namely 
flow-velocity, which is determined by flow and by vessel diameter. Intra-individual 
changes in flow-velocity reliably reflect changes in flow, as it has been demonstrated 
that vessel diameter does not change significantly during tests to assess 
autoregulation or vasomotor reactivity.1,4,5 In contrast, inter-individual differences in 
flow-velocity can importantly be determined by differences in middle cerebral artery 
(MCA) diameter.10 Therefore, comparisons of individual values for absolute 
flow-velocity should not be performed; instead, relative changes in flow-velocity 
(e.g. % change form baseline) must be used in this case. Comparisons of absolute 
flow-velocity values between two groups, as performed in part in chapter 8, are 
acceptable provided that it can be assumed that the distribution of individual 
differences in MCA diameters is equal in both groups. With this in mind, most 
comparisons in chapter 8 were based on relative changes in flow-velocity, which 
eliminates the effect of vessel diameter. Moreover, flow in the MCA does not equal 
global brain blood flow; however, the MCA does provide blood flow to ~70% of the 
brain. Also, estimates of flow measured with TCD can not be compared to brain 
blood flow in the classic sense, expressed as flow per 100 g of brain tissue (“nutrient 
flow”). In chapter 8, we have addressed this issue in part by expressing TCD 
flow-velocity relative to whole brain volume as measured by MRI.
Finally, TCD requires a “temporal window”, to get a reliable signal. In most subjects, 
the structure and density of the temporal bone allows sufficient passage of 
ultrasound waves to create a good quality flow-velocity signal. This small area of the 
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dynamic cerebral autoregulation was not altered by the presence of hypertension in 
these patients.1 Moreover, rapid normalization of blood pressure (to ≤ 140/90 mm 
Hg within 1-2 weeks) did not reduce cerebral perfusion, nor did it affect cerebral 
autoregulation. In chapter 7, we have shown that vasomotor reactivity to CO2 
equally was not affected by hypertension. Moreover, rapid blood pressure reduction 
did not impair vasomotor reactivity. Together, these findings indicate that the 
capacity of cerebral vessels for vasoconstriction and vasodilatation, in response to 
either a change in perfusion pressure or a change in CO2, was not affected by the 
presence of hypertension, nor by rapid reductions in perfusion pressure brought 
about by antihypertensive treatment. These two studies are complimentary. 
For example, a reduction in perfusion pressure may be compensated for by cerebral 
vasodilatation, thus maintaining a stable cerebral perfusion. This would suggest 
that autoregulation is unimpaired. However, if substantial, nearly maximal 
vasodilatation is required to compensate for the reduced perfusion pressure, it will 
be clear that any further reductions in perfusion pressure can no longer be 
compensated for. However, it may not be feasible or even ethical to reduce 
perfusion pressure to such extents. Here, vasomotor reactivity testing provides a 
safe and complimentary test. It has been demonstrated, in patients with carotid 
artery stenosis, that (near-)maximum vasodilatation to compensate for reduced 
perfusion pressure exhausts the capacity for further CO2-induced vasodilatation, 
leading to impaired vasomotor reactivity.20 In this way, the addition of vasomotor 
reactivity testing to a test of pressure autoregulation could unmask a compromised 
cerebral circulation.
These studies address the concern, described in the introduction of this thesis, that 
blood pressure reduction in hypertensive patients may lower cerebral perfusion. 
Here, we have shown that in the patient category that has been studied, this 
concern could be dismissed. 
This leads us to the following caveats. We have studied a limited age range (≈ 40-65 
years), and we can not assume that these results can be extrapolated to much older 
subjects. In addition, we studied newly diagnosed patients, and therefore it is 
unknown how long hypertension had already been present prior to treatment. 
Finally, these subjects did not have clinical signs or a history of cerebrovascular 
disease. 
years, medical research has seen a growing interest in randomized controlled trials 
and epidemiological studies with very large sample sizes. Studies in such large 
numbers of subjects can provide important new perspectives, as they may identify 
associations that would have been missed with observations made in smaller 
numbers of subjects.18 For comparison, studies with large sample sizes provide the 
equivalent of an aerial view of an archeological site, revealing a pattern of soil 
discoloration, consistent with an ancient building complex, that would have gone 
unnoticed when looked at from ground level.19 However, such studies with large 
sample sizes must make sacrifices to the level of detail that can be studied, as they 
can only obtain a limited number of measurements in individual subjects for obvious 
reasons of practicality and costs. Therefore, complementary studies in smaller 
numbers of subjects are warranted to provide the detailed perspective. Using the 
same comparison, such studies can analyze the soil contents in the identified 
patterns of soil discoloration to discover the building materials that were used. 
In this thesis, we have chosen to study the (patho) physiology of the cerebral 
circulation, in order to provide more detailed information on the associations 
between blood pressure, brain perfusion, and brain disease that have been 
identified by epidemiological research. Such detailed studies are limited to small 
numbers of subjects, due to the extensive and time-consuming data-analysis that 
is required. Nevertheless, we think that our findings, which we abstracted from a 
small group of subjects, potentially affect the diagnostics and management in 
Alzheimer’s disease in larger populations. 
Implications
Having described these methodological issues, we will now turn to the implications 
of the findings in this thesis for clinical research in geriatrics.
Hypertension
We have used a new, and more sensitive, method to measure cerebral vasomotor 
reactivity in patients with hypertension (chapter 5 and 7). We have investigated 
middle-aged patients with newly diagnosed mild-to-moderate hypertension. Prior to 
the study investigating vasomotor reactivity, we had already demonstrated that 
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Chapter 2 provides a further discussion on cerebral autoregulation. In a review of the 
literature to date, studies of cerebral hemodynamics in patients with hypertension 
aged up to ≈ 75 years showed no evidence for impaired autoregulation, regardless of 
the method that was used to quantify cerebral hemodynamics. Although this supports 
the findings in chapter 7, further study is required to investigate the effects of 
hypertension and blood pressure reducing treatment on brain perfusion in much older 
hypertensive patients, and in patients with co-existing cerebrovascular disease. The 
methods proposed in this thesis are well-suited to perform this type of research. 
Hypotensive syndromes
Disorders of blood pressure regulation are often referred to as the “hypotensive 
syndromes”, because hypotensive episodes are a prominent feature in all of these 
conditions. These disorders share the fact that the manner in which they affect 
cerebral perfusion strongly determines their clinical consequences.21,22 Cerebral 
autoregulation thus plays an important role, for example, it has been suggested that 
certain patients with neurogenic orthostatic hypotension have augmented or 
expanded cerebral autoregulation, which could explain how these patients can 
tolerate substantial falls in blood pressure.23
Thus far, management of hypotensive syndromes has focused on limiting the 
reduction in blood pressure. The methods described in this thesis make it possible 
to study cerebral perfusion in conjunction with blood pressure.24 This research in 
patients with disorders of blood pressure regulation can help to answer some of the 
following questions: 
1.  Are there inter-individual differences in autoregulation or vasomotor reactivity 
that explain the variation in clinical symptoms, and if so, which patient 
characteristics determine these differences? 
2.  How are autoregulation and vasomotor reactivity affected by different classes 
of medication? For example, antihypertensive agents may be required to 
reduce hypertension, but could aggravate orthostatic hypotension, in a patient 
with a disorder of blood pressure regulation. Angiotensin II receptor blocking 
(ARB) agents potentially enhance cerebral vasodilatation, and may augment 
autoregulation and hence orthostatic tolerance. Therefore, in theory, thiazide 
diuretics and ARB’s may have similar blood pressure lowering properties, but 
different effects on cerebral perfusion. Using the methodology laid out in this 
thesis, it is possible to investigate such differential drug effects on both blood 
pressure and cerebral circulation. 
3.  In neurogenic orthostatic hypotension, treatment has aimed at volume 
expansion, but recent “smart drug” development includes treatment with 
cholinergic agents.23 The effect of cholinergic agents (e.g. physostigmine) on 
postural blood pressure reduction has been studied, however, how do these 
drugs affect cerebral perfusion (see also the discussion on cholinergic 
–vascular innervation in chapter 3)? This also can be studied using the 
methodology laid out in this thesis.
Dementia 
Despite its first description more than 100 years ago, Alzheimer’s disease essentially 
remains a disease of unknown cause and without treatment.25 For comparison, 
AIDS, a comparably devastating disease, was first described less than 30 years 
ago; its cause has been unraveled, and several treatment options are available that 
effectively delay disease progression. Why is it that we have been able to solve the 
HIV/AIDS puzzle, but not the Alzheimer puzzle? Research publications on HIV/AIDS 
in medical literature clearly outnumber those on Alzheimer’s disease, suggesting 
that part of the explanation may lie in differences in research priority and effort. 
Furthermore, it is clear that HIV/AIDS is a monocausal, exogenous (infectious) 
disease, with a relatively short delay between infection and disease onset. If these 
are characteristics that speed up the unraveling of a disease, it can be argued that 
Alzheimer’s disease has not yet been unraveled because it has precisely the 
opposite characteristics. However, it has also been suggested that research in 
Alzheimer’s disease has been looking in the wrong direction,26 or has been trapped 
in mono-causal thinking, ignoring the evidence for multicausality in this disease.25 
It is true that most research to date has focused on the amyloid hypothesis.27 This 
hypothesis regards Alzheimer’s disease as a disease of increased production and/
or decreased clearance of beta-amyloid, leading to aggregation of neurotoxic 
beta-amyloid oligomers.27,28 Treatment strategies along the lines of this hypothesis 
are constantly developing, and several promising drugs are underway. However, 
human trials with several recently developed “promising drugs” have all been 
disappointing. It is this disappointment that has led some to consider this 
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 amyloid-hypothesis as a “wrong direction” for Alzheimer research, one that neglects 
the evidence for a vascular origin of this disease- the vascular hypothesis of 
Alzheimer’s disease.26 In short, this vascular hypothesis suggests that vascular 
alterations lead to increased susceptibility to hypoxia and oxidative stress, which in 
turn lead to Alzheimer pathology. In this hypothesis, beta-amyloid is considered a 
product, not a cause, of Alzheimer’s disease.
Recent advances however suggest that the vascular hypothesis and the amyloid 
hypothesis are not mutually exclusive.3,29 For example, mounting evidence 
demonstrates vascular effects of beta-amyloid, and implicates vascular alterations 
as a source of impaired beta-amyloid clearance.30, 31
This clearly illustrates the importance of further investigations into the aspects of 
vascular alterations in Alzheimer’s disease. In chapter 8, we have shown that, using 
the methods proposed in this thesis, it is feasible to measure cerebral hemodynamics 
in aging subjects with Alzheimer’s disease. In this study, we found indications that 
several aspects of hemodynamics were affected in patients with early Alzheimer’s 
disease. Blood pressure regulation was altered, which could be consistent with 
alterations in baroreflex function as a result of brain pathology, and/or with functional 
vascular effects of circulating beta-amyloid. Cerebral perfusion was reduced, with 
elevated cerebrovascular resistance and reduced oscillations in cerebral blood 
flow. This could be consistent with altered endothelial or smooth-muscle function, 
or with structural alterations in the vascular (capillary) bed. Such alterations have 
been demonstrated in animal studies and in limited in vitro studies with human 
material (see chapter 8). Further research is warranted to confirm these observations 
of hemodynamic alterations in a larger number of patients with Alzheimer’s disease, 
and to elucidate the mechanisms behind these changes. Both detailed small scale 
and more global large scale studies are needed to clarify the position of both the 
amyloid and the vascular factors in the complex, probably multifactorial, and slowly 
progressive pathophysiology of Alzheimer’s disease.25,29 In our lab, for example, 
detailed research, using the methods validated in this thesis, is currently underway 
to investigate hemodynamic changes in a larger number of older patients with 
Alzheimer’s disease and age-matched cognitively normal controls. Moreover, the 
effects of treatment with cholinesterase-inhibitors on cerebral hemodynamics will 
be addressed, in line with the cholinergic-vascular hypothesis.
9
216 217
 29.  Olde Rikkert MG, van der Flier WM, de Leeuw FE et al. Multiple diagnostic tests are needed 
to assess multiple causes of dementia. Arch Neurol 2006; 63(1):144-146.
 30.  Claassen JA. Alzheimer's disease: trade-off for increased survival with atherosclerosis? 
Ann Neurol 2007;DOI 10.1002/ana.21285.
 31.  Deane R, Zlokovic BV. Role of the blood-brain barrier in the pathogenesis of Alzheimer's 
disease. Curr Alzheimer Res 2007; 4(2):191-197.
 13.  Hurn P, Traystman RJ. Changes in arterial gas tension. In: Edvinsson L, Krause D, editors. 
Cerebral blood flow and metabolism.  
2 ed. Philadelphia: Lippincott Williams & Wilkins; 2002: 384-394.
 14.  Wei EP, Kontos HA, Patterson JL, Jr. Dependence of pial arteriolar response to hypercapnia 
on vessel size. Am J Physiol 1980; 238(5):697-703.
 15.  Zhang R, Witkowski S, Fu Q, Claassen JA, Levine BD. Cerebral hemodynamics after short 
and long-term reduction in blood pressure in mild and moderate hypertension. 
Hypertension 2007; 49(5):1149-1155.
 16.  Mehagnoul-Schipper DJ, Vloet LC, Colier WN, Hoefnagels WH, Jansen RW. Cerebral 
oxygenation declines in healthy elderly subjects in response to assuming the upright 
position. Stroke 2000; 31(7):1615-1620.
 17.  Obrig H, Villringer A. Beyond the visible--imaging the human brain with light.  
J Cereb Blood Flow Metab 2003; 23(1):1-18.
 18.  Claassen JA. Epidemiology: friend or foe? BMJ 2004; 329:467.
 19.  Wilson DR. Air Photo Interpretation for Archaeologists. Tempus; 2000.
 20.  Blaser T, Hofmann K, Buerger T, Effenberger O, Wallesch CW, Goertler M. Risk of stroke, 
transient ischemic attack, and vessel occlusion before endarterectomy in patients with 
symptomatic severe carotid stenosis. Stroke 2002; 33(4):1057-1062.
 21.  Claassen JA. Cerebral perfusion in neurogenic orthostatic hypotension.  
Lancet Neurol 2008; 7(7):573-574.
 22.  Low PA, Singer W. Cerebral perfusion in neurogenic orthostatic hypotension - Authors' 
reply. Lancet Neurol 2008; 7(7):574.
 23.  Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update.  
Lancet Neurol 2008; 7(5):451-458.
 24.  Schondorf R, Stein R, Roberts R, Benoit J, Cupples W. Dynamic cerebral autoregulation is 
preserved in neurally mediated syncope. J Appl Physiol 2001; 91(6):2493-2502.
 25.  Olde Rikkert MG, Teunisse JP, Vernooij-Dassen M. One hundred years of Alzheimer's 
disease and the neglected second lesson of Alois Alzheimer on multicausality in dementia. 
Am J Alzheimers Dis Other Demen 2005; 20(5):269-272.
 26.  De La Torre JC. Alzheimer disease as a vascular disorder: nosological evidence.  
Stroke 2002; 33(4):1152-1162.
 27.  Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006; 368(9533):387-403.
 28.  Kukar TL, Ladd TB, Bann MA et al. Substrate-targeting gamma-secretase modulators. 
Nature 2008; 453(7197):925-929.
 
9
Chapter 10
Samenvatting in het Nederlands
220 221
Inleiding
Ontwikkelingen op het gebied van meettechnieken maken het nu mogelijk om 
snelle, dynamische veranderingen in hersendoorbloeding waar te nemen. In dit 
proefschrift zijn deze technieken verder verkend, met specifieke aandacht voor hun 
mogelijke gebruik bij ouderen. Het proefschrift heeft twee hoofdthema’s: 1) 
stoornissen in bloeddrukregulatie en 2) eigenschappen van het hersenvaatbed bij 
dementie. 
Het nauwkeurig kunnen meten van dynamische veranderingen in hersendoorbloeding 
biedt een waardevolle aanvulling op het meten van alleen de bloeddruk, wanneer 
onderzoek wordt gedaan bij patiënten met stoornissen in de bloeddrukregulatie. Dit 
zijn bijvoorbeeld patiënten met ernstige duizeligheid bij opstaan, of patiënten met 
veelvuldige “wegrakingen”. 
Recente ontwikkelingen op het gebied van dementie geven aan dat metingen van 
bloeddruk, cerebrale bloeddoorstroming, en hun interactie, van belang zijn bij 
onderzoek bij patiënten met cognitieve stoornissen en dementie.
Dit hoofdstuk bevat een samenvatting van de bevindingen in dit proefschrift.
Deel 1. Klinische en methodologische achtergrond 
Hoofdstuk 2. Dit hoofdstuk introduceert het concept cerebrale autoregulatie: het 
systeem waarbij hersenbloedvaten reageren op schommelingen in de bloeddruk 
om zo de hersendoorbloeding zo constant mogelijk te houden. Het hoofdstuk biedt 
een klinische achtergrond voor dit begrip, en toont de relevantie ervan aan bij 
verschillende aandoeningen die vaak voorkomen bij ouderen. Uit een uitgebreide 
literatuurstudie in dit hoofdstuk blijkt dat er relatief weinig informatie is over de 
effecten van veroudering op cerebrale autoregulatie, en dat er vrijwel geen 
gegevens beschikbaar zijn voor patiënten ouder dan 75 jaar. Dit hoofdstuk beschrijft 
ook verschillende methoden om cerebrale autoregulatie te analyseren en te 
kwantificeren. Er worden suggesties gedaan voor methoden die zeer geschikt lijken 
voor toepassing bij oudere patiënten. Een van deze methoden is de analyse van 
spontane schommelingen in bloeddruk en cerebrale bloeddoorstroming. Deze 
metingen kunnen namelijk worden verricht in rust, bijvoorbeeld als de patiënt rustig 
zit, en duren niet lang (5-10 minuten). Een nadeel van deze methode is dat spontane 
schommelingen (oscillaties) zwak zijn (ze hebben kleine amplitudes), en dit beperkt 
de analyse en interpretatie. Als een mogelijke oplossing hiervoor wordt voorgesteld 
om door herhaalde bewegingen, zoals zitten-staan, of kniebuigen-staan, sterkere 
schommelingen in bloeddruk en hersendoorbloeding op te wekken.  
Hoofdstuk 3. In het derde hoofdstuk kijken we naar de interactie tussen dementie 
met name de ziekte van Azheimer en de doorstroming van de hersenen. Een van de 
hypothesen over het ontstaan van de ziekte van Alzheimer is de cholinerge 
hypothese, 30 jaar geleden ontwikkeld toen bij post-mortem onderzoek bleek dat er 
een ernstig verlies was van cholinerge innervatie in de hersenen van Alzheimerpatiënten. 
Dit verlies leek gekoppeld aan de achteruitgang in het geheugen. De behandeling 
van de ziekte van Alzheimer met cholinesteraseremmers (in Nederland zijn dit de 
geneesmiddelen rivastigmine (Exelon) en galantamine (Reminyl)) is gebaseerd op 
deze cholinerge hypothese. Deze hypothese biedt echter geen goede verklaring 
voor het gebrek aan specificiteit van de klinische effecten van cholinesteraseremmers 
(bijvoorbeeld verbetering van de cognitieve andere domeinen dan het geheugen, 
zoals aandacht), voor het feit dat vergelijkbare behandeleffecten optreden bij andere 
dementievormen, en voor de sterke en onvoorspelbare intra-individuele variatie in de 
respons op de behandeling. Deze bevindingen kunnen beter worden verklaard door 
de veronderstelling dat cholinesteraseremmers vaatverwijding veroorzaken in de 
hersenen, en daarmee een verbetering van hersendoorbloeding bewerkstelligen. We 
hebben deze hypothese de cholinerge-vasculaire hypothese genoemd. Dit hoofdstuk 
geeft een overzicht van de gegevens uit het preklinisch en klinisch onderzoek op de 
vasculaire rol van het cholinerge neurale systeem. De klinische relevantie van deze 
hypothese wordt besproken, evenals de verhouding met andere hypothesen voor de 
ziekte van Alzheimer: de vasculaire- en de amyloid- hypothese. We bespreken de 
mogelijke rol van het cholinerge systeem in de neurovasculaire koppeling: de locale 
regulatie van hersenactiviteit en doorbloeding. Dit mechanisme kan verduidelijken 
hoe het cholinerge tekort bij de ziekte van Alzheimer bijdraagt aan de klinische en 
pathologische kenmerken van deze ziekte. Dynamische metingen van de cerebrale 
perfusie zijn van belang om dit onderwerp verder te bestuderen.
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Dit hoofdstuk beschrijft een methode voor het analyseren van vasomotore 
reactiviteit door te kijken naar veranderingen in zowel de stroomsnelheid in de 
hersenvaten als de bloeddruk. Door te kijken naar veranderingen in deze parameters 
in opeenvolgende ademteugen komt de niet-lineaire dynamica van de relatie tussen 
CO2 en cerebrale bloeddoorstroming aan het licht. Hierdoor is deze methode 
mogelijk meer gevoelig dan eerder gebruikte methoden, die zijn uitgegaan van een 
lineair verband.  
Hoofdstuk 6. Dit hoofdstuk onderzoekt hoe de verdere analyse van spontane 
schommelingen in bloeddruk en cerebrale bloeddoorstroming kan worden gebruikt 
voor de kwantificering van de dynamische relatie tussen druk en doorbloeding 
(flow). Zoals besproken in hoofdstuk 2 kunnen deze metingen worden verricht in 
rust, waardoor ze vooral geschikt lijken voor toepassing bij oudere patiënten. 
Echter, spontane oscillaties hebben vaak kleine amplitudes, en aan de klinische 
relevantie van deze schommelingen kan dus worden getwijfeld. Spontane oscillaties 
hebben verschillende frequenties (of periodes), van het zeer lage frequentie bereik 
(<0,07 Hz, wat gelijk is aan een schommeling met een periode van 15 seconden of 
langer) naar het hoge frequentiebereik (0,2 - 0,35 Hz, of een periode van 3-5 
seconden). Zoals beschreven in hoofdstuk 2, is de cerebrale autoregulatie bijzonder 
effectief voor zeer laag frequente drukoscillaties, waardoor het van belang is dat dit 
frequentie bereik goed wordt gemeten. Helaas is het vaak moeilijk om aan te tonen 
dat alle waargenomen zeer laagfrequente schommelingen in de cerebrale 
bloeddoorstroming gerelateerd zijn aan schommelingen in de bloeddruk. In dit 
hoofdstuk hebben we onderzocht of het mogelijk en haalbaar zou zijn om herhaalde 
hurk-sta bewegingen (bv. 10 seconden hurkstand afgewisseld door 10 seconden 
staan) te gebruiken om grote schommelingen in de bloeddruk in een frequentie van 
0,025 en 0,05 (in het zeer lage frequentie bereik) en 0,1 Hz (in het lage 
frequentiebereik) te veroorzaken. Inderdaad bleek het mogelijk om grote oscillaties 
op deze specifieke frequenties teweeg te brengen. We concluderen dat het gebruik 
van herhaalde hurk-sta bewegingen ons in staat stelt om dynamische cerebrale 
autoregulatie te bestuderen in de lage frequenties, onder condities van 
hemodynamisch sterke en causaal gerelateerd oscillaties in druk en flow. Dit 
verbetert de nauwkeurigheid van de metingen van dynamische cerebrale 
autoregulatie, en versterkt de klinische relevantie van deze methode omdat de 
sterkte van de veroorzaakte schommelingen in bloeddruk lijkt op die van 
Deel 2. Instrumenten en methoden voor onderzoek naar de cerebrale 
hemodynamiek 
Hoofdstuk 4. Dit hoofdstuk evalueert nabij-infrarood spectroscopie (NIRS). NIRS is 
een niet-invasieve methode om cerebrale hemodynamiek te meten. Alleen, of in 
combinatie met Transcraniële Dopplermetingen, kan deze techniek zeer geschikt 
zijn voor cerebrovasculair onderzoek bij veroudering. Reproduceerbaarheid van 
NIRS is onderzocht bij pasgeborenen en volwassenen, maar er is slechts beperkte 
informatie beschikbaar voor reproduceerbaarheid bij ouderen.
In dit hoofdstuk werd gecontroleerde desaturatie (de O2-methode) toegepast om 
het cerebrale bloed volume (CBV) te meten met NIRS in 16 gezonde personen met 
een leeftijd van 65 tot 88 jaar. Deze methode maakt gebruik van veranderingen in 
gedeoxygeneerd hemoglobine in het hersenbloed. De concentratie van dit 
zuurstofarme hemoglobine wordt veranderd door de gecontroleerde desaturatie, en 
daarmee kan het worden gebruikt als een intravasculaire indicator voor NIRS. 
Herhaalbaarheid (interval tussen de tests: 2 min), korte termijn reproduceerbaarheid 
(intervallen van 20 en 40 min) en lange termijn reproduceerbaarheid (interval> 
2 weken) werden vastgesteld. We vonden een variatiecoëfficiënt (CV) van 12,5% 
voor de herhaalbaarheid en een CV van 11,7% voor de korte termijn reproduceer-
baarheid. De CV voor de lange termijn reproduceerbaarheid was 15%. We 
concluderen dat NIRS reproduceerbaar het CBV kan meten bij personen van 65 jaar 
en ouder, met behulp van de O2-methode. In deze groep van gezonde proefpersonen 
werd deze methode bovendien goed verdragen. 
 
Hoofdstuk 5. Cerebrale bloedvaten reageren sterk op veranderingen in CO2. 
Dit verschijnsel heet vasomotore reactiviteit, en is al uitvoerig gebruikt in de 
klinische praktijk en in onderzoek om de hersenvaatfunctie te evalueren. Vaak wordt 
Transcraniële Doppler echografie (TCD) gebruikt voor het meten van veranderingen 
in de cerebrale bloeddoorstroming-snelheid, samen met veranderingen in het eind-
expiratoire CO2 (als maat voor de hoeveelheid arterieel CO2 (de partiële druk of 
pCO2). Echter niet alleen de hersendoorbloeding, maar ook de bloeddruk wordt 
beïnvloed door veranderingen in CO2. De effecten van deze bloeddrukveranderingen 
op de cerebrale bloeddoorstroming zullen de interpretatie verstoren van de directe 
effecten van CO2 op de hersenvaten (de vasomotore reactiviteit van CO2). 
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cerebrale autoregulatie te kwantificeren. Deze analyse maakt gebruik van specifieke 
parameters zoals demping (gain), faseverschuiving en coherentie voor de 
kwantificering van de relatie tussen de bloeddruk en de hersenendoorbloeding. In 
deze pilotstudy hebben we aangetoond dat de toepassing van deze methoden 
haalbaar is. Hoewel wij een klein aantal personen bestudeerden en de Alzheimer 
patiënten onderzocht werden in een vroeg stadium van de ziekte, vonden we 
opmerkelijke veranderingen in bloeddrukregulatie en hersenendoorbloeding bij 
deze patiënten. De cerebrovasculaire weerstand was verhoogd, en de cerebrale 
bloeddoorstroming was verminderd, zelfs als werd gecorrigeerd voor verschillen in 
het totale hersenenvolume. Bovendien waren de spontane oscillaties in de cerebrale 
bloeddoorstroming verlaagd bij de ziekte van Alzheimer ondanks versterkte 
bloeddruk oscillaties. Deze bevindingen wijzen erop dat al in een vroeg-klinische 
fase, de ziekte van Alzheimer geassocieerd is met hemodynamische veranderingen. 
Bovendien konden deze veranderingen worden beschreven met behulp van de 
methoden die in dit proefschrift zijn beschreven.  
hemodynamische veranderingen die gepaard gaan met houdingsveranderingen in 
het dagelijks leven.  
Deel 3. Toepassing in klinisch onderzoek 
In dit hoofdstuk hebben we de methode beschreven in hoofdstuk 5, toegepast, om 
cerebrale vasomotore reactiviteit voor CO2 te onderzoeken bij patiënten van 
middelbare leeftijd met hypertensie (gemiddelde leeftijd 52 jaar, spreiding 40 -66). 
Bij hypertensie kan de cerebrale vasomotore reactiviteit voor CO2 verminderd zijn 
als gevolg van cerebrovasculaire “remodeling” (veranderingen in structuur, 
wanddikte en diameter van hersenvaten) en endotheeldysfunctie. Bij nieuw 
gediagnosticeerde nog onbehandeld patiënten met hoge bloeddruk, zou verlaging 
van de bloeddruk door behandeling een nadelige invloed kunnen hebben op de 
CO2-reactiviteit. In dit hoofdstuk hebben we 11 patiënten onderzocht met nieuw 
gediagnosticeerde, onbehandelde lichte tot matige hypertensie en 8 controles. Bij 
de uitgangsmeting bleek hypertensie niet geassocieerd met verminderde CO2-
reactiviteit. Bij patiënten werd door de behandeling met losartan / hydrochloorthiazide 
de bloeddruk effectief verlaagd. Na 1-2 weken van de behandeling, en na 3 
maanden van de behandeling, was de cerebrovasculaire weerstand afgenomen 
(duidend op vasodilatatie) en de cerebrale bloeddoorstromingssnelheid bleef 
stabiel, maar de CO2-reactiviteit werd niet beïnvloed. In een eerdere studie hebben 
we aangetoond dat dynamische cerebrale autoregulatie niet wordt aangetast door 
een milde hypertensie, noch door een snelle danwel een langdurige verlaging van 
de bloeddruk. Deze studie vormt een aanvulling op deze bevindingen door aan te 
tonen dat de reactiviteit van CO2 evenmin is aangetast. Eerdere suggesties waarbij 
hypertensie in verband wordt gebracht met een verminderde vasomotore reactiviteit 
lijken te worden verklaard door cerebrovasculaire comorbiditeit of een tevens 
bestaande diabetes.  
  
Hoofdstuk 8. Hier zijn de methoden, beschreven in hoofdstuk 5 en hoofdstuk 6, 
toegepast om na te gaan of er verschil is in cerebrale hemodynamische 
eigenschappen tussen patiënten met de ziekte van Alzheimer en gezonde controles 
van vergelijkbare leeftijd. In dit hoofdstuk wordt de nadruk gelegd op de 
overdrachtsfunctieanalyse (transfer function analysis) als methode om dynamische 
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